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ABSTRACT 
Zachary Paul Neeb 
 
DIET-INDUCED DYSLIPIDEMIA DRIVES STORE-OPERATED Ca2+ ENTRY, Ca2+ 
DYSREGULATION, NON-ALCOHOLIC STEATOHEPATITIS, AND CORONARY 
ATHEROGENESIS IN METABOLIC SYNDROME 
 
Risk of coronary artery disease (CAD), the leading cause of death, greatly 
increases in metabolic syndrome. Metabolic syndrome (MetS; obesity, insulin resistance, 
glucose intolerance, dyslipidemia, and hypertension) is increasing in prevalence with 
sedentary lifestyles and poor nutrition. Non-alcoholic steatohepatitis (NASH; i.e. MetS 
liver) is progressive and decreases life expectancy, with CAD as the leading cause of 
death. Pathogenic Ca2+ regulation transforms coronary artery smooth muscle from a 
healthy, quiescent state to a diseased, proliferative phenotype thus majorly contributing 
to the development of CAD. In particular, store-operated Ca2+ entry (SOCE) in vascular 
smooth muscle is associated with atherosclerosis. Genetic predisposition may render 
individuals more susceptible to Ca2+ dysregulation, CAD, NASH, and MetS. However, 
the metabolic and cellular mechanisms underlying these disease states are poorly 
understood. Accordingly, the goal of this dissertation was to investigate the role of 
dyslipidemia within MetS in the development of Ca2+ dysregulation, CAD, and NASH. 
The overarching hypothesis was that dyslipidemia within MetS would be necessary for 
induction of NASH and increased SOCE that would primarily mediate development of 
CAD. To test this hypothesis we utilized the Ossabaw miniature swine model of MetS. 
Swine were fed one of five diets for different lengths of time to induce varying severity of 
MetS. Lean swine were fed normal maintenance chow diet. F/MetS swine were fed high 
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Fructose (20% kcal) diet that induced normolipidemic MetS. TMetS were fed excess 
high Trans-fat/cholesterol atherogenic diet that induced mildly dyslipidemic MetS and 
CAD. XMetS were TMetS swine with eXercise. DMetS (TMetS + high fructose) were 
moderately dyslipidemic and developed MetS and extensive CAD. sDMetS (Short-term 
DMetS) developed MetS with mild dyslipidemia, but no CAD. MMetS (Mixed-source-
fat/cholesterol/fructose) were severely dyslipidemic, exhibited NASH, and developed 
severe CAD. Dyslipidemia in MetS predicted NASH severity (all groups < DMetS << 
MMetS), CAD severity (i.e. Lean, F/MetS, sDMetS < XMetS < TMetS < DMetS < 
MMetS), and was necessary for STIM1/TRPC1-mediated SOCE, which preceded CAD. 
Exercise ameliorated SOCE and CAD compared to TMetS. In conclusion, dyslipidemia 
elicits TRPC1/STIM1 SOCE that mediates CAD, is necessary for and predictive of 
NASH and CAD, and whose affects are attenuated by exercise. 
 
Michael Sturek, PhD, Chair 
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Chapter 1 
Metabolic syndrome 
Metabolic syndrome (MetS; “prediabetes”) afflicts up to 27% of the United States 
population while continuing to dramatically increase in prevalence (30). No precise 
definition of MetS has been universally accepted with three competing, although similar, 
criteria set forth first by the World Health Organization, followed by the Adult Treatment 
Panel III, then the International Diabetes Federation, and most recently through a joint 
scientific statement (with American Diabetes Association notably abstaining) (31-33). 
Although the clinical necessity of MetS classification has recently been questioned (34-
37), MetS is generally diagnosed with the presence of three or more of the following 
conditions: obesity, insulin resistance, glucose intolerance, dyslipidemia (e.g. increased 
low density lipoprotein [LDL], decreased high density lipoprotein [HDL], increased 
LDL/HDL, and increased triglycerides), and hypertension. 
MetS is strikingly prevalent (38) with the incidence of MetS continuing to rise with 
obesity and sedentary lifestyle (33). This is important as MetS is a strong predictor of 
several comorbidities including the incidence, severity, and interventional outcome in 
atherosclerosis (36;39;40), progression from non-alcoholic fatty liver disease (NAFLD) to 
non-alcoholic steatohepatitis (NASH; (41;42)), and progression from pre-diabetes to type 
2 diabetes mellitus (43). 
 
Diabetes mellitus 
Diabetes mellitus is a condition most commonly defined simply by elevated 
fasting blood glucose (hyperglycemia; (44)). The fasting blood glucose threshold for 
diagnosis in humans is 126 mg/dL (45) and a vast majority of patients with diabetes are 
classified as either type 1 or type 2 diabetic. While the etiology of type 1 and type 2 
diabetes was not determined until the 1970’s, it has been recognized for over a century 
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that fat (gras) and skinny (maigre) diabetes are diametrically opposed (reviewed in (46)). 
Whereas type 1 diabetes (insulin-dependent) is initiated by auto-immune response 
ablation of insulin-producing pancreatic β-cells, the progression towards type 2 diabetes 
(non insulin-dependent) is mediated by increased circulating insulin and the inability of 
various tissues/organs to appropriately respond to insulin (insulin resistance). 
 
Type 2 diabetes 
Type 2 diabetes is a progressive disease (reviewed elsewhere (44)) that is often 
preceded by years of mildly elevated blood glucose levels, hyperinsulinemia, and insulin 
resistance before the threshold of diagnosis is achieved (progression outlined in Figure 
1.2; (47)). Elevated fasting and post-prandial blood glucose precede the diagnosis of 
type 2 diabetes. During this “prediabetes” stage, insulin resistance and elevated plasma 
insulin contribute to increased pancreatic β-cell work and decreasing function. 
Hyperinsulinemia drives progressively worse hepatic and peripheral insulin sensitivity, 
while continual stress and hyper-production of insulin lead to failed compensatory 
pancreas insulin production. Diagnosis of type 2 diabetes occurs when fasting blood 
glucose reaches the threshold of 126 mg/dL. In summary, the onset of type 2 diabetes is 
primarily mediated by three defects: increased hepatic glucose production, diminished 
insulin secretion, and insulin resistance (48).  
Slow progression and often negligible symptoms of early stage type 2 diabetes 
lead to under-diagnosis of prediabetes (49). However, early diagnosis and treatment are 
vital for long-term outcomes and quality of life (50). Medical management of type 2 
diabetes focuses primarily on limiting hyperglycemia, but reducing concomitant risk 
factors of MetS and CAD are also important (reviewed elsewhere (51)). Despite dietary, 
exercise, and medical intervention CAD is the leading cause of death in patients with 
  3   
 
diabetes (52;53). Additionally, NAFLD is closely associated with incidence of type 2 
diabetes mellitus (54). 
 
Non-alcoholic steatohepatitis 
NAFLD, considered the hepatic manifestation of MetS (55), is one of the most 
common chronic liver diseases present in about one third of the general population 
(41;56-58) and continues to increase in incidence (59;60). NAFLD is histologically 
characterized by microvesicular steatosis without additional signs of liver injury (8). 
NAFLD is benign when presented as simple steatosis, however NASH, a progressive 
form of NAFLD, can lead to advanced fibrosis, cirrhosis, and liver failure (41;56-58). 
NASH is histologically characterized by macrovesicular steatosis, inflammation, 
hepatocyte ballooning, and fibrosis (61). Up to 25% of patients with NAFLD typically 
progress to NASH (42;62). Importantly, patients with NASH have increased risk of death 
from cardiovascular disease (63), such that death from CAD exceeds even that of liver 
cirrhosis in NASH (64).  
 
Coronary artery disease 
Coronary artery disease (CAD) is the leading cause of heart disease and stroke. 
The risk for CAD increases 3- to 4-fold in the presence of MetS (65;66). Sedentary living, 
hypercaloric/lipidemic diet, diabetes, metabolic syndrome, non-alcoholic steatohepatitis, 
and gender are major risk factors for the progression of CAD (reviewed elsewhere (67)). 
There are several striking features of MetS CAD; in particular, pervasive, “diffuse CAD” 
is a hallmark of diabetic CAD (68-73;73-87). MetS also increases CAD: 1) plaque 
cellularity, 2) instability, 3) inflammation, and 4) calcification compared to non-diabetic 
patients (82). 
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Atherosclerosis (reviewed elsewhere (67;88)) is ubiquitous, often evident in early 
childhood of even healthy individuals (89), and progressive, advancing through eight 
stages characterized in detail by Stary (Figure 1.1; (90)). Monocytes infiltrate the vessel 
wall to scavenge fatty acids and cholesterol that have accumulated between endothelial 
cells and the internal elastic lamina. Lipid-laden monocytes transform to foam cells, 
contributing to the inflammatory response in the vessel wall leading to coronary smooth 
muscle (CSM) dedifferentiation, migration through the internal elastic lamina, 
proliferation, and secretion of connective collagen and elastin fibrils thus contributing to 
the building plaque (Figure 1.1). 
 
Coronary circulation 
Left and right coronary artery ostia (openings) originate from the left and right 
sinuses of Valsalva (bulges of the ascending aorta immediately distal to aortic valve; 
Figure 1.1). Coronary arteries are primarily apical, residing on top of the cardiac muscle, 
however Ossabaw swine, unlike canine, coronary artery branches dive into the cardiac 
muscle almost immediately after branching. The left coronary ostium connects with an 
almost undetectable left main artery, which bifurcates to form the left anterior 
descending (LAD) and circumflex (CFX) arteries. The LAD largely follows the cardiac 
septum all the way to the apex of the heart, while the CFX wraps around the base of the 
left ventricle just apical to the left atrium. The right coronary artery wraps around the 
base of the right ventricle, apical to the right atrium, until the septum where it abruptly 
turns towards the apex of the heart, providing blood flow to the posterior septal wall and 
thereby defining the pig as right dominant. This is one of the many striking similarities to 
the human coronary circulation. 
The walls of coronary arteries are comprised of three major sections: adventitia, 
media, and intima (Figure 1.1). Two circumferential fibrous bands composed primarily of 
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elastin, the external and internal elastic laminae, form distinct borders between the three 
sections. Adventitia surrounds the exterior of the artery and is composed primarily of 
collagen fibrils and fibroblasts. The medial layer is bounded by the internal and external 
laminae and composed primarily of CSM. CSM cells in healthy arteries are quiescent, 
proliferating at very low levels, and contractile, mediating vessel tone. Intercellular 
connexins allow movement of small molecules and ions between neighboring CSM and 
endothelial cells. Endothelial cells form a thin monolayer on the lumenal side of the 
internal elastic lamina in direct contact with blood flowing through the artery. The primary 
functions of endothelial cells are the production of vasoreactive compounds that 
influence the contractile state of the artery, formation of a tight barrier to allow proper 
blood flow and prevent interaction between blood and underlying CSM, and regulate 
growth and cytodifferentiation of CSM. 
 
Treatment of CAD 
The primary end-point for treatment of occlusive CAD is revascularization of the 
affected artery or arteries, thus relieving ishchemia and preventing/minimizing tissue 
damage, necrosis, and reduced cardiac function. Coronary stenting is the primary 
surgical intervention for occlusive CAD (outlined in Figure 1.3; (68)).  
Complications following revascularization include re-occlusion, thrombosis, 
myocardial infarction, and the need for repeat revascularization procedure (91-93), 
Despite similar completeness of revascularization compared to non-diabetics (68), 
complications are significantly greater in diabetics following revascularization (94). This 
is likely due to the diffuse nature of diabetic CAD and the effect of stent placement on 
“peri-stent” disease (95). The Food and Drug Administration (FDA) advises more studies 
are needed involving complex patients, including those with MetS and diabetes, 
receiving drug eluting stent (DES) treatment (96). However, no model of MetS and type 
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2 diabetes that naturally develops occlusive atherosclerosis has been available for 
clinical studies involving efficacy of revascularization attempts.  
Due to lack of significant native atherosclerosis in an animal model, the current 
FDA protocol for the study of stent efficacy involves mechanical injury of the vascular 
wall by over-expansion of stents to induce neointimal hyperplasia in completely healthy 
swine juvenile with no CAD (reviewed elsewhere (97-100)). The current study design 
recommended by the FDA is in sharp contrast to clinical practice where vascular wall 
injury during stent placement is avoided to minimize endothelial damage, vascular 
inflammation, and surgical complications (i.e. coronary dissection). As a result of the 
inability to generate significant native CAD, no pre-clinical study has ever involved stent 
placement in an artery with severe native CAD. It is entirely possible that recent 
questions regarding the safety of drug-eluting stents (99;101) could have been avoided 
had a more appropriate model of CAD been available. 
 
Swine in cardiovascular research 
Swine (sus scrufa) are an excellent model for cardiovascular research for several 
major reasons: 1) coronary anatomy is strikingly similar to humans (102) 2) neointimal 
structure and thrombosis cascade mimic and humans (103), 3) omnivorous diet and lipid 
metabolism similar to humans, 4) docile and sedentary behavior, and 5) size. Miniature 
swine are sexually mature at approximately 3 months of age, corresponding to ~50 kg. 
This allows serial blood sampling and tissue biopsy without adverse reactions. 
Additionally, swine are large enough to perform interventional surgical procedures 
common to those used in humans with cardiovascular disease (i.e. percutaneous 
intervention, angiography, stent placement, and etc.). 
The Yucatan is a lean swine breed widely used for many years in cardiovascular 
research. Atherogenic diet induces dyslipidemia but not insulin resistance and/or 
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glucose intolerance in Yucatan swine (3;4;7-10). Correspondingly, mild atherosclerotic 
lesions, primarily focused in the proximal portion of the coronary vasculature, develop in 
Yucatan swine fed atherogenic diet (3;4;4;6;8;11;12;17-24). Several studies have 
produced severe CAD in Yucatan swine, however this was not due to naturally 
developing MetS or diabetes, but through streptozotocin-induced pancreatic β-cell 
ablation (104-107). Demonstrating the clinical utility of swine, experiments in Yucatan 
swine involving angioplasty overexpansion-injury have elucidated important mechanisms 
of vascular disease (108).  
Göttingen swine (Yucatan x Göttinger cross-breed) is used less commonly than 
the Yucatan, but has been shown to produce dyslipidemia and coronary disease when 
fed atherogenic diet (109). As in Yucatan swine, streptozotocin has been used to induce 
diabetes in Göttingen. However, Göttingen swine did not develop fasting hyperglycemia 
in the absence of chemically-induced pancreatic β-cell ablation, as evidenced in a ~2-
year study of Göttingen swine fed atherogenic diet (110), thus indicating that Göttingen 
develop dyslipidemia, but do not progress to type 2 diabetes. 
Several animal models recapitulate MetS (111-116); however, none are able to 
fully reproduce symptoms of MetS and CAD, except Ossabaw swine. A major outcome 
of this thesis work is demonstration of progression to type 2 diabetes in Ossabaw swine. 
 
Ossabaw model of MetS and CAD 
Our laboratory characterized the Ossabaw miniature swine model which faithfully 
replicates many of the human characteristics of MetS when fed excess calorie 
atherogenic diet (3;4;7;8;29), including hypertension, central obesity, insulin resistance, 
glucose intolerance, dyslipidemia (elevated LDL, LDL/HDL ratio, and total cholesterol), 
and hypertriglyceridemia. Trans-fatty acids and fructose have been shown to be 
important in the development of severe dyslipidemia, mild atherosclerosis, and MetS 
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(3;29), while a modified atherogenic diet supplemented with fructose, trans-fatty acids, 
and lard produced severe MetS with accompanying NASH (7), the first report of NASH in 
a large animal model of MetS induced by atherogenic diet. In addition to developing 
NASH, MetS, and (outlined in this report) type 2 diabetes, Ossabaw swine faithfully 
develop CAD that is strikingly similar to CAD in humans with regard to plaque 
morphology and cellular composition. As such, Ossabaw swine provide an ideal 
opportunity for the study of cellular mechanisms underlying progressive CAD in MetS 
(e.g. Ca2+ signaling in CSM). 
 
Ca2+ regulation in CSM 
Ca2+ regulation is vital to cellular health and function (reviewed elsewhere (117)). 
CSM actively regulate Ca2+ using an elaborate system of intracellular depots, pumps, 
and channels (outlined in Figure 1.4). CSM differentiation (118), proliferation (119), 
gene expression (120), and contraction (121) are tightly associated with its ability to 
effectively moderate free (ionized) intracellular concentrations of Ca2+ (Ca2+i). Ca2+i must 
come from one of two sources, entry across the plasma membrane, or release from 
intracellular Ca2+ stores. 
While the nucleus (122), mitochondria (123), and intracellular Ca2+ binding 
proteins (124) may contribute to the regulation of Ca2+i, the primary intracellular Ca2+ 
store in CSM is the sarcoplasmic reticulum (SR). SR Ca2+ regulation is mediated by Ca2+ 
uptake and extrusion across the SR membrane. Sarco/endoplasmic Ca2+ adenosine 
triphosphatase (SERCA), a Ca2+ pump located in the SR membrane, is primarily 
responsible for Ca2+ sequestration into the SR (reviewed elsewhere (125)). SERCA is 
continually functioning to counteract passive leak of Ca2+ out of the SR and into the 
cytosol (reviewed elsewhere (126)), and SERCA molecular (127) and functional 
expression (125) have been shown to be regulated by Ca2+i. Once Ca2+ enters the SR, it 
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is immediately chelated by Ca2+-binding proteins, greatly increasing the functional ability 
of the SR as an intracellular Ca2+ store (128). Active release of Ca2+ from the SR store is 
mediated by inositol 1,4,5 trisphosphate (IP3)- or ryanodine-sensitive channels (RyR; 
reviewed in (129)). RyR in the SR, in close apposition to the plasma membrane, work to 
mediate Ca2+-induced Ca2+ release (130-132). Thus, SR Ca2+ regulation does not act in 
isolation, but rather is tightly orchestrated with Ca2+ permeability of the plasma 
membrane. 
Strong electromotive and diffusion forces exist for Ca2+ influx across the plasma 
membrane. The electromotive force is a consequence of the negative membrane 
potential of CSM (MV ;~-60 mV) and is mediated by relative rates of charged particle 
transport across the plasma membrane. In CSM, K+ conductance is the major 
determinant of MV under normal resting conditions (reviewed elsewhere (133)); however, 
Na+, Ca2+, and Cl- conductance also contribute to MV. 
The diffusion force is due to the tight regulation of resting Ca2+i in the range of 
~10-7M. This diffusion force is established by Ca2+ pumps (e.g. plasma membrane Ca2+ 
ATPase; PMCA) and antiporters (e.g. Na+/Ca2+ exchanger; NCX) in the plasma 
membrane regulating intracellular Ca2+ near 100 nM, while in vivo extracellular Ca2+ 
(outside Ca2+; Ca2+o) ranges from 1-2 mM, an incredible 20,000-fold gradient (yielding an 
equilibrium potential for Ca2+ (ECa) of ~+120 mV). The PMCA and NCX each are 
responsible for approximately one third of the Ca2+ buffering in CSM, with SERCA 
accounting for the remainder (134). The strong diffusion force produced by the PMCA 
and NCX allows Ca2+ influx that is mediated by voltage gated, receptor-operated, and 
store-operated Ca2+ channels (reviewed elsewhere (117)). Ca2+ influx through ligand-
gated channels may occur, but does not likely account for large Ca2+i increases in CSM 
(135), although Na+ influx may contribute to depolarization and activation of voltage 
gated Ca2+ channels (reviewed elsewhere (129)). 
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Voltage gated Ca2+ channels are mediated by perhaps the most intuitive 
mechanism in that voltage sensors within the channel move when membrane voltage 
changes causing activation of the channel, much like a switch. Two main types of 
voltage gated Ca2+ channels exist in CSM, low-voltage-activated (T-type) and high-
voltage-activated (L-type) (136-138). While relatively little is known about T-type channel 
activity in CSM (139), it is well established that Ca2+ influx through L-type Ca2+ channels 
leads to contraction (138;140) and contributes to hypertension (141;142). 
Receptor-operated Ca2+ channels (ROC) are activated by intracellular 2nd 
messengers potentiated by agonist binding to a separate receptor entity (reviewed 
elsewhere (143)). Importantly, this definition of ROC is operationally based, and not 
dependent on a particular molecular identity. Well described pathways activating ROC 
include 2nd messengers inositol trisphosphate (144), cyclic GMP (145), and cyclic AMP 
(146). G-protein coupled receptors are common initiators of the 2nd messenger cascade 
in ROC (147).  
The previous definition of ROC allows for inclusion of the putative store-operated 
Ca2+ channels (SOC). The precise definition of what constitutes a SOC has been the 
focus of several excellent reviews (117). Rigorously defined, SOC activation demands 
only depletion of SR Ca2+ store (148), but this store depletion may be achieved 
physiologically through second messenger, hormone, and ROC pathways. While 
activation via store-depletion is a prerequisite feature of any SOC, it has become 
increasingly evident that particular SOC may also be activated via ROC-like 
mechanisms (149). This has led to the term multiple-operated Ca2+ channel (MOC; 
(149;150)). Regardless of MOC or ROC classification, a recent consensus in the 
literature concerning the mechanism of SOC activation upon store depletion has been 
reached. 
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It has been generally accepted that SOC are activated by SR membrane protein 
stromal interaction molecule 1 (STIM1) upon SR Ca2+ store depletion (151). STIM1 has 
been demonstrated to sense ER/SR Ca2+ store depletion, form puncta in regions of the 
ER/SR in close apposition to the plasma membrane, form protein interactions with 
several SOC proteins, and be necessary for SOC activation (reviewed elsewhere (117)). 
Previous to this revelation, three major mechanisms linking SR store depletion and SOC 
activation in the plasma membrane: a diffusible second messenger signaling between 
the SR and plasma membrane, vesicle translocation containing SOC, and direct protein 
interaction between a sensor protein and SOC (e.g. STIM1) (reviewed elsewhere (152)). 
At least two SOC have been identified to be activated by STIM1, Orai1 and 
transient receptor potential canonical 1 (TRPC1) (153). STIM1, TRPC1, and Orai1 have 
been shown, in an overexpression model, to form ternary complexes with the putative 
identity of Ca2+ influx channels (154). Additionally, TRPC1-mediated store operated Ca2+ 
entry (SOCE) has been shown to be dependent on Orai1 expression (155), and TRPC1 
expression has been shown to augment Orai1-mediated SOCE (156). While STIM1 and 
Orai1 have been shown to be necessary components for SOCE (153;155;156), there is 
a clear involvement of TRPC1 in SOCE. TRPC1-mediated SOCE is strongly associated 
with smooth muscle proliferation, migration, and in vitro atherosclerosis (reviewed 
elsewhere (157)). As such, it is yet undetermined if SOCE and TRPC1, Orai1, and 
STIM1 play a pivotal role in the development of CAD, especially within the context of 
MetS and diabetes. 
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Major Hypotheses Tested in this Thesis 
1. TRPC1-mediated store-operated Ca2+ entry in coronary smooth muscle is a major 
contributor to the development of native coronary artery disease and stent-induced 
stenosis in metabolic syndrome. 
2. Exercise attenuates TRPC1 expression and function in metabolic syndrome, thereby 
protecting against development of CAD and stent-induced stenosis. 
3. Dyslipidemia is a primary component of metabolic syndrome necessary for the 
development of coronary artery disease and non-alcoholic steatohepatitis and 
synergizes progression to type 2 diabetes. 
4. Ossabaw swine have a genetic propensity towards obesity and metabolic syndrome 
related coronary disease and dysfunction compared to the lean Yucatan swine 
breed. 
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Figure Legends 
Figure 1.1 Coronary artery (wall) anatomy. A Left and right coronary artery ostia 
(openings) originate from the left and right sinuses of Valsalva (bulges of the ascending 
aorta immediately distal to aortic valve). Coronary arteries are primarily apical, residing 
on top of the cardiac muscle, however Ossabaw swine, unlike canine, coronary artery 
branches dive into the cardiac muscle almost immediately after branching. The left 
coronary ostium bifurcates to form the left anterior descending (LAD) and circumflex 
(CFX) arteries. The LAD largely follows the cardiac septum all the way to the apex of the 
heart. Swine are left coronary dominant, meaning the heart apex statuary is the left 
coronary artery. The CFX wraps around the base of the left ventricle just apical to the left 
atrium, while the right coronary artery wraps around the base of the right ventricle, apical 
to the right atrium, until the septum where it abruptly turns towards the apex of the heart. 
B Masson’s trichrome, a standard histological preparation, of a sectioned RCA stains the 
adventitia (primarily collagen) blue and media (primarily smooth muscle) in red. This 
section of RCA is mildly atherosclerotic with a small fibro-fatty lesion (*). C Surrounding 
the lumen of coronary arteries (a), the wall is comprised of three major sections: intima 
(b), media (c), and adventitia (d). Two circumferential fibrous bands composed primarily 
of elastin, the external and internal elastic laminae, form distinct borders between the 
three sections. d Adventitia surrounds the exterior of the artery and is composed 
primarily of collagen fibrils and fibroblasts. c The medial layer is bounded by the internal 
and external laminae and composed primarily of smooth muscle cells. Smooth muscle 
cells (SMC) in healthy arteries are quiescent, proliferating at very low levels, and 
contractile, mediating vessel tone. Intercellular connexins allow movement of small 
molecules and ions between SMC and neighboring endothelial cells (EC). b EC form a 
thin monolayer on the lumenal side of the internal elastic lamina in direct contact with 
blood flowing through the artery. The primary functions of EC are the production of 
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vasoreactive compounds that influence the contractile state of the artery and formation 
of a tight barrier to allow proper blood flow and prevent interaction between blood and 
underlying CSM. 
 
Atherosclerosis is a progressive disease advancing through several stages 
characterized in detail by Starry (illustrated in D, (89)). Monocytes infiltrate the vessel 
wall to scavenge fatty acids and cholesterol that have accumulated between ECs and 
the internal elastic lamina. Lipid-laden monocytes transform to foam cells, contributing to 
the inflammatory response in the vessel wall leading to SMC dedifferentiation, migration 
through the internal elastic lamina, proliferation, and secretion of connective collagen 
and fibrin thus contributing to the building plaque. 
 
Figure 1.2 Progression to type 2 diabetes in humans. Elevated fasting and post-
prandial blood glucose precede the diagnosis of type 2 diabetes. During this 
“prediabetes” stage, insulin resistance and elevated plasma insulin contribute to 
increased pancreatic β-cell work and decreasing function. Hyperinsulinemia drives 
progressively worse hepatic and peripheral insulin sensitivity, while continual stress and 
hyper-production of insulin lead to failed compensatory pancreas insulin production. 
Diagnosis of type 2 diabetes occurs years to decades following onset of prediabetes 
when fasting blood glucose reaches the threshold of 126 mg/dL. Unless dietary, 
exercise, and medical intervention are successful in reversing/minimizing peripheral 
insulin resistance and hyperglycemia, β-cell collapse will ensue resulting in significantly 
diminished insulin production. While insulin production decreases, insulin resistance 
remains elevated leading to worsening hyperglycemia. 
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Figure 1.3 Stent revascularizes stenotic coronary artery in Ossabaw pig. A 
Angiography revealed stenotic lesion in proximal left anterior descending coronary artery 
(arrow). B Intravascular ultrasound (IVUS) image of cross-sectional stenosis 
demonstrates method of IVUS image quantification. C Custom bare metal stent (8-mm 
length, 3-mm diameter) deployed on angioplasty balloon (20-mm length) inflated to 
nominal pressure. D IVUS confirmed stenotic lesion with original lumen diameter of ~3-
mm. E IVUS following stent deployment confirmed revascularization of target lesion to 
optimal diameter. Yellow arrows denote stent struts. 
 
Figure 1.4 Regulation of intracellular Ca2+ in coronary smooth muscle. A 
Ratiometric analysis of Ca2+ handling in coronary smooth muscle (CSM), loaded with 
Ca2+-sensitive fluorescent dye fura-2, that were enzymatically isolated from healthy 
artery. B Basal Ca2+ regulation primarily mediated by Ca2+ pumps in the plasma 
membrane (PM) and sarcoplasmic reticulum (SR). Low-level Ca2+ leak from the SR is 
compensated by sarco/endoplasmic reticulum ATPase (Serca; SERCA). PM Ca2+ flux is 
primarily mediated by plasma membrane Ca2+ ATPase (P; PMCA) and forward mode 
Na+/Ca2+ exchanger (Ncx; NCX), as receptor-operated (R) and voltage-gated (L; L-type) 
Ca2+ channels are active at low levels. Membrane potential is dominated by K+ channel 
activity (K+; reversal potential = ~-90mV in physiological extracellular solution). C High 
extracellular K+ shifts the K+ reversal potential to less negative values, depolarizing the 
membrane potential and activating L-type channels leading to massive Ca2+ influx. NCX, 
PMCA, and SERCA activity increase, but are unable to compensate for L-type-mediated 
Ca2+ influx until high K+ is removed. Upon removal of high K+, cells return to baseline. D 
Caffeine (Caff; 5 mM) and cyclopiazonic acid (CPA; 10-5 M) inhibit SERCA and activate 
ryanodine receptors (Ry) in the SR, leading to massive depletion of the SR Ca2+ store 
into the cell, thus raising intracellular Ca2+. NCX and PMCA mediated Ca2+ efflux return 
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cell to normal intracellular Ca2+ as the SR Ca2+ store remains depleted. Stromal 
interaction molecule 1 (STIM1; S) proteins in the SR membrane sense depletion of the 
SR Ca2+ store and homomultimerize into distinct puncta in regions of the SR in close 
apposition to the PM. E In CSM from metabolic syndrome swine, F STIM1 activates 
store-operated Ca2+ entry leading to elevated Ca2+i. 
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Abstract 
Metabolic syndrome (MetS), a compilation of associated risk factors, increases 
the risk of type 2 diabetes and coronary artery disease (CAD; atherosclerosis), which 
can progress to the point of occlusion. Stents are the primary interventional treatment for 
occlusive CAD and patients with MetS and hyperinsulinemia have increased restenosis. 
The Ossabaw pig is a model of MetS due to its thrifty genotype. We compared Ossabaw 
swine to the widely used Yucatan swine. Each breed was fed two separate diets which 
were calorie matched for normal growth maintenance of Yucatan and divided into two 
groups each for 40 weeks: control chow diet (C) and high fat/cholesterol atherogenic diet 
(H). A bare metal stent was deployed in the circumflex artery and pigs recovered 3 
weeks. Characteristics of MetS, macrovascular and microvascular CAD, and in-stent 
stenosis and coronary smooth muscle Ca2+ signaling were evaluated. Ossabaw swine 
had greater characteristics of MetS, including obesity, glucose intolerance, 
hyperinsulinemia, and hypertension, compared to Yucatan. Ossabaw swine with MetS 
had more extensive and diffuse native CAD and in-stent stenosis and impaired coronary 
blood flow regulation compared to Yucatan. Atherosclerotic lesions in Ossabaw coronary 
arteries were less fibrous and more cellular. Coronary smooth muscle cells from 
Ossabaw had impaired Ca2+ efflux and intracellular sequestration vs. Yucatan cells. 
These comparative studies indicate that Ossabaw swine are a superior model of MetS, 
subsequent CAD, and cellular Ca2+ signaling defects, while Yucatan swine are leaner 
and relatively resistant to MetS and CAD.  
 
Keywords: stent, coronary blood flow, calcium, SERCA, animal model 
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Introduction 
 Atherosclerotic coronary artery disease (CAD) is increased at least 2-fold in 
patients with metabolic syndrome (MetS) (39) and is accompanied by significant 
microvascular dysfunction that further impairs coronary blood flow (158). MetS is 
generally diagnosed by the presence of three or more of the following conditions: 
obesity, insulin resistance, glucose intolerance, dyslipidemia, and hypertension 
(159;160). Complications, including restenosis, thrombosis, and death (34;91;92;94) are 
significantly greater in diabetics following percutaneous coronary revascularization, e.g. 
stenting, (94). This is possibly due to the pervasive, “diffuse CAD” that is a hallmark of 
diabetic CAD and progression of vascular disease in regions adjacent to the stent, i.e. 
“peri-stent” disease (80;86;95). There is strong support for the role of the 
hyperinsulinemia component of MetS in increased restenosis after percutaneous 
coronary interventions (161-164). Further, our group has shown severe coronary 
microvascular dysfunction in MetS (8). Since MetS (“pre-diabetes”) afflicts up to 27% of 
the United States population, is drastically increasing in prevalence (30), and will 
progress to type 2 diabetes, there is an urgent need for basic research performed using 
animal models that accurately mimic MetS and the accompanying CAD. Clearly, there is 
need for study of MetS-induced CAD and in-stent stenosis and the underlying cellular 
and molecular mechanisms. 
Several animal models recapitulate MetS (111-116); however, none are able to 
fully reproduce the combined symptoms of MetS and CAD. Further, transgenic mouse 
models are simply not adequate for coronary vascular interventions using stents 
identical to those used in humans (4;20;21;100;103;165-167), which is essential for 
translation to the clinic. Yucatan and domestic swine are commonly used large animal 
models for study of cardiovascular disease due to their ability to mimic neointimal 
formation and thrombosis observed in humans (103). For example, Gerrity et al. and 
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others produced severe CAD in swine, however this was not due to naturally developing 
MetS or diabetes, but through toxin-induced pancreatic β-cell ablation and atherogenic 
diet (2;9;12;14;17;18;104). Currently, there is a paucity of large animal models that 
reproduce MetS and CAD (115).  
Research on the obesity-prone Ossabaw miniature swine (168) indicates clear 
MetS and cardiovascular disease when fed a high calorie atherogenic diet (3;4;6-8;22-
24;29). Female Ossabaw swine on excess calorie atherogenic diet nearly doubled 
percent body fat in only 9 weeks, showed insulin resistance, impaired glucose tolerance, 
dyslipidemia (profound increase in LDL/HDL cholesterol, hypertriglyceridemia), 
hypertension, and early coronary atherosclerosis (3). These data are in contrast to male 
Yucatan miniature pigs, which did not develop MetS after 20 weeks on comparable 
excess calorie atherogenic diet (1;2;9). Yucatan swine do not develop MetS through diet 
manipulation, unlike Ossabaw swine, which consistently recapitulate all MetS 
characteristics. However, important differences in study design have not allowed direct 
comparison between Yucatan and Ossabaw swine. 
It is clear that cytosolic Ca2+ signaling is involved in "phenotypic modulation" of 
coronary smooth muscle (CSM), characterized by proliferation and migration in several 
in vitro cell culture models (169-172) and in vivo rodent models of the peripheral 
circulation (e.g. (173)). In the Yucatan swine model of diabetic dyslipidemia there is 
altered Ca2+ extrusion (10), Ca2+ sequestration by the sarcoplasmic reticulum 
(13;16;174), and Ca2+ influx through voltage-gated Ca2+ channels (13). Currently, there 
are no direct comparisons of Ca2+ signaling in MetS Ossabaw compared to Yucatan 
swine. 
Therefore, the purpose of this study was to compare male Ossabaw and Yucatan 
pigs on calorie matched standard chow and atherogenic diets (Yucatan maintenance 
diet, e.g. (1;2)). The goal was not to develop morbidly obese pigs, but to test the 
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hypothesis that Ossabaw swine have a greater propensity to MetS and CAD with 
impaired Ca2+ handling in CSM compared to Yucatan swine. 
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Materials and Methods 
Animal care and use. All protocols involving animals were approved by an 
Institutional Animal Care and Use Committee and complied fully with recommendations 
outlined by the National Research Council and American Veterinary Medical Association 
(175;176). Eighteen male Ossabaw swine and 18 male Yucatan were assigned to one of 
four groups: Ossabaw control (Ossabaw C, N=9), Yucatan control (Yucatan C, N=9), 
Ossabaw high fat/cholesterol, atherogenic diet (Ossabaw H, N=9), and Yucatan H 
(Yucatan H, N=9). The control groups from both breeds were fed a calorie-matched diet 
for 43 weeks. The control diet contained 22% kcal from protein, 70% kcal from 
carbohydrates, and 8% kcal from fat. The pigs in the control groups ate 3200 kcal/day 
until sacrifice, which was a standard amount for maintaining lean, normal body growth in 
Yucatan swine (4). The H diet was composed of control chow supplemented with 
(percent by weight): cholesterol 2.0, coconut oil 17, corn oil 2.5, and sodium cholate 0.7. 
This mixture yielded a composition of 13% kcal from protein, 40% kcal from 
carbohydrates and 47% kcal from fat. The animals in the H groups ate 3200 kcal/day 
(calorie-matched the control diet) for 43 weeks until they were sacrificed. All animals 
were housed and fed in individual pens and provided a 12-hr light/12-hr dark cycle. 
Water was provided ad libitum. 
Body composition. Backfat and carcass fat were measured as previously 
described (1;177). Body mass index (BMI) was determined, similar to that in humans 
(178), as body weight in kg divided by the square of the pig’s length from the end of the 
snout to the base of the tail. 
 Intravenous glucose tolerance test. Swine were acclimatized to restraint in a 
specialized sling for 5-7 days before the IVGTT was conducted. Swine were then fasted 
overnight, and anesthetized with isoflurane (maintained at 2% by mask with 
supplemental O2). The right jugular vein was catheterized percutaneously (3;4;179). 
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Following catheterization, swine were allowed to recover for 3 h. before the IVGTT to 
avoid any effect of isoflurane on insulin signaling (9). Conscious swine were restrained in 
the sling and baseline blood samples were obtained. Glucose (0.5 g/kg body weight; i.v.) 
was administered and timed blood samples were collected (9). Blood glucose was 
measured using YSI 2300 STAT Plus Glucose analyzer. Plasma insulin assays were 
performed by Linco Research Laboratories (St. Charles, MO). 
 Plasma lipid assays. Venous blood samples were obtained following overnight 
fasting and were analyzed for triglyceride and total cholesterol [fractionated into high 
density lipoprotein (HDL) and low density lipoprotein (LDL) components]. Cholesterol in 
lipoprotein fractions was determined after precipitation of HDL using minor modifications 
of standard methods (3;180). Specifically, apolipoprotein-B-containing lipoproteins were 
precipitated with heparin-MnCl2 and the supernatant was assayed. LDL was calculated 
from the Friedewald equation: LDL = total cholesterol – HDL – (triglyceride ÷ 5).  
 Stent procedure. After 40 weeks on the diets a bare metal was deployed in the 
circumflex coronary artery of all pigs and then were euthanized after 3 weeks recovery, 
similar to previous reports (4;20;21;29). Swine received 325 mg aspirin as antiplatelet 
therapy starting the day prior to the stent procedure and continuing for the 3 weeks after 
stent deployment. Following an overnight fast, swine received (in mg/kg; IM) 0.05 
atropine, 2.2 xylazine, and 5.5 telazol. Swine were intubated and anesthesia was 
maintained with isoflurane (2-4%, with supplemental O2). The isoflurane level was 
adjusted to maintain anesthesia with stable hemodynamics. Heart rate, aortic blood 
pressure, respiratory rate, and electrocardiographic data were continuously monitored 
throughout the procedure. Under sterile conditions, a 7F vascular introducer sheath was 
inserted into the right femoral artery and heparin (200 U/kg) administered. A 7F guiding 
catheter (Amplatz L, sizes 0.75-2.0; Cordis) was advanced to engage the left main 
coronary ostium. A 3.2F, 30 MHz Intravascular Ultrasound (IVUS) catheter (Boston 
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Scientific) was advanced over a guide wire and positioned in the coronary artery. 
Automated IVUS pullbacks were performed at 0.5 mm/sec. Video images were analyzed 
off-line (Sonos Intravascular Imaging System; Hewlett Packard). The IVUS catheter was 
removed and a coronary stent (2.5-4.0 mm diameter by 8 mm length, Express2; Boston 
Scientific) catheter was deployed. Stents were chosen to match artery diameter at 
optimal inflation pressure. One stent was placed in the circumflex artery (CFX) at 1.0x 
lumen diameter. Angiography and IVUS were repeated to confirm proper stent 
deployment. The IVUS catheter, guide catheter, and introducer sheath were removed 
and the right femoral artery ligated. The incision was closed and the animal was allowed 
to recover. Cephalexin (1000 mg) was given twice a day for six days following the stent 
procedure. 
 Coronary blood flow. The ostium of the left main artery was engaged with the 
guiding catheter and a 0.014-inch diameter Doppler flow wire (JoMed Inc., Rancho 
Cordova, CA) was advanced down the circumflex artery (CFX) (17). After angiography-
aided placement of the flow wire in a non-branching section of the CFX, flow velocity 
signals were allowed to stabilize for several minutes. The analog Doppler signals were 
continuously digitized both as instantaneous peak velocity (IPV) and averaged peak 
velocity (APV) values. Each APV value was calculated on-line as an average of 
instantaneous peak velocity over 2 consecutive cardiac cycles. All flow data were stored 
on videotape and personal computer for further off-line analysis. Data are shown as 
coronary flow reserve, which is the adenosine- or bradykinin-induced flow divided by 
baseline flow velocity.  
 Cell dispersion. The procedure for the isolation of the non-stented right coronary 
artery and the acute enzymatic dispersal of coronary smooth muscle cells has been 
previously described (10;13;16;26;169;174). Arteries were incubated in collagenase 
solution for 45 minutes to disperse endothelial cells, followed by a second period of 30 
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minutes for the smooth muscle cell fraction.  
 Intracellular Ca2+ measurements. Measurements of whole cell intracellular Ca2+ 
levels were obtained at room temperature (22–25°C) using the fluorescent Ca2+ 
indicator, fura-2, and the InCa++ Ca2+ Imaging System (Intracellular Imaging, Cincinnati, 
OH) as previously described by our laboratory (10;13;16;26;169;174).  
Histology. Verhoeff-van Gieson and trichrome staining were performed on 
sections of stented arteries (20;29). Neointima formation was determined by obtaining 
area measurements bounded by the external elastic lamina and internal elastic lamina 
(tunica media) or internal elastic lamina and lumen (neointima) using commercially 
available software (ImagePro 3.0). The percent stenosis was calculated by dividing the 
area of the neointima by the area of the tunica media plus neointima and multiplying by 
100. Collagen content in the sections of the stented arteries was determined by 
colorimetric analysis of trichrome histology. The adventitia, which is composed 
predominantly of collagen, was used as the reference color template against which the 
rest of the section was compared (11;29). 
Assessment of native atheroma. IVUS pullbacks performed during the stenting 
procedure and before stent placement were used to assess native atheroma. 
Measurements were obtained every 2 mm through the length of the artery. Each cross-
sectional IVUS image was divided into 16 equal segments. Percent wall coverage was 
calculated as (# segments containing atheroma ÷ 16) x 100 similar to previous reports 
(6;14;18;29).  
 Statistical analysis. Analyses were performed using commercially available 
software (Prism 4.0). One-way analysis of variance (ANOVA) or 2 x 2 ANOVA with 
student-Newman Keuls or Bonferroni post hoc tests, respectively, were used where 
appropriate. In all tests, p < 0.05 was the criterion for statistical significance. 
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Results  
 To test the hypothesis that Ossabaw swine were MetS-prone a metabolic profile 
was obtained for Ossabaw C and H and Yucatan C and H. Ossabaw C and H groups 
had a greater body weight and body mass index (BMI) than Yucatan C and H at sacrifice 
despite calorie matched diets in all groups throughout the study, (Table 2.1). 
Hyperlipidemic (H) diet increased total cholesterol, LDL, and HDL levels compared to 
control diet (C), although no increases in triglycerides were observed (Table 2.1). While 
systolic and diastolic blood pressure trended towards an increase in Ossabaw, mean 
arterial pressure (MAP) was significantly greater in Ossabaw compared to Yucatan 
swine. 
 To determine if increased adipose tissue was responsible for increased body 
weight and BMI observed in Ossabaw, back fat was measured by ultrasound. Backfat 
was increased in Ossabaw H compared to all groups while Ossabaw C was increased 
compared to Yucatan C and Yucatan H (Figure 2.1A). Ossabaw swine also 
demonstrated significantly greater whole carcass fat as a percent of body weight 
compared to Yucatan (Figure 2.1B), however they were not morbidly obese. 
Concurrently, plasma leptin levels were not increased in Ossabaw compared to Yucatan, 
while plasma leptin was increased in H diet compared to C diet (Figure 2.1C). In a 
subset of Ossabaw pigs fed a very high fat diet (VH) consisting of 75% total calories 
from fat, leptin levels were only 55% greater compared to Ossabaw C (Figure 2.1D). 
This increase is modest compared to Yucatan VH shown previously to have a 130% 
increase in plasma leptin over control Yucatan (1).  
 Hyperglycemia (glucose intolerance) defines diabetes, and is often preceded by 
primary insulin resistance in major target tissues, i.e. skeletal muscle and adipose. Both 
hyperglycemia and insulin resistance are major components of metabolic syndrome 
(MetS) and were assessed in this study using the intravenous glucose tolerance test. 
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After a 0.5 mg/kg bolus glucose injection Ossabaw H had significantly higher blood 
glucose concentrations at 5 and 10 minutes after bolus glucose injection compared to 
Yucatan C, Yucatan H, and Ossabaw C (Figure 2.2A). Further, peak plasma insulin was 
significantly elevated in Ossabaw C, Ossabaw H, and Yucatan H compared to Yucatan 
C. (Figure 2.2C). To evaluate the contribution of breed alone on blood glucose and 
plasma insulin during the IVGTT, we combined C and H groups in each pig breed. 
Ossabaw had significantly greater peak glucose at 5 and 10 minutes, and plasma insulin 
at 10 minutes after bolus glucose injection (Figure 2.2 B&D). Homeostasis model 
assessment (HOMA) is used to diagnose insulin resistance under fasting conditions 
(181). We measured insulin x glucose near the peak (10 minutes after bolus glucose 
injection) during the IVGTT resulting in a modified HOMA value (182). Modified HOMA 
values were significantly greater in both Ossabaw C and Ossabaw H compared to 
Yucatan C and Yucatan H (Figure 2.2E). When C and H diets are combined in each 
breed, we observed significantly greater modified HOMA values in Ossabaw over 
Yucatan (Figure 2.2F).  
 Microvascular dysfunction is a major characteristic of MetS (158). We assessed 
coronary microvascular function in Ossabaw and Yucatan swine by measuring blood 
flow velocity and calculating coronary flow reserve (CFR) in response to bradykinin and 
adenosine, two well characterized vasodilators of coronary vasculature (17). Placement 
of the flow wire in the circumflex artery is show in Figure 2.3A. CFR to adenosine was 
impaired in Ossabaw compared to Yucatan (Figure 2.3B). Additionally, endothelial cell 
dysfunction in response to bradykinin was apparent in Ossabaw compared to Yucatan 
(Figure 2.3C). 
One hallmark of MetS CAD is diffuse atherosclerosis (95), which we assessed by 
measuring neointimal formation in proximal, intermediate, and distal segments of the left 
anterior descending (LAD) and circumflex (CFX) coronary arteries highlighted in a 
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coronary angiogram (Figure 2.4A) and schematic (Figure 2.4B) preceding stent 
placement. Atheroma was quantified by measuring the percent of the artery wall with 
neointimal formation demonstrated in Figure 2.4C in which a calcified lesion covers 15% 
of the cross-section of the coronary wall. Yucatan H had elevated atherosclerosis in the 
proximal segment, but was indistinguishable from Ossabaw and Yucatan C through the 
intermediate segment. Importantly, Ossabaw H remained elevated through all segments 
measured, demonstrating MetS Ossabaw swine develop diffuse CAD while Yucatan 
swine do not (Figure 2.4D). 
 Swine have been touted as the “ideal” model for studying stent efficacy 
(100;103;166;167), but recent clinical studies with complications not predicted in 
preclinical swine experiments suggest a better model is needed (183;184). Therefore, 
we tested the hypothesis that hyperinsulinemic Ossabaw swine have a propensity to 
increased in-stent CAD compared to Yucatan. Figure 2.5A is a coronary angiogram 
immediately before stent expansion. Figure 2.5B is a coronary angiogram during stent 
expansion with radio-opaque dye within the inflated balloon. Verhoeff’s elastin (Figure 
2.5 C&D), hematoxylin and eosin (Figure 2.5 E&F), and trichrome collagen (Figure 2.5 
G&H) stains were used to characterize in-stent CAD and stenosis in Ossabaw and 
Yucatan swine. All swine were allowed to recover three weeks following stent 
placement. In-stent neointimal hyperplasia was 2.5-fold greater in Ossabaw compared to 
Yucatan, regardless of diet (Figure 2.5I). Ossabaw also exhibited increased cells per 
mm2 (Figure 2.5J) and decreased in-stent collagen content (Figure 2.5K) compared to 
Yucatan in-stent neointima. Thus, in-stent neointima of Ossabaw swine is more 
occlusive, less fibrous, and more cellular compared to Yucatan. Histological evaluation 
of the neointima of non-stent artery segments, revealed percent collagen was greater in 
Yucatan than in Ossabaw, with diet having no significant effect (Figure 2.5L), while 
cellularity was not changed (data not shown). CAD in non-stent segments proximal to 
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the stent and immediately adjacent to the stent, i.e. peri-stent, quantified with IVUS is 
shown in Figure 2.6. The most striking results were the ~5-fold greater peri-stent CAD in 
Ossabaw C compared to Yucatan C pigs and increases in peri-stent CAD after 
atherogenic diet.  
  We previously reported that intracellular Ca2+ signaling events are altered in 
coronary arteries with atherosclerotic lesions (6;10;13;16-18;174). High extracellular 
potassium (High K+, 80 mM) depolarizes the cell membrane activating voltage-gated 
Ca2+ channels in coronary smooth muscle (CSM) leading to Ca2+ influx and a rise in 
intracellular Ca2+ levels (Figure 2.7A). High K+ application also maximally loads the 
sarcoplasmic reticulum (SR) Ca2+ store. The area under the curve of the High K+ 
response was not different between Yucatan C and Ossabaw C (Figure 2.7B). 
Subsequent to SR Ca2+ release by caffeine, intracellular Ca2+ levels initially rise 
transiently, then fall over time due to Ca2+ extrusion (efflux) and sequestration 
mechanisms (Figure 2.7A). Baseline-subtracted peak Ca2+ response to caffeine was not 
different between Yucatan C and Ossabaw C (Figure 2.7C). Overall buffering of 
intracellular Ca2+ was measured as time from peak Ca2+ response to caffeine to ½ the 
initial baseline. Ossabaw C CSM displayed increased time to ½ minimum from peak 
Ca2+ response to caffeine compared to Yucatan C in Ca2+-containing and Ca2+-free 
solution (Figure 2.7D), thus providing evidence for decreased Ca2+ efflux in Ossabaw C 
compared to Yucatan C. CSM from peri-stent and non-stent artery segments of Yucatan 
C, Yucatan H, Ossabaw C, and Ossabaw H were assessed for sarcoplasmic reticulum 
(SR) / endoplasmic reticulum Ca2+ ATPase (SERCA) function. CSM were depolarized 
with High K+ to load the SR (Figure 2.8A). SR Ca2+ release was elicited by application of 
endothelin-1 (ET-1, 30 nM), while thapsigargin (TG, 1μM) prevented Ca2+ uptake into the 
SR by blocking SERCA. SERCA buffering of Ca2+ was assessed by the effect of full 
SERCA inhibition by thapsigargin on the peak Ca2+ response to ET-1. SERCA buffering 
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of Ca2+ was not involved in Ca2+ response to ET-1 in Yucatan C in either peri- or non-
stent CSM (Figure 2.8 B&C). SERCA significantly contributed to buffering ET-1 
released Ca2+ in CSM from non-stent Yucatan H segments as evidenced by increased 
peak Ca2+ response to ET-1 with application of TG (Figure 2.8D). In other words, 
SERCA function was increased in native atherosclerotic arterial segments. Importantly, 
peri-stent CSM from Yucatan H have SERCA dysfunction, because the peak Ca2+ 
response to ET-1 is similar to non- and peri-stent with full inhibition of SERCA by TG. 
Ossabaw C CSM from non- and peri-stent segments have increased SERCA function 
evidenced by increased peak Ca2+ response to ET-1 in the presence of TG (Figure 
2.8E). Incredibly, SERCA function is virtually non-existent in CSM from Ossabaw H non- 
and peri-stent as peak Ca2+ response to ET-1 is elevated in the absence of TG (Figure 
2.8F). In summary, SERCA function in the buffering of peak Ca2+ response to ET-1 
transitions of from increased SERCA function in mild CAD through dysfunction in more 
severe CAD.  
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Discussion 
 The major findings of this study are that Ossabaw swine compared to Yucatan 
have: 1) greater in 4 metabolic features of MetS, 2) coronary microvascular dysfunction 
in response to adenosine (primarily smooth muscle mediated) and bradykinin 
(endothelial mediated), 3) significantly greater native atheroma, diffuse atheroma, in-
stent neointimal hyperplasia, and peri-stent atheroma, 4) less fibrous and more cellular 
atherosclerotic lesions within non-stented and stented segments of coronary artery, and 
5) impaired coronary smooth muscle intracellular Ca2+ buffering and efflux following Ca2+ 
release from the sarcoplasmic reticulum. This is the first study to directly compare 
multiple symptoms of the MetS, CAD, and in-stent restenosis between Ossabaw swine 
and Yucatan fed calorie matched control chow and high fat/cholesterol atherogenic diet.  
 Phenomenal work has been done on transgenic and gene ablation (knockout) 
mouse models (e.g. (113)) and summarized recently from work of the Animal Models of 
Diabetic Complications Consortium (AMDCC) (116) to understand mechanisms of 
obesity and MetS. However, transgenic mouse models are simply not adequate for 
vascular interventions using stents identical to those used in humans 
(4;20;21;100;103;165-167), which is essential for translation to the clinic. Since the 
Ossabaw miniature swine model of MetS also develops mature, clinically significant 
atheroma (24), there is potential to improve vastly over all other stenting studies that 
employed injury of healthy arteries (100;103;166;167).  
 A primary advantage of Ossabaw miniature swine use in research is the 
predisposition to obesity and natural occurrence of MetS and progression to type 2 
diabetes, which is unique for the Ossabaw. Table 2.2 compares the major features of 
MetS (items 1-6) present (Yes) or not (No) in Yucatan vs. Ossabaw miniature swine and 
their utility as cardiovascular disease models and comparison of Ca2+ signaling (items 7-
12). The Yucatan is our comparison because of our extensive, ~20 years of work with 
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this genetically leaner pig that is the predominantly used miniature swine for laboratory 
research. Relatively mild differences in metabolic parameters (e.g. body mass index, 
hyperglycemia, hyperinsulinemia, and hypercholesterolemia) were induced by 
atherogenic diet feeding compared to previous reports in Ossabaw and Yucatan swine 
(summary in Table 2.2). This was a direct result of our study’s aim to sensitively 
measure breed differences by calorie matching C and H diets to that required for 
maintenance of normal body weight in adult Yucatan swine, rather than inducing 
maximal MetS by overfeeding the H groups. Rigorous comparison shows much greater 
propensity to obesity, i.e. “thriftiness” of Ossabaw compared to Yucatan. Increased back 
and carcass fat were noted in Ossabaw H vs. C, but no increase in Yucatan H vs. C 
(Figure 2.1 A&B).  
In healthy humans, leptin limits the accumulation of ectopic fat accumulation, 
whereas in obese humans, leptin levels rise and the body develops leptin insensitivity. 
Leptin insensitivity leads to ectopic lipid accumulation, in turn contributing to insulin 
insensitivity (185). Although Ossabaw H have greater backfat and carcass fat compared 
to Yucatan H, plasma leptin was similarly and modestly elevated in Ossabaw H and 
Yucatan H above their respective control. Lending support to this idea are our previously 
published data, which revealed hypercaloric H fed Yucatan had an 84% increase in 
leptin above Yucatan H in this study ( (1), Figure 2.1C). In contrast, hypercaloric H fed 
Ossabaw (VH) only displayed an 11% increase in plasma leptin above Ossabaw H 
(Figure 2.1 C&D), although VH were much more obese (data not shown). This suggests 
Ossabaw pigs may have a relatively deficient (blunted) leptin response to increased 
adipose, which may in part explain increased weight gain which contributes to metabolic 
syndrome, a situation strikingly similar to leptin deficiency, obesity, and MetS in humans 
(186). In summary, Ossabaws clearly show greater propensity to obesity than Yucatans 
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and direct measures show a greater accumulation of visceral fat on rigorously controlled 
experimental diets.  
Despite intensive efforts to induce insulin resistance and glucose intolerance in 
Yucatan swine on high fat, high cholesterol, and high sucrose diets, we have found that 
currently available Yucatan pigs do not naturally develop obesity-associated insulin 
resistance ( (9;111;187;188); Table 2.2, items 2, 3). In contrast, Ossabaw swine fed a 
high caloric diet display a natural pathogenesis of MetS with hyperinsulinemia and 
eventual progression to type 2 diabetes, as evidenced by significantly increased fasting 
blood glucose. Other miniature swine breeds currently available for laboratory animal 
medicine, i.e. Yucatan and Gottingen, do not progress to type 2 diabetes (e.g. 
(9;111;189)). Gottingen pigs (110;189-191), however, will develop mild MetS. Although 
outstanding work shows that a line of crossbred domestic pigs with familial 
hypercholesterolemia will develop MetS (115), use of the standard sized domestic swine 
is not practical because they weigh >250 kg and are 2 years of age before type 2 
diabetes occurs. A 250 kg pig is not amenable to use of conventional angiography 
instrumentation needed for stent deployment compared to the convenient small stature 
of Ossabaw miniature swine (Table 2.2, item 8; see below). Dyslipidemia of Yucatan 
and Ossabaw was comparable in the present study (Table 2.2, items 4, 5), but other 
studies using hypercaloric diets showed robust increases LDL/HDL ratio and 
triglycerides in Ossabaws. Genetically leaner Yucatan pigs made mildly obese and 
hyperlipidemic by consumption of excess calorie atherogenic diet did not become 
hypertensive ((2;9;10), Table 2.2, item 6). In contrast, in all of our chronic studies of 
hypercaloric feeding Ossabaw swine hypertension was a clear finding, thus indicating 
MetS. Convincing evidence for “obesity hypertension” (192) is the robust, 5-fold 
increases in plasma renin and aldosterone in Ossabaw swine (193).  
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In the current study, we show mild MetS in Ossabaw swine increases CAD. 
Although Ossabaw H and Yucatan H have similar levels of CAD in proximal segments, 
Ossabaw H, the only group to exhibit elevated peak glucose in response to glucose 
tolerance test, have diffuse atherosclerosis, a hallmark of patients with diabetes 
((80;86;95); Table 2.2, item 7). This difference in CAD between Yucatan and Ossabaw 
is especially striking considering the modest metabolic differences.  
  MetS patients have increased incidence of CAD (39), and those presenting with 
flow-limiting coronary occlusions are primarily treated by stent deployment. Drug eluting 
stents have significantly reduced restenosis rates; however, restenosis is still a major 
concern when treatment is complicated by diffuse and severe atheroma which 
progresses much more aggressively in regions adjacent to the stent (“peri-stent” CAD) 
(80;86;95). Ossabaw swine, which we show have 6 features of MetS (Table 2.2), have 
increased peri- and in-stent CAD (Figures 2.5 and 2.6) compared to Yucatan. 
Interestingly, pig breed, but not diet, is associated with increased in-stent stenosis. This 
differs from non-stent segments in that only the combination of the Ossabaw breed and 
high fat/cholesterol atherogenic diet elicited diffuse atherosclerosis. These findings 
suggest factors key to Ossabaw swine CAD drive the greater peri- and in-stent CAD 
compared to Yucatan swine, including possibilities such as: 1) other MetS milieu 
components not measured in our study, 2) other inflammatory mediators, or 3) other 
genetic components beyond the thrifty genotype, e.g. vascular wall differences, that 
render coronary arteries more sensitive to stenting. The most likely difference, however, 
is hyperinsulinemia, which was present in Ossabaw compared to Yucatan. Although 
some reports indicate no greater coronary restenosis in MetS compared to non-MetS 
patients (194), there is strong support for the role of the hyperinsulinemia component 
MetS in increased restenosis after percutaneous coronary interventions (161-164). 
Especially compelling support for the role of hyperinsulinemia is the study of Takagi et 
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al. (163) showing serial intravascular ultrasound measures of coronary restenosis in 
humans.  
One possibility for underlying mechanisms of greater CAD and in-stent 
neointimal hyperplasia in MetS is the coronary smooth muscle cell (CSM), the 
predominant cell type in atherosclerotic tissue (195). Mechanisms underlying CAD and 
vascular response to injury are not completely understood, but we and others have 
reported altered CSM Ca2+ signaling is involved in diabetic CAD 
(10;13;14;16;18;29;174;196). Intracellular free Ca2+ concentration is determined by three 
major mechanisms: Ca2+ influx, Ca2+ extrusion, and intracellular Ca2+ sequestration by 
the sarcoplasmic reticulum (SR). Important observations in this study include no 
difference in Ca2+ influx in response to depolarizing extracellular solution (Figure 2.7B; 
quantifies mainly voltage-gated Ca2+ channel activity in plasma membrane (13;16)) or 
peak Ca2+ in response to caffeine treatment (Figure 2.7C; quantifies SR Ca2+ store 
(26;197;198)) between Ossabaw and Yucatan swine. In the presence and absence of 
extracellular Ca2+, increased time to ½ minimum in response to caffeine indicates 
decreased Ca2+ extrusion across the plasma membrane (Ca2+ efflux (13;26)) in 
Ossabaw CSM vs. Yucatan (Figure 2.7D). Importantly there was no difference in time to 
½ minimum despite the presence or absence of extracellular Ca2+ for either breed 
(Figure 2.7D), suggesting store-operated Ca2+ entry (SOCE) was not a major factor. 
The lack of SOCE in Ossabaw CSM may appear to contradict recently published 
results from our laboratory (Edwards et al. (29)) implicating the SOCE channel transient 
receptor potential classical 1 (TRPC1) in MetS- and stent-induced CAD in Ossabaw 
swine (29). However, an important difference in Edwards et al. (hypercaloric atherogenic 
diet) is the induction of robust MetS and severe CAD compared to the relatively mild 
MetS and CAD induced in this study. The finding of this study that SOCE is not evident 
in Yucatan CSM confirms previous reports by our laboratory (e.g. (27;28)), although we 
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have observed robust SOCE in endothelial cells (199). Interestingly, sarcoplasmic 
reticulum/endoplasmic reticulum Ca2+ ATPase (SERCA) does not influence the peak 
response to endothelin-1 (ET-1) in CSM from Yucatan C non- and peri-stent (Figure 
2.8C). The Ca2+ response is maintained at normal levels with increased SERCA function 
in both non- and peri-stent Ossabaw C CSM (Figure 2.8E), compared to Yucatan C. 
SERCA function increases in CSM from Yucatan H non-stent with maintained peak 
response compared to Yucatan C, but Yucatan H peri-stent CSM are unable to maintain 
peak response despite increased SERCA function (Figure 2.8D). Incredibly, SERCA is 
virtually non-functional in CSM from Ossabaw H non- and peri-stent (Figure 2.8F), as 
assessed by peak response to ET-1 with or without TG. 
  Complex and unstable plaque formation lead to increased risk of thrombosis 
(200), resulting in acute myocardial infarction. We have observed more than 500 
Yucatan coronary arteries without documenting calcified coronary lesions, however 
Ossabaw coronary arteries contain calcified lesions as shown in Figure 2.3C 
(references in Table 2.2). Previously published data demonstrated collagen-rich 
atherosclerotic tissue in restenotic specimens was greater in humans with diabetes than 
in non-diabetic patients (201). In contrast, we show a 34-fold greater increase in percent 
collagen in stented segments in Yucatan compared to Ossabaw. One possible 
explanation is that the atherosclerotic tissue in the human study is more mature, 
whereas the atherosclerotic tissue in our study is in early stage of progression which is 
characterized by less stable plaque formation. The complex (highly cellular, calcified, 
and less fibrous) neointimal composition observed in stented segments of Ossabaw 
coronary artery suggests a complex, mature, proliferative, and/or lipid-laden 
composition; thus potentially more vulnerable plaque rupture. 
 Ossabaw swine were used as a laboratory animal model almost 40 years ago 
(168) and may be more relevant now than ever due to the increasing incidence of MetS 
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and type 2 diabetes in western society (30). Ossabaw swine remarkably mimic MetS and 
advanced CAD observed in humans and serve as an excellent large animal model for 
study metabolic abnormalities and coronary artery disease in the future.  
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Figure Legends 
Figure 2.1 Body fat is greater in Ossabaw swine and leptin increase is blunted 
compared to Yucatan on calorie-matched diets. A Backfat measured by ultrasound at 
5th rib. *p < 0.05 Ossabaw C vs. all other groups, **p<0.05 Ossabaw H vs. all other 
groups. B Percentage of carcass as fat measured by direct chemical analysis. *p < 0.05 
Ossabaw H vs. all other groups. C Plasma leptin is increased similarly by H diet in both 
Ossabaw and Yucatan. *p < 0.05 H vs. C. D Plasma leptin is increased in a subset of 
Ossabaw fed a very high (VH) fat diet consisting of 75% of kcal from fat. *p < 0.05 
Ossabaw C vs. VH.  
 
Figure 2.2 Ossabaw swine are glucose-intolerant and insulin-resistant compared 
to Yucatan. Intravenous glucose tolerance test (IVGTT) in Yucatan and Ossabaw swine 
was initiated by infusion of 0.5 g glucose/kg body weight at time 0. A Time course of 
blood glucose responses in Yucatan C (filled circles), Yucatan H (open circles), 
Ossabaw C (filled triangles), and Ossabaw H (open triangles), * indicates Ossabaw H 
greater than all groups. B Combined C and H diets to compare glucose in breeds. C 
Simultaneous measurement of insulin responses during IVGTT, * indicates all groups 
greater than Yucatan C. D Combined C and H diets to compare insulin between breeds. 
E Ossabaw C and H have greater insulin x glucose at near peak (10 minutes) during 
IVGTT than Yucatan C and H. F Combined C and H diets to compare insulin x glucose 
at peak (10 minutes). A-D: *p < 0.05 by two-way repeated measures ANOVA with SNK 
post-hoc analysis. E-F: *p < 0.05 by 2x2 ANOVA.  
 
Figure 2.3 Ossabaw swine exhibit coronary microvascular dysfunction compared 
to Yucatan. A Coronary schematic illustrates flow wire positioning in circumflex artery 
(from right anterior oblique view) and downstream microvasculature. B Ossabaw 
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coronary flow reserve is reduced in response to adenosine compared to Yucatan swine. 
C Ossabaw swine exhibit endothelial dysfunction compared to Yucatan swine in 
response to bradykinin. * p < 0.05 by two-way ANOVA with Bonferroni post-test. 
 
Figure 2.4 Diffuse atherosclerosis is prominent in Ossabaw compared to Yucatan. 
A Angiogram of left coronary arteries with circumflex (CFX) and left anterior descending 
(LAD) arteries labeled. B The most proximal segment (Proximal) is defined as 0 to 10 
mm from the bifurcation of the LAD and CFX arteries. The middle segment 
(Intermediate) is defined as 20 to 30 mm from the bifurcation of the LAD and CFX. The 
most distal segment (Distal) is defined as (x-10 mm) to x mm where x is the most distal 
measurement of the intravascular ultrasound (IVUS) pullback. The right coronary (RC) 
artery shown here for completeness is not shown in the angiogram. IVUS recordings 
were acquired to assess native atheroma before stent placement as in Figure 6B. C 
IVUS image showing 15% wall coverage by calcified neointimal formation. Calcification 
is identified by signal dropout peripheral to the IVUS imaging transducer and is 
highlighted by dotted lines. D Native atheroma coverage of the artery wall as a 
percentage of the artery wall area (% wall coverage) is graphed along three segments of 
the CFX coronary artery. Each segment represents 10 mm of the CFX artery. 
Measurements of % wall coverage were taken every 2 mm. *p < 0.05 H vs. C; † p < 0.05 
Ossabaw H vs. Yucatan H. 
 
Figure 2.5 In-stent stenosis is greater in Ossabaw compared to Yucatan. A 
Coronary angiogram in right anterior oblique 30° view prior to stent deployment and B 
during stent deployment. C Representative VVG stain of Yucatan C in-stent CAD. D 
Representative VVG stain of Ossabaw C in-stent CAD illustrating adventitia (A), 
neointima (Neo), media (M), lumen (L), pre-stent lumen border (dotted line), and post-
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stent lumen border of neointimal hyperplasia (dashed line). E Image of hematoxylin and 
eosin stained cell nuclei in Yucatan and F Ossabaw neointima. G&H Histology using 
Masson’s trichrome collagen staining (blue). Open spaces to the left and below NEO are 
from stent struts that were removed in sectioning. I Percent cross-sectional area 
stenosis calculated by histology is greater in Ossabaw C and H than Yucatan C and H, 
with no effect of atherogenic diet (H). J Ossabaw C and H have greater cell nuclei/unit 
area than Yucatan C and H. K Percent collagen in neointima area of in-stent and L non-
stent artery segment. * p < 0.05 Ossabaw vs. Yucatan; † p < 0.05 C vs. H diet.  
 
Figure 2.6 Peri-stent coronary artery disease is greater in Ossabaw compared to 
Yucatan and hyperlipidemia increases proximal non-stent and peri-stent coronary 
artery disease. A&B Representative IVUS images of Yucatan (A) and Ossabaw (B) 
peri-stent CAD. Solid and dotted lines show partial boundaries of lumen with neointima 
and neointima with echolucent media, respectively, used to calculate neointimal area 
and percent stenosis. White arrow in B illustrates IVUS guidewire artifact. C 
Hyperlipidemia increases both proximal non-stent and peri-stent CAD in Yucatan. D 
Peri-stent disease increased in Ossabaw H vs. C and vs. respective Yucatan C and H.. 
Group differences assessed by two-way ANOVA with Bonferroni post-test. 
 
Figure 2.7 Dysfunctional Ca2+ efflux in Ossabaw vs. Yucatan coronary smooth 
muscle. A Duration of exposure to solutions is shown by horizontal lines. 
Representative Ca2+ tracing (fura-2 ratio) demonstrates Ca2+ influx response to 80 mM 
K+ depolarizing solution (High K+), peak Ca2+ response to caffeine (Caff, 5 mM), and time 
to half minimum from caffeine-induced Ca2+ peaks. B Integral of the intracellular Ca2+ 
response to depolarizing solution (High K+, 80 mM extracellular) is not different between 
Ossabaw control (C) and Yucatan C CSM. C Peak Ca2+ response to caffeine is not 
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different between Yucatan and Ossabaw CSM. D Time to ½ minimum from peak is 
increased in Ossabaw C CSM compared to Yucatan C. 
 
Figure 2.8 Sarco/endoplasmic reticulum Ca2+ ATPase Ca2+ buffering function 
progresses from increased function to virtually complete dysfunction with 
severity of CAD. A Duration of exposure to solutions is shown by horizontal lines. 
Representative Ca2+ tracing (fura-2 ratio) in Yucatan H demonstrates Ca2+ influx 
response to 80 mM K+ depolarizing solution (High K+) and peak Ca2+ response to 
endothelin-1 (ET-1, 30 nM) in coronary smooth muscle (CSM) cells in the presence 
(black tracing) or absence (gray tracing) of thapsigargin (TG, 1μM). B Coronary artery 
schematic illustrates non-stent and peri-stent segments from which CSM cells were 
dispersed. C SERCA function does not alter peak Ca2+ response to caffeine in CSM 
from lean, healthy Yucatan C. D TG inhibition of SERCA in Yucatan H CSM reveals 
increased role of SERCA in attenuating the ET-1 induced increase in intracellular Ca2+ in 
non- and peri-stent CSM. E SERCA attenuates peak Ca2+ response to ET 1 in Ossabaw 
C CSM. F SERCA function is inhibited in Ossabaw H CSM. 
     
 
Table 2.1 
  Yucatan C Yucatan H Ossabaw C Ossabaw H 
p < 
0.05 
Body weight (kg) 59 ± 2 58 ± 3 74 ± 2 76 ± 2 Y<O 
Starting BMI (kg/m2) 32 ± 1 34 ± 1 28 ± 1 28 ± 1 Y>O 
End BMI (kg/m2) 38 ± 1 38 ± 3 47 ± 6 45 ± 1 Y<O 
Total cholesterol (mg/dL) 52 ± 4 420 ± 72 62 ± 3 338 ± 28 C<H 
HDL (mg/dL) 30 ± 3 60 ± 10 34 ± 1 75 ± 9 C<H 
LDL (mg/dL) 14 ± 3 351 ± 76 20 ± 4 255 ± 29 C<H 
Triglycerides (mg/dL) 38 ± 6 41 ± 6 19 ± 3 41 ± 7 None  
Systolic blood pressure  
(mm Hg) 77 ± 4 79 ± 9 88 ± 7 91 ± 3 None 
Diastolic blood pressure 
(mm Hg) 48 ± 3 54 ± 1 59 ± 8 56 ± 3 None 
Mean arterial pressure  
(mm Hg) 
57 ± 4 62 ± 1 68 ± 7 67 ± 3 Y<O 
Heart wt./ Body wt.  
 
0.0039 ± 
.00012 
0.00436 ± 
.00023 
0.0031 ± 
.0001 
0.003 ± 
.00006 Y>O 
Coronary artery diameter 
(mm) 2.7 ± 0.1 2.5 ± 0.1 2.3 ± 0.3 2.3 ± 0.1 Y>O 
Table 2.1. Phenotypic characteristics of Yucatan and Ossabaw swine fed control chow (C) or high fat/cholesterol (H) 
atherogenic diet. BMI = body mass index; wt. = weight; Y = Yucatan swine; O = Ossabaw swine. 
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Table 2.2 
 
Characteristic Yucatan Ossabaw References, Figures and Table 2.1 
1.  Obesity No Oss>Yuc  (1-8); Table 2.1, Figure 2.1 
2.  Insulin resistance No Yes  (3;4;7-10); Figure 2.2 
3.  Glucose intolerance (or 
impaired glucose tolerance, 
[IGT]) 
No Yes  (1-4;4;6-13); Figure 2.2 
4.  Dyslipidemia (↑LDL/HDL or 
↑LDL/TC) 
Yes Yes  (3;4;7;8;11;13-15); Table 2.1 
5.  Dyslipidemia (↑ triglycerides) No Yes  (1;3;4;7;8;10-12;15;16) 
6.  Hypertension  No Yes  (3;4;9); Table 2.1 
7.  Cardiovascular disease, 
atherosclerosis  
Yes Yes  (3;4;4;6;8;11;12;17-24); Figures 2.3-2.6 
8.  Small stature  Yes Yes  (1-4;25); Table 2.1 
9.  Other – vascular calcification, 
AMP kinase alleles  
No Yes  (23;24); Figure 2.3 
10.  CSM Ca2+ efflux dysfunction Yes Oss>Yuc  (13;26); Figure 2.7 
11.  CSM SERCA dysfunction Yes Oss>Yuc  (13;16); Figure 2.8 
12.. CSM store-operated Ca2+ 
entry 
No Yes  (27-29); Figure 2.8  
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Table 2.2 Brief review of Ossabaw and Yucatan metabolic disease and Ca2+ regulation. Oss = Ossabaw swine; Yuc = Yucatan 
swine; AMP = 5′ adenosine monophosphate -activated protein; CSM = coronary smooth muscle; SERCA = sarco/endoplasmic 
reticulum ATPase; TC = total cholesterol; LDL = low density lipoprotein; HDL = high density lipoprotein.  
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Figure 2.1 
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Figure 2.2 
 
  52 
Figure 2.3 
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Figure 2.4 
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Figure 2.5 
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Figure 2.6 
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Figure 2.7 
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Abstract 
Risk of coronary artery disease (CAD) is increased in patients with metabolic 
syndrome (MetS) and non-alcoholic steatohepatitis (NASH); however, the relative 
importance of each component of MetS (i.e. obesity, insulin resistance, glucose 
intolerance, dyslipidemia, hypertension) remains controversial. We hypothesized that 
occlusive and complex CAD and NASH are primarily driven by dyslipidemia within the 
MetS milieu and that all other components of MetS combined are not sufficient. 
Ossabaw swine were fed standard chow (Lean; N=16), chow with fructose (FMetS; 
N=9), trans-fat/cholesterol/fructose (TMetS; N=14), or mixed-source 
fat/cholesterol/fructose (MMetS; N=6) for 22-24 weeks. FMetS developed MetS without 
dyslipidemia. TMetS, and to a greater extent MMetS, developed MetS that included the 
dyslipidemia component. Lean demonstrated mild CAD and no NASH. Although FMetS 
developed MetS CAD and NASH were virtually non-existent. CAD and liver disease 
were directly related to dyslipidemia in MetS, with TMetS showing fatty/fibrous atheroma 
and MMetS progressing to stenotic, diffuse, and complex CAD and NASH. Total 
monounsaturated/polyunsaturated fatty acid ratio and fatty acid metabolism enzyme 
indices were associated with CAD and NASH, however LDL-gram years most reliably 
predicted CAD and NASH. Thus, dyslipidemia was a necessary component of MetS for 
eliciting severe CAD and NASH in swine that superbly mimic human pathologies. 
 
Keywords: Ossabaw miniature swine, intravascular ultrasound, fatty acid methyl ester, 
coronary artery disease, non-alcoholic steatohepatitis 
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Introduction 
Patients with metabolic syndrome (MetS; “pre-diabetes”) have a 3- to 4-fold 
increase in the risk of coronary artery disease (CAD) (39). There are several striking 
features of MetS CAD; in particular, pervasive, “diffuse CAD” is a hallmark of diabetic 
CAD (80;86;95). MetS also increases plaque cellularity, instability, inflammation, and 
calcification compared to non-diabetic patients (82;202). Generally, the presence of 
three or more of the following risk factors renders a diagnosis of MetS (159;160): 
obesity, insulin resistance, glucose intolerance, increased proportion of low-density 
lipoprotein (LDL) cholesterol, decreased high-density lipoprotein (HDL) cholesterol, 
increased LDL:HDL ratio, increased triglycerides, and hypertension (159;160). However, 
it is not clear whether any individual component, specifically dyslipidemia, provides the 
principal driving mechanism in developing CAD and associated diseases.  
MetS and CAD are strongly associated with non-alcoholic fatty liver disease 
(NAFLD), one of the most common chronic liver diseases (41;56-58). NAFLD is benign 
when presented as simple steatosis, however non-alcoholic steatohepatitis (NASH), a 
progressive form of NAFLD, can lead to advanced fibrosis, cirrhosis, and liver failure 
(41;56-58). Approximately 30% of U.S. adults have NAFLD, while up to 25% of those 
patients have progressed to NASH (42;62). Importantly, patients with NASH have 
increased risk of death from cardiovascular disease (63), such that death from coronary 
disease exceeds even that of liver cirrhosis in NASH (64). 
Despite the growing need for preclinical models of MetS and CAD, no animal 
model of MetS has ever demonstrated diffuse, stenotic, calcified, or complex coronary 
artery lesions. Gerrity et al. and others have demonstrated profound coronary 
atherosclerosis in streptozotocin-induced diabetic hyperlipidemic swine, but never 
without pancreatic β-cell ablation (104;106;203). Our laboratory has characterized the 
Ossabaw miniature swine model which faithfully replicates many of the human 
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characteristics of MetS when fed excess calorie atherogenic diet (3;4;6-8;29), including 
hypertension, obesity, insulin resistance, glucose intolerance, elevated LDL cholesterol 
and LDL:HDL ratio, and hypertriglyceridemia. Lee et al. utilized a modified atherogenic 
diet supplemented with fructose, trans-fatty acids, and lard in Ossabaw swine and 
observed severe MetS with accompanying NASH (7), the first report of NASH in a large 
animal model of MetS induced by atherogenic diet.  
 Utilizing the only model of MetS that develops severe NASH and CAD, we 
focused on and eliminated dyslipidemia, while retaining all other major components in 
the MetS milieu. This experimental design provided a unique opportunity to test the 
hypothesis that dyslipidemia is the primary component of the complex MetS milieu 
necessary for the induction of NASH and CAD.  
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Results 
Lipids and integrated cardiovascular phenotype (Table 3.1). In Ossabaw swine, a 
hypercaloric chow diet supplemented with fructose produced MetS (FMetS). Additionally, 
supplementation with fat/fructose/cholesterol also produced MetS in TMetS and MMetS, 
while the source of fat (i.e. trans-fat versus trans- and saturated fat) dictated the severity 
of the phenotype. Body weight was significantly higher in FMetS, TMetS, and MMetS 
compared to Lean. FMetS, TMetS, and MMetS heart rates were increased over Lean, 
with MMetS being greater than FMetS and TMetS. Dyslipidemia was apparent in TMetS 
and MMetS as total cholesterol, HDL, LDL, LDL:HDL ratio, and triglycerides were all 
elevated compared to Lean and FMetS. FMetS were not dyslipidemic as defined by total 
cholesterol and LDL not being different from Lean, although LDL:HDL ratio was 
significantly increased, due to decreased HDL cholesterol compared to Lean. In addition, 
total cholesterol, LDL cholesterol, LDL:HDL ratio, and triglycerides were higher in MMetS 
compared to TMetS. FMetS, TMetS, and MMetS were hypertensive with elevated resting 
heart rate, systolic and diastolic blood pressure, and mean arterial pressure over Lean. 
Glucose intolerance. After bolus intravenous glucose load, grouped MetS swine 
had significantly elevated peak blood glucose above Lean, demonstrating glucose 
intolerance (Figure 3.1A). FMetS, TMetS, and MMetS blood glucose area-under-the-
curve (AUC) was significantly higher than Lean, with TMetS and MMetS elevated above 
FMetS (Figure 3.1D). Elevated fasting blood glucose clinically defines type 2 diabetes. 
Consistent with MetS and type 2 diabetes MMetS fasting glucose was elevated above 
Lean, while FMetS and TMetS strongly trended toward an increase (Figure 3.1C). 
Insulin resistance. To assess insulin resistance, plasma insulin was measured 
after overnight fast and during the IVGTT. MetS exhibited significantly higher insulin at 
every measured time point of the IVGTT following glucose bolus compared to Lean 
(Figure 3.1B). Further indicating insulin resistance, FMetS, TMetS, and MMetS plasma 
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insulin levels were significantly higher compared to Lean as measured by the integral 
(Figure 3.1E). FMetS, TMetS, and MMetS demonstrated elevated homeostasis model 
assessment (HOMA) index compared to Lean (Figure 3.1F). In the early stages of type 
2 diabetes, pancreatic β-cells increase insulin production as a compensatory mechanism 
for reduced insulin sensitivity of peripheral tissues. Importantly, FMetS, TMetS, and 
MMetS swine demonstrated increased percent insulin-positive area compared to Lean in 
histological analysis of pancreatic tissue (Figure 3.1 G,H,I), suggesting a compensatory 
pancreatic β-cell response due to peripheral insulin resistance. Adipose tissue insulin 
resistance (Adipo-IR), calculated by the product of fasting insulin resistance (pM) and 
free fatty acids (mM), was elevated in FMetS, TMetS, and MMetS compared to Lean 
(Table 3.1) and correlated to NASH scores (r = 0.53, p <0.05), but not CAD (r = 0.42, 
NS). 
Serum fatty acid methyl esters and unbound free fatty acids. Total serum 
monounsaturated fatty acids (TOTM), polyunsaturated fatty acids, and unbound free 
fatty acids were quantified. TOTM increased with severity of MetS (Figure 3.2A; i.e. 
Lean < FMetS < TMetS < MMetS), whereas PUFA decreased with severity of MetS 
(Figure 3.2B). As such, TOTM:PUFA ratio increased with severity of MetS (Figure 
3.2C). FFA were elevated in FMetS and MMetS compared to Lean, but not TMetS due 
to variability (Figure 3.2D). 
Atherosclerosis in Ossabaw swine. The severity of atherosclerosis in MMetS 
swine was grossly apparent in the coronary arteries by “pearly atherosclerotic lesions” 
visible on the exterior of the heart (Figure 3.3A), which was a novel and profound 
finding. CAD was quantitatively assessed in the coronary arteries in vivo using 
intravascular ultrasound (IVUS). Three segments (proximal, intermediate, and distal) of 
the left anterior descending artery (LAD) (Figure 3.3B) were analyzed for CAD burden. 
A representative IVUS image from within the circumflex artery (CFX) shows the arterial 
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lumen and the anatomy of a complex lesion (Figure 3.3C). IVUS was used to measure 
plaque coverage of the LAD wall, percent lumen stenosis in the CFX, and plaque 
composition (e.g. calcified lesions). Diffuse CAD, as measured by percent 
circumferential wall coverage (defined in Figure 3.3C), was observed in TMetS and, to a 
much greater extent, in MMetS compared to Lean (Figure 3.3D). Amazingly, FMetS 
CAD was similar to Lean, despite FMetS having all of the 6 components of MetS, except 
dyslipidemia. Significant stenosis (Figure 3.3F) and calcifications (Figure 3.3E) were 
only observed in MMetS swine, which are novel findings in a swine model of MetS. 
In patients with MetS, coronary atherosclerosis has a propensity for diffuse 
distribution, calcifications (e.g. MMetS in Figure 3.3), increased vulnerability, and 
cellularity (202). The stability of an atherosclerotic plaque can be attributed to many 
factors, including the collagen content of the plaque. Diffuse MMetS plaques contained a 
substantial lipid core (Figure 3.4C) and significantly less collagen as a percent of total 
plaque area compared to TMetS (Figure 3.4F), while the collagen content of the arterial 
media in Lean, TMetS, and MMetS remained unchanged (Figure 3.4F). Cellularity of the 
atherosclerotic lesions was less in MMetS compared to TMetS (Figure 3.4J) and 
MMetS, potentially due to the greater lipid content in MMetS (Figure 3.4K). 
Fatty acid methyl esters and fatty acid metabolism in metabolic syndrome, 
coronary artery disease, and non-alcoholic steatohepatitis. FMetS, TMetS, and MMetS 
developed insulin resistant MetS with FMetS normolipidemic, TMetS dyslipidemic, and 
MMetS severely dyslipidemic (Table 3.1; Figure 3.1). This provided a unique 
opportunity to determine the relative importance of dyslipidemia within the complex MetS 
milieu in the development of CAD and NASH. FAME were measured in serum and from 
liver biopsies. Each individually quantified FAME (Table 3.2) and groupings of FAME 
(Table 3.3) were correlated to CAD along the length of the artery and to NASH scores. 
Saturated FAME 14:0 directly correlated to CAD and NASH (Table 3.2). Individual 
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mono-unsaturated fatty acids tended to directly correlate with severity of CAD and 
NASH, while individual PUFA tended to negatively correlate to CAD and NASH (Table 
3.2). TOTM and the ratio of TOTM to PUFA strongly and directly correlated with diffuse 
CAD and NASH (Table 3.3). PUFA, in particular n-6 PUFA (Table 3.3), demonstrated 
strong, inverse correlations with CAD and NASH (Table 3.3). FFA did not correlate to 
CAD or NASH (Table 3.3). Fatty acid Δ5, Δ6, and Δ9 convertase indices (20:4n-6/20:3n-
6, 18:3n-6/18:2n-6, and 16:1n-7/16:0, respectively), elongase index (18:0/16:0), 
lipogenic index (16:0/18:2n-6), and microsomal stearoyl-CoA desaturase1 (SCD1; 
18:1/18:0) from both serum and liver tissue samples significantly correlated to NASH 
scores (Table 3.4). 
Predictive dyslipidemia, non-alcoholic steatohepatitis, and coronary artery 
disease relationship. Histological liver NASH scores were elevated in TMetS compared 
to FMetS and Lean, while MMetS demonstrated strikingly severe NASH compared to all 
groups (Figure 3.5A, as previously reported (7)). The relationship of NASH with CAD 
was shown by the strong direct correlation (Figure 3.5B). LDL-gram years had 
phenomenal predictive ability as to the severity of CAD as well as NASH (Figure 3.5 
C&D). 
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Discussion  
The most significant and novel finding was that dyslipidemia is the major 
component of the complex MetS that elicits occlusive, complex, and calcified 
atherosclerotic lesions and NASH. In the rare, naturally occurring Ossabaw swine breed 
that is genetically predisposed to obesity, feeding hypercaloric diets high in mixed fatty 
acids or high in trans fatty acids (MMetS and TMetS, respectively), high cholesterol and 
fructose, we produced MetS characterized by obesity, increased total cholesterol, 
increased LDL, increased LDL:HDL ratio, increased triglycerides, glucose intolerance, 
insulin resistance, and hypertension. Importantly, high fructose diet was sufficient to 
induce MetS with all these features, except dyslipidemia (FMetS) and no CAD or NASH. 
Additional important findings in this study include the strong associations between 
specific FAME and groups of FAME with diffuse CAD and NASH and associations of 
fatty acid metabolism indices and Adipo-IR to NASH. 
MMetS Ossabaw swine developed diffuse atherosclerosis (Figure 3.3), a 
hallmark of patients with diabetes (80;204;205), and significantly elevated fasting blood 
glucose (Figure 3.1C), which defines diabetes. Additionally, MMetS Ossabaw swine 
were severely insulin resistant and glucose intolerant. Insulin resistance was defined by 
1) prolonged insulin and glucose response to intravenous glucose load (Figure 3.1 
D&E) and 2) fasting HOMA values (Figure 3.1F). Importantly, HOMA values in all MetS 
swine were directly comparable to values seen in patients with type 2 diabetes (181;206-
208). Percent insulin-positive area in the pancreas was increased in all MetS swine 
(Figure 3.1I), indicating β-cell hypertrophy, again consistent with the pathogenesis of 
type 2 diabetes in humans (reviewed elsewhere (209)). Thus, MMetS swine progress to 
overt type 2 diabetes induced by excess atherogenic diet, providing future opportunity 
for high-throughput studies of type 2 diabetes in a large animal model of MetS, NASH, 
and CAD. 
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There is significant evidence that patients with the constellation of risk factors 
that manifest MetS have a much higher incidence of CAD and NASH (39). It is difficult, 
by definition, to separate the individual influence of specific MetS risk components on 
CAD and NASH in patients with MetS. We used the only animal model of MetS, NASH, 
and CAD to focus on and eliminate dyslipidemia from the MetS milieu. We also point out 
that “dyslipidemia” is often defined as the combination of dyslipoproteinemia and 
hypertriglyceridemia (210). Hypercaloric, high fructose fed swine (FMetS) developed 
MetS defined by insulin resistance, glucose intolerance, hypertension, and obesity 
without dyslipidemia (measured as increased total cholesterol, LDL, and triglycerides; 
Table 3.1, Figure 3.1) and without increases in CAD or NASH compared to Lean (CAD, 
Figure 3.2; NASH, Figure 3.5 and as previously reported (7)). Supplementation with 
partially hydrogenated soybean oil and cholesterol, in addition to fructose, (TMetS) led to 
MetS comparable to FMetS, while the TMetS had the additional factor of dyslipidemia 
(Table 3.1, Figure 3.1). Dyslipidemic TMetS developed diffuse CAD, no NASH, and only 
mildly fatty liver (CAD, Figures 3 and 4; NASH, Figure 3.5 as previously reported (7)). 
Mixed source fat, cholesterol, and fructose fed MMetS developed overt type 2 diabetes, 
defined by elevated fasting blood glucose, and severe dyslipidemia (Table 3.1, Figure 
3.1 and 5). MMetS had advanced stenotic CAD (Figures 3 and 4) and severe NASH 
(Figure 3.5 and as previously published by Lee et al. (7)). It was not the intent of this 
study to isolate the effects of specific diet components on MetS, CAD, and NASH, but to 
maximize the MMetS phenotype and investigate potential phenotypic differences that 
may provide a physiological mechanism for MetS, CAD, and NASH. Thus, we cannot 
discount that minor changes in the protein source and nutrient content (increased casein 
and mildly reduced choline) may have influenced the results; however, the direct 
association of progressive dyslipidemia (i.e. Lean < FMetS < TMetS < MMetS) with CAD 
  68 
and NASH severity provides compelling evidence for the significant contribution of 
dyslipidemia to the development of CAD and NASH in Ossabaw swine. 
Total serum free fatty acids (FFA) did not correlate with the extent of CAD or 
NASH (Table 3.3). These results are consistent with a recent study that revealed strong 
associations of FFA with MetS in cross-sectional analysis, while no relationship was 
found in longitudinal analysis, thus supporting the overall conclusion that FFA are not 
causative in MetS or diabetes (211). Our powerful study design allowed clear dissection 
of potential FFA effects on CAD and NASH without the confounding effects of 
dyslipidemia (i.e. FMetS). Thus, this is the first report that increased FFA per se are not 
a primary factor eliciting CAD and NASH within the MetS milieu. 
Total FFA did not sufficiently predict CAD or NASH, so individual (Table 3.2) and 
grouped fatty acid methyl esters (FAME; Figure 3.2 and Table 3.3) were investigated. 
Individual monounsaturated fatty acids (MUFA) had the most predictive power with 
serum palmitoleic acid (16:1n7), heptadecaenoic acid (17:1n7), vaccinate acid (18:1n7), 
and oleic acid (18:1n9) all directly correlated to diffuse CAD and all four of these MUFA 
derived from liver tissue (liver) directly correlated to NASH (Table 3.2). It follows that 
total MUFA (TOTM) also directly correlated to the extent of diffuse CAD and severity of 
NASH (Table 3.3). Linoleic acid (18:2n-6), an essential polyunsaturated fatty acid 
(PUFA), negatively correlated to diffuse CAD and NASH (serum and liver derived; Table 
3.2). Total PUFA also negatively correlated to CAD and NASH (Table 3.3). The powerful 
ability of individual and grouped FAME to predict the extent of CAD strongly resonates 
with the recent Atherosclerosis Risk in Communities (ARIC) study which found 
directionally identical associations of palmitoleic acid, oleic acid, TOTM, linoleic acid, 
and PUFA to incidence of heart failure in humans (212). The ARIC study, however, did 
not address heptadecaenoic and vaccinate acid associations with CAD or any FAME 
associations with NASH. Thus, this is the first report addressing the predictive power of 
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individual and grouped FAME, derived from both serum and liver tissue, to the degree of 
NASH. 
Fatty acid synthase and de novo lipogenesis are central to fatty acid metabolism 
and substantially increased in patients with NAFLD (213;214). The progression of de 
novo lipogenesis is mediated by several enzymes including elongase that have a strong, 
inverse association with insulin resistance and obesity (215;216). Ratios of product and 
precursor FAME from liver and serum samples were used to estimated de novo 
lipogenesis (lipogenic index; 16:0/18:2n-6) and elongase activity (18:0/16:0). Liver 
sample lipogenic index directly correlated with NASH score, as previously reported in 
human NAFLD (217), but serum sample lipogenic index was inversely correlated with 
NASH score (Table 3.4), suggesting increased liver and decreased adipose lipogenesis. 
These findings are consistent with previous reports that high fructose diet shifts primary 
lipogenesis from adipose to liver (218), as well as reports that adipose and liver fatty 
acid synthase mRNA expression are almost reciprocal (219). Conversely, liver sample 
elongase activity inversely correlated with NASH, while serum elongase activity 
positively correlated with NASH (Table 3.4). Taken together, we speculate these 
findings support a primary role of fructose in NASH, whereby de novo lipogenesis is 
increased the liver in effort to reduce hepatic damage from oxidized fatty acids, despite 
elevated dietary lipid intake. Additionally, the relatively weak predictive ability of Adipo-IR 
in the development of NASH and its absolute inability to predict CAD (Table 3.1), 
especially compared to strongly determinant LDL-gram years (Figure 3.5 C&D), suggest 
peripheral insulin resistance does not play a primary role in the progression of NASH 
and development of CAD in MetS. 
International studies have clearly demonstrated that long-term elevations in LDL 
levels are associated with drastically increased coronary mortality rates (reviewed 
elsewhere (220)). However, reduced LDL levels through statin treatment over a period of 
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five years has resulted in relatively low reduction in incidence of cardiac death (221). It 
has been recently put forth that integrated measure of high LDL exposure may be more 
predictive than static measures (222), similar to the utility of pack-years in quantifying a 
patient’s life-time exposure to cigarette smoke (223). Here we report a compelling, direct 
association between NASH and CAD severity (Figure 3.5B), corresponding to liver 
cirrhosis trials finding CAD as the leading cause of death in patients with NASH (64). As 
such, the immensely predictive power of LDL gram-years for the severity of CAD and 
NASH (Figure 3.5 C&D) are the first of such measurements in a large animal model of 
CAD and/or NASH, and may provide further insight into the primary driving mechanism 
of CAD and NASH. 
Until now, no animal model of MetS and type 2 diabetes that naturally develops 
occlusive atherosclerosis and NASH has been available for clinical studies involving 
complete and complex metabolic disease. For example, as a result of the inability to 
generate significant native CAD, no pre-clinical study of stent efficacy has ever involved 
stent placement in an artery with severe native CAD. It is entirely possible that recent 
questions regarding the safety of drug-eluting stents (99;101) could have been avoided 
had a more appropriate model of CAD been available. Additionally, while extensive 
studies of NAFLD have been completed in rodents, there has been no opportunity to 
directly investigate NASH in any model, until the groundbreaking report by Lee et al. (7), 
let alone a large animal model allowing longitudinal studies with serial blood sampling 
and liver biopsies. Our unique and powerful study design allowed us to be the first to 
elucidate 1) the absolute requirement of dyslipidemia in the development of 
macrovascular CAD within MetS, 2) the most severe and advanced CAD in any current 
animal model of MetS and type 2 diabetes, 3) strong associations between individual 
and group FAME and CAD and NASH that concur with and expand upon important 
human clinical studies, 4) no independent association between total FFA to CAD and 
  71 
NASH without the confounding influence of concomitant dyslipidemia, and 5) 
phenomenally predictive integrative LDL exposure (LDL gram-years) for CAD and 
NASH. 
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Methods 
 Animal care and use. All protocols involving animals were approved by an 
Institutional Animal Care and Use Committee and complied fully with standards 
(175;176). Forty-five mixed gender Ossabaw swine at the age of ten to fifteen months 
(adult) were assigned to four diet groups for 22-24 weeks. Lean control swine (Lean, 
N=10) were fed standard chow. In all MetS groups, high calorie (~2-fold increase above 
Lean) feeding was necessary to induce components of MetS. The fructose (FMetS; N=9) 
was fed a high fructose (20% kcal) diet (7). The trans fatty acid MetS (TMetS, N=9) 
group was fed a high fat/fructose/2% cholesterol (w/w) atherogenic diet (hydrogenated 
soybean oil; 56% trans fatty acid) (6;7;29). The mixed fat (MMetS, N=8) was fed a high 
fat/fructose/2% cholesterol (w/w) atherogenic diet (mixture of lard, hydrogenated 
soybean oil, and hydrogenated coconut oil) (7). Pigs in FMetS and MMetS groups were 
the same as those used by Lee et al. (7). 
Intravenous glucose tolerance test. IVGTT was performed between weeks 22 
and 24 of the study as previously described by our lab (3;4;9;29). Briefly, conscious 
swine acclimatized to low-stress restraint in a sling were fasted overnight and baseline 
blood samples were obtained. Glucose (1g/kg body weight; i.v.) was administered and 
timed blood samples were collected. 
 Plasma lipid assays. Venous blood samples were obtained following overnight 
fasting and analyzed for triglyceride and total cholesterol [fractionated into high density 
lipoprotein (HDL) and low density lipoprotein (LDL) components]. Apolipoprotein-B-
containing lipoproteins were precipitated with heparin-MnCl2 and the supernatant was 
assayed to determine cholesterol in lipoprotein fractions (3). LDL was calculated from 
the Friedewald equation: LDL = total cholesterol – HDL – (triglyceride ÷ 5). 
Assessment of coronary artery disease. IVUS pullbacks performed at the end of 
the study were used to assess native atheroma and percent circumferential wall 
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coverage was calculated similar to previous reports (3;6;20;29). Severity of native 
atheroma was also quantified as percent stenosis calculated as (plaque area ÷ total 
lumen area) x 100%. To assess diffuse atheroma, three segments were defined as 
proximal (0-10 mm from the LAD/LCX bifurcation), intermediate (20-30 mm from the 
LAD/LCX bifurcation), and distal (0-10 mm from the most distal part of the IVUS pullback 
towards the LAD/LCX bifurcation). Calcified lesions defined by signal dropout peripheral 
to the IVUS imaging transducer were assessed along the length of the entire artery. 
Assessment of collagen content and non-alcoholic steatohepatitis. After fixation 
by immersion in formalin, tissues were routinely processed and paraffin embedded for 
standard histological analysis (11;29). NASH score was determined on liver samples 
and included macrovesicular steatosis, microvesicular steatosis, hepatocyte ballooning, 
Kupffer cell vacuoles, Kupfer cell fat, inflammation, and fibrosis characteristics assessed 
blindly by a histopathologist. 
Assessment of insulin-positive area. Pancreas tissue was sectioned and imaged 
as outlined in above section. The 5-μm pancreas sections were mounted on glass slides 
and assessed for insulin-positive area using mouse anti-insulin primary antibody (Sigma 
#I2018; a generous gift from Dr. Deborah Thurmond, Indiana University Purdue 
University Indianapolis) and mouse biotinylated secondary antibody (Vectastain Elite 
ABC Kit PK-6102). DAB (Sigma Fast D-4168) was used for visualization as previously 
described (9). Sections were counterstained with Mayer’s hematoxylin.  
Fatty acid methyl esters. The analysis of FAME in serum and live tissues was 
conducted by the gas liquid chromatography, as previously described (7). FAME were 
identified based on the retention time determined from authentic standards (Nu-Chek-
Prep Inc., Elysian, MN), and results are presented as area percentages. FMetS and 
MMetS FAME values were a subset of data from Lee et al. (7) for which CAD data was 
obtained. 
  74 
Statistical analysis. One-way or two-way analysis of variance with Student-
Newman-Kuels or Bonferroni post-hoc analysis, as appropriate, were performed using 
commercially available software (Prism 4.0) when comparing multiple groups. 
Independent t-test was used for comparing just two groups. In all tests, p <0.05 was the 
criterion for statistical significance. Unless otherwise noted, the following symbols were 
used: *, p <0.05 compared to Lean; **, p <0.05 compared to Lean and FMetS; ***, p 
<0.05 compared to all other groups. 
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Table 3.1 
Table 3.1 Phenotypic characteristics of Lean, TMetS, and MMetS Ossabaw swine 
at the end of the study. Statistical differences between groups are indicated in the right 
column. Adipo-IR, adipose tissue insulin resistance. 
 Lean FMetS TMetS MMetS Significance 
Body Weight (kg) 51 ± 3 94 ± 6 91 ± 6 87 ± 13 
Lean < FMetS, TMetS, 
MMetS 
Heart rate 
(beats/min) 
65 ± 1 87 ± 4 94 ± 2 101 ± 3 
Lean < FMetS, TMetS < 
MMetS 
Total cholesterol 
(mg/dL) 
80 ± 4 60 ± 4 373 ± 40 
666 ± 
80 
Lean, FMetS < TMetS < 
MMetS 
HDL (mg/dL) 40 ± 3 25 ± 5 85 ± 6 90 ± 9 
FMetS < Lean < TMetS, 
MMetS 
LDL (mg/dL) 35 ± 2 35 ± 3 281 ± 35 
553 ± 
73 
Lean, FMetS < TMetS < 
MMetS 
LDL:HDL  
0.9 ± 
0.1 
2.5 ± 
0.7 
3.2 ± 
0.2 
6.1 ± 
0.5 
Lean < FMetS < TMetS 
< MMetS 
Triglycerides 
(mg/dL) 
22 ± 4 30± 2 37 ± 2 
120 ± 
24 
Lean, FMetS < TMetS < 
MMetS 
Mean arterial 
pressure (mmHg) 
94 ± 1 110 ± 5 131 ± 3 140 ± 4 
Lean < FMetS < TMetS, 
MMetS 
Adipo-IR 40 ± 9 
139 ± 
28 
142 ± 
24 
149 ± 
30 
Lean < FMetS, TMetS, 
MMetS 
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Table 3.2 
 CAD (Percent wall coverage) NASH 
FAME 
Proximal Intermediate Distal Serum Liver 
r p r p r p r p r p 
14:0 0.65 * 0.81 * 0.64 * 0.56 * 0.72 * 
16:1t 0.44 * 0.49 * 0.50 * 0.75 * 0.18 NS 
16:1n7 0.79 * 0.86 * 0.81 * -0.22 NS 0.81 * 
17:1n7 0.64 * 0.68 * 0.51 * 0.32 NS 0.83 * 
18:0 -0.53 * -0.52 * -0.50 * -0.85 * -0.90 * 
18:1n9 0.65 * 0.59 * 0.53 * 0.48 * 0.85 * 
18:1n7 0.68 * 0.64 * 0.63 * 0.80 * 0.85 * 
18:2n-6 -0.69 * -0.64 * -0.50 * -0.75 * -0.89 * 
Table 3.2 Fatty acid methyl esters (FAME) predict coronary artery disease (CAD) 
and non-alcoholic steatohepatitis (NASH) in Ossabaw swine. Serum FAME 
correlations to proximal, intermediate, and distal CAD and serum or liver tissue FAME 
correlations to modified NASH score are reported as indicated. Correlations statistically 
significant at p <0.05 are indicated with asterisks; NS = non-significant. FAME showing 
no correlations to both CAD and NASH were 15:0, 16:0, 17:0, 18:1t, 18:1, 18:3n6, 
18:3n3, 20:1n9, 20:2n6, 20:3n6, 20:4n6, 20:3n3, 20:5n3, 22:4n6, 22:5n3, and 22:6n3 
and shown in Supplemental Table 3.1. 
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Table 3.3 
 CAD (Percent wall coverage) NASH 
FAME 
Proximal Intermediate Distal Serum Liver 
r p r p r p r p r p 
Total FFA 0.33 NS NC 0.35 NS 0.20 NS NC 
TOTM 0.66 * 0.62 * 0.58 * 0.78 * 0.86 * 
PUFA -0.73 * -0.69 * -0.60 * -0.75 * -0.88 * 
n-6 PUFA -0.74 * -0.70 * -0.61 * -0.73 * -0.88 * 
TOTS/TOTM -0.51 * -0.46 * -0.45 NS -0.72 * -0.82 * 
TOTM/PUFA 0.79 * 0.76 * 0.66 * 0.85 * 0.88 * 
TOTS/PUFA 0.65 * 0.63 * 0.36 NS 0.51 * 0.39 * 
Table 3.3 Fatty acid methyl esters (FAME) groups predict coronary artery disease 
(CAD) and non-alcoholic steatohepatitis (NASH) in Ossabaw swine. Serum FAME 
group correlations to proximal, intermediate, and distal CAD and serum or liver tissue 
FAME group correlations to modified NASH score are reported as indicated. 
Correlations statistically significant at p <0.05 are indicated with asterisks; NS = non-
significant; NC = not completed. FAME groups showing no correlations to both CAD and 
NASH were 16:1t + 18:1t, TOTS, TOTM + PUFA, n-3 PUFA, n-6 LC, n-3 LC, 
TOTS/(TOTM + PUFA), n-6 LC/n-3 LC, and n-6/n-3 and shown in Supplemental Table 
3.2. Abbreviations: FFA, free fatty acids (FA), TOTS, total saturated FA; TOTM, total 
monounsaturated FA; PUFA, total polyunsaturated FA; n-6, unsaturation at carbon 6; n-
3, unsaturation at carbon 3; LC, long chain FA. 
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Table 3.4 
Enzyme function index 
Serum Liver 
r p r p 
Δ5 desaturase (20:4n-6/20:3n-6) -0.49 * -0.61 * 
Δ6 desaturase (18:3n-6/18:2n-6)  0.44 * 0.47 * 
Δ9 desaturase (16:1n-7/16:0) 0.71 * 0.85 * 
Elongase (18:0/16:0) 0.74 * -0.83 * 
Lipogenic index (16:0/18:2n-6) -0.75 * 0.62 * 
stearoyl-CoA desaturase 1 (18:1/18:0) 0.75 * 0.74 * 
Table 3.4 Liver enzyme function predicts non-alcoholic steatohepatitis (NASH) in 
Ossabaw swine. Liver enzyme function indices derived from serum or liver FAME are 
correlated to NASH score. Correlations statistically significant at p <0.05 are indicated 
with asterisks. 
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Figure Legends 
Figure 3.1 Insulin resistance and glucose intolerance. Combined MetS groups (solid) 
blood glucose (A) and insulin (B) remained elevated compared to Lean (dotted) for all 
time points during the IVGTT. C Fasting blood glucose concentrations were elevated in 
MMetS compared to Lean, while FMetS and TMetS were not significantly elevated. D 
Integral (area-under-curve) of plasma glucose concentrations during IVGTT were 
elevated in FMetS, TMetS, and MMetS compared to Lean, while TMetS and MMetS 
were also increased above FMetS. E Integral of plasma insulin concentrations during 
IVGTT were elevated in FMetS, TMetS, and MMetS compared to Lean. F HOMA index 
values were elevated in FMetS, TMetS, and MMetS compared to Lean. Representative 
pancreatic sections from Lean (G) and MetS (H) showing insulin staining (arrow). I 
Positive insulin staining area as a percent of total pancreas tissue area is increased in 
FMetS, TMetS, and MMetS compared to Lean. 
 
Figure 3.2 Elevated serum fatty acid methyl esters and free fatty acids in 
metabolic syndrome. A Serum total mono-unsaturated FAME (TOTM) increased with 
severity of MetS. B Serum poly-unsaturated FAME (PUFA) decrease with severity of 
MetS. C The ratio between TOTM and PUFA (TOTM:PUFA) increased with severity of 
MetS. D Serum free fatty acids are increased in FMetS and MMetS compared to Lean, 
while TMetS was not different compared to Lean. 
 
Figure 3.3 Coronary artery disease is increased with severity of metabolic 
syndrome. A Representative heart taken from a MMetS pig. Inset grossly demonstrates 
severity of coronary atheroma in arteries on left and right of the image. B Representative 
angiography image with labeled LAD and LCX arteries, and proximal, intermediate, and 
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distal segments. C Sample IVUS image demonstrating complex atheroma and method 
of quantifying % wall coverage (D&F). D Diffuse atheroma of the LAD is present in 
MMetS and in TMetS to a much lesser extent. E Calcification is quantified as the percent 
of artery segments with calcification present. F Percent stenosis of the LCX illustrates 
massive atheroma load in the MMetS.  
 
Figure 3.4 Atheromous plaques contain less collagen with increased severity of 
metabolic syndrome. A Representative image of trichrome staining in Lean right 
coronary artery. B&D Representative images of trichrome staining in TMetS. C&E 
Representative images of trichrome staining in MMetS. F (Upper) Coronary media 
collagen, quantified as percent of total medial area, is not different between groups. 
(Lower) Percent neointima collagen is decreased in MMetS compared to TMetS. G 
Representative image of hematoxylin and eosin (H&E) staining in MMetS illustrating 
calcifications. Inset Magnification on calcified region of artery wall (e). H Representative 
image of H&E staining in TMetS. I Representative image of H&E staining in MMetS. J 
Plaque cellularity, quantified as cells per unit area, decreased in MMetS compared to 
TMetS. K Representative image of Oil Red O illustrates massive amount of lipid 
accumulation in MMetS plaque. *, p <0.05 compared to TMetS. a, adventitia; b, media; c, 
intima; d, lumen; e, calcification. 
 
Figure 3.5 LDL gram-years predicts strongly correlated coronary artery disease 
and non-alcoholic steatohepatitis. A TMeTS and MMetS NASH are increased 
compared to FMetS and Lean, with MMetS NASH greater than TMetS. B NASH directly 
correlates to diffuse coronary artery disease. C and D LDL gram-years is strongly 
predictive of CAD and NASH. 
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Figure 3.1 
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Figure 3.2 
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Figure 3.3 
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Figure 3.4 
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Figure 3.5 
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Abstract 
Aim. Stenting attenuates restenosis, but accelerated coronary artery disease 
(CAD) adjacent to the stent (peri-stent CAD) remains a concern in metabolic syndrome 
(MetS). Smooth muscle cell proliferation, a major mechanism of CAD, is mediated partly 
by myoplasmic Ca2+ dysregulation and store-operated Ca2+ entry (SOCE) via canonical 
transient receptor potential 1 (TRPC1) channels is proposed to play a key role. Exercise 
is known to prevent Ca2+ dysregulation in CAD. We tested the hypothesis that MetS 
increases SOCE and peri-stent CAD and exercise attenuates these events.  
Methods. Groups (N=9 pigs each) were 1) healthy lean Ossabaw swine fed 
standard chow, 2) excess calorie atherogenic diet fed (MetS), and 3) aerobically 
exercise trained starting after 50 weeks of development of MetS (XMetS). Bare metal 
stents were placed after 54 weeks on diets and CAD and SOCE were assessed 4 weeks 
later. Coronary cells were dispersed proximal to the stent (peri-stent) and non-stented 
segments and fura-2 fluorescence assessed SOCE, which was verified by block by Ni2+ 
and insensitivity to nifedipine.  
Results. XMetS pigs had increased physical work capacity and decreased 
LDL/HDL (p<0.05), but no attenuation of robust insulin resistance, glucose intolerance, 
hypertriglyceridemia, or hypertension. CAD was greater in peri-stented vs. non-stented 
artery segments. MetS had the greatest CAD, SOCE, and TRPC1 and STIM1 mRNA 
and protein expression, which were all attenuated in XMetS.  
Conclusion. This is the first report of the protective effect of exercise on native 
CAD, peri-stent CAD, SOCE, and molecular expression of TRPC1, STIM1, and Orai1 in 
MetS. 
 
Keywords: transient receptor potential 1 (TRPC1) channel, STIM1, Orai1, store-operated 
calcium channel, intravascular ultrasound, coronary smooth muscle, Ossabaw miniature 
swine. 
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Introduction 
Metabolic syndrome (MetS) is defined as the combination of several risk factors 
including: central obesity, dyslipidemia (increased LDL/HDL and triglycerides), 
hypertension, impaired glucose tolerance, and insulin resistance (160). Generally the 
presence of three of these characteristics renders a diagnosis of MetS (160). This 
combination of risk factors, also termed “pre-diabetes”, ultimately leads to type 2 
diabetes and increased prevalence and severity of coronary artery disease (CAD) (224).  
 Untreated CAD will progress to the point where neointimal formation occludes 
coronary blood flow and impairs cardiac function. The primary interventional treatment 
for occlusive CAD is deployment of a coronary stent. Drug-eluting stents have 
substantially decreased such restenosis; however, artery segments adjacent to the 
stent’s edge (peri-stent) are sites of significant stenosis (225). Accelerated peri-stent 
CAD progression increases the need for repeat stent procedures (68;225;226) and 
shows a greater prevalence in patients with diabetes (74). Since peri-stent CAD may be 
a milder representation of in-stent restenosis due to stent-induced injury, there is need 
for study of the cellular and molecular mechanisms underlying peri-stent CAD.  
 Clearly, coronary smooth muscle (CSM) proliferation is largely responsible for 
neointima formation after coronary stenting (227). Intracellular Ca2+ plays several roles in 
smooth muscle cells, such as regulation of contraction and gene expression (228), and 
altered intracellular Ca2+ signaling is associated with smooth muscle cell proliferation 
(169). The primary Ca2+ store within the CSM cell is the sarcoplasmic reticulum (SR). 
Depletion of the SR Ca2+ store leads to store-operated Ca2+ entry (SOCE) across the 
plasma membrane in smooth muscle (229). SOCE (or Ca2+-release activated Ca2+ 
[CRAC] entry) historically has been described in purely electrophysiological terms, as 
the molecular entity was not known (as reviewed in (117;230)). In recent years, various 
candidates have been proposed to be involved in SOCE, including TRPC1, TRPC6, 
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STIM1, and Orai1 (as reviewed in (117;230)). Importantly, the transient receptor 
potential canonical 1 (TRPC1) channel that contributes to SOCE in smooth muscle is 
linked to hypertrophy and proliferation (196;228;229). Balloon injury-induced CSM cell 
proliferation in healthy juvenile swine is associated with upregulation of TRPC1 channels 
(196). In addition to pharmacological antagonism of aberrant Ca2+ signaling (18), we 
have shown that exercise therapy prevents CSM Ca2+ dysregulation in CAD (13;17). 
While TRPC1 channels are strongly associated with smooth muscle proliferation and 
have been implicated in CAD, no studies have examined changes in TRPC1 channels in 
native (non-stent) and peri-stent CAD in MetS or whether exercise training can attenuate 
these processes. 
Our group has developed Ossabaw miniature swine as an excellent large animal 
model of MetS (3;4;7). We tested the hypothesis that MetS increases SOCE and CAD in 
non-stent and peri-stent segments of coronary artery and exercise attenuates these 
events. Our data provide the first cellular and molecular evidence that exercise protects 
against increases in SOCE, TRPC1, and STIM1 protein, and native and peri-stent CAD 
in MetS. These findings in the Ossabaw miniature swine model, which superbly mimics 
CAD in MetS, are critical links for translation to clinical medicine.  
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Methods 
 Animal care and use. The investigation conforms with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996). All protocols involving animals were approved by 
an Institutional Animal Care and Use Committee and complied fully with 
recommendations in the Guide for the Care and Use of Laboratory Animals (176)1 and 
the American Veterinary Medical Association Panel on Euthanasia 22. Male Ossabaw 
swine at the age of seven months (sexually mature adult) were assigned to three diet 
groups for 55 weeks before stenting. Lean control swine (Lean, N=9) were fed lean 
chow containing 22% kcal from protein, 70% kcal from carbohydrates, and 8% kcal from 
fat. Pigs in the lean group ate 2500 kcal/day. Sedentary MetS (N=9) and exercise 
trained (XMetS, N=9) groups were fed a high fat/2% cholesterol atherogenic diet 
composed of lean chow supplemented with (percent by weight): cholesterol 2.0, 
hydrogenated soybean oil 16.7 (contains 56% trans fatty acids), corn oil 2.5, and sodium 
cholate 0.7. This mixture yielded a composition of 11% kcal from protein, 43% kcal from 
carbohydrates and 46% kcal from fat. Atherogenic diet groups ate 6000 kcal/day until 
sacrifice. All animals were housed in individual pens and provided a 12 hr light/12 hr 
dark cycle. Water was provided ad libitum. 
 Exercise Training. Pigs randomized to the exercise group began treadmill 
training 4 weeks prior to initial cardiac catheterization. To prevent any detrimental 
cardiac event in obese, MetS swine with CAD and after stenting, the endurance exercise 
training protocol was modified from our previous studies (e.g. 15). This protocol complied 
fully with guidelines in the “APS Resource Book for the Design of Animal Exercise 
Protocols” 23. Briefly, exercise training consisted of treadmill running performed 4 
days/week. During the first week of training, pigs were acclimated to the treadmill at 4 
km/h (endurance) with 0% grade for 20-30 minutes and at 5.6 km/h for 15 minutes. After 
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acclimation the daily 45 minutes training bout consisted of four stages: 1) 5 minutes 
warm-up at 2.2 km/h, 2) 5 minutes at 6.1 km/h (~40-50% maximum heart rate), 3) 30 
minutes at 7.7 km/h with a variable grade (~65-75% of maximum heart rate), and 4) 5 
minutes cool down at 3.5 km/h. Heart rates were monitored continuously using an 
external monitor (T51H, Polar,Lake Success, NY). Throughout the total 7 week training 
period, training intensity was maintained in the desired heart rate range by altering the 
treadmill grade. Each pig resumed exercise training 48 hours following coronary stenting 
procedure and this regimen was maintained for 3 weeks following stenting before repeat 
cardiac catheterization and euthanasia. 
 Intravenous glucose tolerance test. Swine were acclimatized to low-stress 
restraint in a specialized sling for 5-7 days before the IVGTT was conducted 17-19(3;4;9). 
Swine were then fasted overnight, and anesthetized with isoflurane (maintained at 4% 
by mask with supplemental O2). The right jugular vein was catheterized percutaneously. 
Following catheterization, swine were allowed to recover for 3 h before the IVGTT to 
avoid any effect of isoflurane on insulin signaling 19. For IVGTT, conscious swine were 
restrained by sling and baseline blood samples were obtained. Glucose (1g/kg body 
weight; i.v.) was administered and timed blood samples were collected 19. Blood glucose 
was measured using YSI 2300 STAT Plus Glucose analyzer. Plasma insulin assays 
were performed by Linco Research Laboratories (St. Charles, MO). 
 Plasma lipid assays. Venous blood samples were obtained following overnight 
fasting. Fasting samples were analyzed for triglyceride and total cholesterol [fractionated 
into high density lipoprotein (HDL) and low density lipoprotein (LDL) components] 17. 
Cholesterol in lipoprotein fractions was determined after precipitation of HDL using minor 
modifications of standard methods 24. Specifically, apolipoprotein-B-containing 
lipoproteins were precipitated with heparin-MnCl2 and the supernatant was assayed. 
  93 
LDL was calculated from the Friedewald equation: LDL = total cholesterol – HDL – 
(triglyceride ÷ 5).  
 Stent procedure. Procedures were similar to previous reports 18,25,26. Swine 
received 325 mg aspirin and 25 mg Plavix (clopidogrel) daily as anti-platelet therapy 
which began one day prior to the stent procedure and continued for the duration of the 
study. Following an overnight fast, swine received (in mg/kg; i.m.) 0.05 atropine, 2.2 
xylazine, and 5.5 telazol. Swine were intubated and anesthesia was maintained with 
isoflurane (2-4%, with supplemental O2). The isoflurane level was adjusted to maintain 
anesthesia with stable hemodynamics. Heart rate, aortic blood pressure, respiratory 
rate, and electrocardiographic data were continuously monitored throughout the 
procedure. Under sterile conditions, a 7F vascular introducer sheath was inserted into 
the right femoral artery and heparin (200 U/kg) administered. A 7F guiding catheter 
(Amplatz L, sizes 0.75-2.0; Cordis) was advanced to engage the left main coronary 
ostium. A 3.2F, 30 MHz intravascular ultrasound (IVUS) catheter (Boston Scientific) was 
advanced over a guide wire and positioned in the coronary artery. Automated IVUS 
pullbacks were performed at 0.5 mm/sec. Video images were analyzed off-line (Sonos 
Intravascular Imaging System; Hewlett Packard). The IVUS catheter was removed and a 
coronary stent (2.5-4.0 mm diameter by 8 mm length, Express2; Boston Scientific) 
catheter was deployed. Stent diameter was chosen to match artery diameter using 
optimal balloon inflation pressure. Two stents were deployed in each animal. One stent 
was placed in the circumflex artery (CFX), while the second stent was placed in the left 
anterior descending artery (LAD). Angiography was performed to ensure proper 
longitudinal stent placement and IVUS was repeated to confirm deployment of the stent 
to the proper arterial lumen diameter (1.0x normal artery reference) 18,25,26. The IVUS 
catheter, guide catheter, and introducer sheath were removed and the right femoral 
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artery ligated. The incision was closed and the animal was allowed to recover. 
Cephalexin (1000 mg) was given twice a day for six days following the stent procedure. 
 Intra-stent histology. Stented coronary segments were placed in zinc-buffered 
formalin at sacrifice for histological analysis. Stent histology was performed by 
MicaGenix Corp. (Indianapolis, Indiana, USA, as we have described previously 27. 
Images were captured with a Nikon CoolPix 990 (3.34 MegaPixel) digital camera. 
Measurements were made with Image Pro Plus v.4.1 software (Media Cybernetics, 
Silver Springs, Maryland, USA). Collagen content in the media and intima was 
determined as we previously described (11). Cell count was assessed using hematoxylin 
and eosin. 
 Cell dispersion. The procedure for the isolation of the right coronary artery and 
the enzymatic dispersal of porcine coronary smooth muscle cells has been previously 
described 9,15. Briefly, arteries were freshly dissected and smooth muscle cells 
dispersed. Arteries were incubated in a physiological salt solution containing 
collagenase for 45 minutes to disperse endothelial cells, followed by a second period of 
30 minutes to isolate the smooth muscle cell fraction. 
 Intracellular Ca2+ measurements. Whole cell intracellular Ca2+ levels were 
obtained at room temperature (22–23°C) using the fluorescent Ca2+ indicator, fura-2, and 
the InCa++ Ca2+ Imaging System (Intracellular Imaging, Cincinnati, OH) as previously 
described by our laboratory 9,14,15. 
 Patch clamp electrophysiology. All electrophysiological experiments were 
performed using a Axopatch 200B integrating patch-clamp amplifier and a DigiData 
1440A analog-digital converter and analyzed using Axon PCLAMP 10 software package. 
Cells were voltage-clamped at a holding potential of -60 mV and 300 ms voltage ramps 
from -100 to +100 mV were applied at 5 sec intervals similar to previous protocols (231). 
The pipette solution contained (mM): 135 CsMeSO3, 10 CsCl, 2 MgCl2, 10 EGTA, 20 
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HEPES (pH 7.2). Extracellular solutions contained (mM): 150 NaCl, 2 MgCl2, 1.2 CaCl2, 
5.5 glucose, 10 HEPES (standard extracellular solution, pH 7.2) or divalent cation free 
solution having: 150 NaCl, 1 EGTA, 5.5 glucose, 10 HEPES (pH 7.2) and 5 mM caffeine 
added where indicated. 
 Reverse transcription-polymerase chain reaction. The total RNA from pig 
coronary arteries was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA). The full-
length transcripts of TRPC1 were amplified using the one-step SuperScript RT-PCR 
platinum Taq HiFi system (Invitrogen, Carlsbad, CA). Primers for PCR amplification of 
TRPC1 were designed for the Ossabaw TRPC1 sequence and were as follows: forward, 
ATGGCGGCCCTGTACCCGAG; reverse: CATAGCATATTTAGAAGTCCGAAAGCC. 
The transcripts were confirmed to be the pig TRPC1 by sequencing. 
 Quantitative reverse transcriptase polymerase chain reaction analysis. BioRad 
iScript cDNA Synthesis kit was used to reverse transcribe cDNA using total RNA 
isolated from coronary of 18 pigs (6 Lean, MetS, and XMetS) as templates. The Applied 
Biosystems 7500 Real Time PCR System was used and data were quantified using 
comparative Ct (ddCt) method. The endogenous control (18S rRNA) was amplified using 
TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA), whereas 
TRPC/Orai/Stim was amplified using SYBR Green Master mix (Applied Biosystems, 
Foster City, CA). The dissociation curves were run for all completed SYBR Green 
reactions to rule out non-specific amplifications and primer-dimers. The non-template 
control was performed as negative control. 
 Immunoblots. Protein extracts were subjected to 10.5% SDS-PAGE separating 
gel (4% stacking gel) and transferred to nitrocellulose membranes. The membrane 
(blocked with 5% casein) was incubated with the primary antibodies and then with an 
anti-rabbit or mouse HRP-conjugated antibody (Pierce, Rockford, IL, 1:20,000). Bound 
HRP-conjugates were detected using a SuperSignal West Femto Kit (Pierce), according 
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to the manufacturer’s instructions. The monoclonal anti-TRPC1 antibody was a gift from 
Dr.Tsiokas (University of Oklahoma Health Sciences Center). STIM1 and ORAI1 
antibodies were from Alomone labs (Rehovet, Israel). 
 Assessment of coronary artery disease. IVUS pullbacks performed during the 
stenting procedure and before stent placement were used to assess native atheroma 
16,26. Measurements were obtained every 2 mm through the length of the artery. Each 
cross-sectional IVUS image was divided into 16 equal segments. Percent circumferential 
wall coverage was calculated as (# segments containing atheroma ÷ 16) x 100%, similar 
to previous reports 17,26. 
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Results 
 To determine if excess kcal atherogenic diet induces metabolic syndrome in 
Ossabaw swine, we evaluated the major parameters associated with MetS (Table 4.1). 
Several characteristics were elevated in MetS and XMetS above Lean, including 
bodyweight, LDL, systolic and diastolic blood pressure, and fasting blood glucose. 
LDL/HDL ratio was the only metabolic parameter attenuated by exercise training in 
XMetS vs. MetS. Efficacy of exercise training was evidenced as decreased resting heart 
rate, increased work load (treadmill grade) at a constant heart rate (65-75% maximum), 
and decreased heart rate at a constant work load during the treadmill stress test (Figure 
4.1A).  
 Glucose intolerance and insulin resistance are major components of MetS and 
the development of type 2 diabetes. MetS had significantly greater blood glucose 
concentrations than Lean at 10, 20, 30, 40, and 50 minutes after bolus glucose injection 
(Figure 4.1B). In addition, XMetS had significantly elevated blood glucose above Lean 
at 10, 30, 40, and 50 minute time points (Figure 4.1B). MetS also elicited significant 
elevation in plasma insulin response above Lean at all times after glucose injection 
(Figure 4.1C). Likewise, XMetS plasma insulin was significantly elevated above Lean 
with the exception of the 60 minute time point (Figure 4.1C). Taken together, both 
glucose and insulin IVGTT results indicate glucose intolerance and primary insulin 
resistance in MetS and XMetS, with minimal effect of this short-term (7 weeks) exercise 
training program on these metabolic parameters. 
To determine the effects of metabolic syndrome on CAD, atherosclerosis was 
imaged by IVUS and quantified as percent circumferential wall coverage. Figure 4.2A is 
a schematic of the coronary vasculature showing the location of peri-stent and non-stent 
segments studied. Figure 4.2B illustrates an in vivo coronary angiogram at right anterior 
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oblique 30˚ ang le. Representative IVUS image from the CFX artery demonstrates 
atherosclerotic neointima formation (Figure 4.2C). IVUS images before (Figure 4.2D) 
and after stent (Figure 4.2E) deployment verified proper stent diameter. Representative 
longitudinal IVUS analysis of CFX before and 4 weeks after stent deployment illustrates 
relatively mild and diffuse atherosclerosis through the more distal regions of the artery 
(Figure 4.2F). Increased percent wall coverage was found in proximal and distal non-
stented segments of coronary arteries in MetS compared to Lean, which was attenuated 
with exercise (XMetS) (Figure 4.2 G&H). Similar to non-stent segments, exercise 
(XMetS) completely prevented the increase in percent wall coverage observed in MetS 
compared to Lean in peri-stent segments of coronary artery (Figure 4.2I), but did not 
affect in-stent neointimal hyperplasia (Figure 4.2J). 
 Verhoff-Van Giessen (VVG), Masson’s trichrome, and hematoxylin and eosin 
(H&E) stains were performed to assess in-stent plaque morphology. Figure 4.3 A&B 
show representative in-stent plaque from trichrom and H&E, respectively. Neointimal 
hyperplasia was not different across groups (Figure 4.3C). Exercise reduced the amount 
of collagen (Figure 4.3D), but there was no difference in cell density between groups in 
the in-stent regions (Figure 4.3E). 
Since alterations in SOCE signaling mechanisms have been associated with 
atherosclerosis (196;228;229), we studied SOCE in smooth muscle cells freshly isolated 
from non-stent and peri-stent artery segments of Lean, MetS, and XMetS groups. To 
assess SOCE, we first employed a typical store-depletion protocol similar to that 
reviewed by Landsberg et al. (229). Figure 4.4A shows a representative record of 
intracellular Ca2+ changes in a peri-stent MetS CSM cell obtained during such an 
experiment. Baseline intracellular [Ca2+] was established from minutes 0-2 in 
physiological salt solution containing normal 2 mM Ca2+. From minutes 3-7, the caffeine-
sensitive SR Ca2+ stores were depleted in the presence of caffeine and the SERCA 
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inhibitor cyclopiazonic acid (CPA) in Ca2+ free solution. At minutes 17-22, Ca2+ was 
reintroduced and SOCE was quantified in non-stent and peri-stent cells. CSM SOCE 
was sensitive to the non-selective Ca2+ channel blocker Ni2+, but insensitive to the L-type 
Ca2+ channel blocker nicardipine. Peak SOCE was not significantly different in the CSM 
cells from peri-stent segments of Lean and MetS in Ca2+ imaging experiments, but was 
markedly attenuated in XMetS (Figure 4.4B).  
In a separate chronic study, SOCE was evaluated by Mn2+ quench in cells of 
non-stent and peri-stent segments. A Mn2+-dependent decrease in the fluorescence 
intensity of fura-2 excited at 360 nm (the fura-2 Ca2+-insensitive isosbestic point) is 
indicative of divalent cation influx. Caffeine and CPA were used to deplete intracellular 
Ca2+ stores in CSM cells. Mn2+ quench confirmed that store-depletion resulted in divalent 
cation influx sensitive to the non-selective Ca2+ channel blocker Ni2+ (Figure 4.4C). 
Mn2+-influx was significantly greater in MetS compared to Lean in both non-stent and 
peri-stent cells (Figure 4.4D).  
A less extreme Ca2+ store depletion protocol using caffeine alone in the absence 
of CPA demonstrated significant Mn2+ quench (Figure 4.4E), which was greater in MetS 
compared to the Lean group (Figure 4.4F). Mn2+ quench observed in Figure 4.4 D&F 
confirmed that store-depletion results in divalent cation influx in CSM cells without 
inhibition of SERCA. Whole cell patch clamp electrophysiology was performed using a 
similar protocol to Figure 4.4E. Caffeine-induced inward current was sustained for 
longer than 5 minutes (Figure 4.4G), indicating it was not due to transient Ca2+-sensitive 
Cl- channels activated by Ca2+- release stimulated by caffeine. A current-voltage 
relationship plot of the sustained inward current was ohmic with a reversal potential of 
approximately 0 mV (Figure 4.4H). 
While our patch clamp data suggested SOCE was due to TRPC1, we determined 
if changes in the molecular expression of TRPC1 or other SOCE related proteins (e.g. 
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STIM1 and Orai1) could account for the increased SOCE. In RT-PCR experiments the 
presence of TRPC1, STIM1, and Orai1 was shown in all groups (Figure 4.5 A-D). Group 
data demonstrated significantly greater TRPC1 mRNA expression in the MetS group 
compared to Lean, which was attenuated by exercise training (Figure 4.5B). STIM1 and 
Orai1 mRNA expression were also increased in the MetS group, but remained increased 
even with exercise (Figure 4.5 C&D). Immunoblots from coronary lysates showed 
TRPC1 protein in MetS was attenuated in XMetS and STIM1 protein in MetS was 
abolished in XMetS compared to Lean (Figure 4.5 F&G), while Orai1 protein expression 
shows no statistical difference between any group (p=0.1) (Figure 4.5H). Agarose gel 
images demonstrate the expression of only TRPC1 and TRPC6 gene in MetS coronary 
arteries (Figure 4.5 I&J). TRPC6 mRNA was increased in MetS compared to Lean 
(Figure 4.5K). 
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Discussion 
 The novel findings of this study are: 1) exercise decreases A) non-stent and peri-
stent CAD, B) store-operated Ca2+ channel function and TRPC1/STIM1 molecular 
expression, and C) in-stent collagen content in MetS and 2) SOCE current-voltage 
relationship in coronary smooth muscle is ohmic and non-selective, which is consistent 
with TRPC1. Excess kcal atherogenic diet elicited robust MetS, which accompanied 
greater atherosclerosis in peri-stent segments of coronary arteries than in non-stented 
arteries. Functional store-depletion mediated Ca2+ influx and TRPC1/STIM1 molecular 
expression correlated with the extent of atherosclerosis amongst groups, while Orai1 
protein expression did not change. The effect of exercise to attenuate progression of 
peri-stent CAD, but not in-stent stenosis, in Ossabaw miniature swine with MetS is 
consistent with the clinical study in humans by Belardinelli (226) and non-diabetic swine 
(232). Our Ca2+ signaling and molecular expression data provide evidence of cellular 
and molecular events underlying this vitally important clinical phenomenon and extend 
those findings (226;232) to MetS.  
Patient complication following stent deployment is well documented (233) with 
diabetes increasing patient risk (234). Consistent with human data, MetS Ossabaw 
swine displayed increased atherosclerosis in non-stent artery segments compared to 
Lean. Peri-stent CAD has been observed by several groups and is more prevalent in 
patients with diabetes (74); which may be due to the overall greater diffuse CAD in MetS 
and diabetes (86). Despite this remarkable clinical observation, no studies have 
examined mechanisms which underlie peri-stent atherosclerosis in MetS. Similar to 
previous findings, peri-stent atherosclerosis, although augmented in all groups, mirrored 
non-stent atherosclerosis in that it was greater in MetS than Lean. Exercise has an 
independent role in primary prevention of CAD (235;236), reduction of coronary 
stenosis, and rates of hospital readmission after coronary angioplasty (226). 
  102 
Nonetheless, mechanisms which underlie these changes are unclear. In the current 
study, seven weeks of exercise training attenuated the increased non-stent 
atherosclerosis and abolished increased peri-stent atherosclerosis observed in MetS. 
Although 20 weeks of exercise training of non-diabetic swine attenuated neointimal 
hyperplasia, i.e. progression to stenosis, after angioplasty balloon induced injury (232), 
in the present study MetS and the shorter training duration (7 weeks) are key differences 
that may have minimized the protective effects of exercise. 
Our group captured feral swine from Ossabaw Island, GA, which naturally 
developed a thrifty genotype in response to the evolutionary selection pressure of 
seasonal shortages of food (4). When fed excess calorie atherogenic diet, Ossabaw 
swine develop MetS similar to humans (3;4;7). Also, MetS Ossabaw swine, like humans 
(but different from many other laboratory animal models), develop CAD. Consistent with 
these findings, male Ossabaw swine in this study show increased bodyweight, plasma 
LDL, LDL/HDL ratio, and triglyceride, systolic and diastolic pressure, and heart rate. A 
major extension of this work is our finding that short term exercise training reverses the 
elevated LDL/HDL ratio observed in MetS. 
Obese, MetS Ossabaw swine showed classical cardiovascular adaptations to 
exercise training, including increased physical work capacity, resting bradycardia, and 
decreased heart rate response to a submaximal exercise stress test, indicating efficacy 
of the exercise program. The lack of exercise attenuation of other MetS characteristics is 
somewhat surprising, since exercise is a first line treatment for pre-diabetes / MetS 
(237). Factors may have mitigated the typical effects of exercise on MetS characteristics 
in Ossabaw swine. First, our study design was to maintain the atherogenic diet and 
obesity of the pigs, unlike the typical exercise training regimen and that in human clinical 
studies, in which diet improvements are also implemented (237). Second, Ossabaw 
miniature swine have a loss-of-function mutation in the AMP kinase gamma 3 subunit in 
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skeletal muscle, which is a pivotal enzyme in fatty acid oxidation and glucose uptake 
(238). Exercise is not as effective in activating AMP kinase in pigs having the mutation, 
thus the full benefit of exercise on skeletal muscle metabolism might not be seen in 
Ossabaw miniature swine (238).  
 Because of the widely reported occurrence of SOCE and distribution of TRPC 
channels in numerous cell types, including vascular cells (239), it might be considered 
dogma that SOCE and TRPC channels should be abundant in CSM and regulate Ca2+ 
signaling and contraction under normal conditions. We emphasize that we have never 
found activation of SOCE in Yucatan swine “healthy” CSM (13;240), despite robust 
SOCE in coronary endothelial cells (199). However, previous studies report increased 
expression of TRPC1 in diseased vascular smooth muscle cells (196;229). The results 
of our study are in agreement with the concept that TRPC1 channels are strongly 
associated with CAD, as shown by increased TRPC1 mRNA and protein expression, as 
well as the ohmic and non-selective current voltage relationship of SOCE in coronary 
smooth muscle consistent with current expected of TRPC1-channel (241). TRPC6 and 
Orai1, known SOCE mediators, expression is increased with MetS, however both 
TRPC6 (242) and Orai1 (243) have distinct and vastly different current-voltage 
relationships than that observed in this study. While STIM1 protein expression mirrors 
that of TRPC1, STIM1 operates as a sensor of the intracellular Ca2+-store and not as a 
distinct functional ion channel (151). Additionally, TRPC1 protein is proportional to 
function, i.e. Ca2+ influx (Figures 4, 5). We can largely rule out other TRPC isoforms, 
because they are not expressed in coronary artery ((244), Figure 4.5I). The current 
study further extends our knowledge concerning the role of TRPC1 by the novel finding 
that metabolic syndrome increases SOCE and TRPC1 expression in conjunction with 
CAD, all of which are attenuated by exercise training. 
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Our findings indicate that TRPC1 is closely associated with neointimal 
hyperplasia, not only in non-stent, but also peri-stent segments of coronary artery. This 
is important because neointimal hyperplasia in non-stented segments is considered a 
natural progression of disease, whereas peri-stent atherosclerosis may be considered 
an arterial response to injury (245;246). Together these data suggest TRPC1 channels 
play a fundamental role promoting atherosclerosis in both non-stent and peri-stent 
segments of coronary artery. Thus, inhibition of TRPC1 channels may serve as a 
possible therapeutic target for the treatment of CAD. The concept of exercise and 
TRPC1 as potential therapeutic modes and targets is especially important because of 
the recent finding that treatment of conventional risk factors such as hyperglycemia had 
negligible effects on prevention of cardiovascular disease in type 2 diabetic humans and 
had detrimental side effects (247).  
 In conclusion, our data support the hypothesis that Ossabaw swine with robust 
MetS have increased SOCE and CAD in non-stent and peri-stent segments of coronary 
artery and exercise attenuates these events. Further, increased TRPC1/STIM1 protein 
expression was attenuated by exercise. The implications are that in human patients with 
metabolic syndrome who undergo coronary stenting and have attenuated peri-stent CAD 
with exercise training underlying cellular events may involve TRPC1 channels and 
STIM1. Future studies will focus on establishing a causative role of TRPC1 channels in 
the progression of CAD in ex vivo and in vivo models.  
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Table 4.1. 
Parameter Lean MetS XMetS Significance 
 Weight (kg) 64 + 3 111 + 9 120 + 5 XMetS, MetS > Lean 
 Total Cholesterol (mg/dL) 48 + 2 215 + 31 219 + 6 XMetS, MetS > Lean 
Low density lipoprotein (LDL, mg/dL) 26 + 4 155 + 4 136 + 16 XMetS, MetS > Lean 
High density lipoprotein (HDL, mg/dL) 18 + 3 56 + 10 83 + 6 XMetS, MetS > Lean 
 LDL/HDL  1.8 + 0.4 3.5 + 0.7 1.7 + 0.2 MetS > XMetS, Lean 
 Triglycerides (TG, mg/dL) 25 + 3 39 + 1 40 + 2 XMetS, MetS > Lean 
 Systolic Blood Pressure (mm Hg) 116 + 1 160 + 1 146 + 6 XMetS, MetS > Lean 
 Diastolic Blood Pressure (mm Hg) 77 + 2 108 + 5 94 + 7 XMetS, MetS > Lean 
Fasting Blood Glucose  67 + 2 83 + 2 82 + 2 XMetS, MetS > Lean 
Resting Heart Rate (bpm) 69 + 3 93 + 4 78 + 1 MetS > XMetS > Lean 
Resting heart rate start exercise training (bpm) ---- ---- 102 ± 1 End < Start training 
Treadmill grade at 65-75% maximum heart rate  
 
 
 
     Start exercise training  ---- ---- 3% ---- 
     End exercise training ---- ---- 8 ± 0.3 % End > Start training 
Submaximal stress test heart rate (bpm)  
 
 
 
     Start exercise training ---- ---- 173 ± 2 ---- 
     End exercise training ---- ---- 150 ± 2 End < Start training 
Table 4.1. Phenotypic characteristics of Ossabaw miniature swine groups at end of study. Lean control, MetS = metabolic 
syndrome, XMetS = exercise trained MetS. 
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Figure Legends 
Figure 4.1 Ossabaw swine fed excess atherogenic diet are glucose intolerant and 
insulin-resistant and exercise training improves physical work capacity. A. 
Timeframe of study treatments and exercise stress test (See Methods). B. Time course 
of blood glucose responses during IVGTT. C. Time course of plasma insulin responses 
during IVGTT.  
 
Figure 4.2 Greater coronary atherosclerosis in metabolic syndrome swine versus 
lean is attenuated by exercise training, but in-stent neointimal hyperplasia is not 
affected. A. Schematic of coronary vasculature. B. Coronary angiogram showing 
circumflex (CFX) and its large obtuse marginal branches and the left anterior descending 
(LAD) coronary arteries in right anterior oblique view. C. IVUS image. Dotted line 
indicates small section of internal elastic lamina and solid line indicates lumen boundary 
where showing 25% circumferential wall coverage of this cross-section of artery. 
Representative IVUS image of artery segment to receive stent immediately preceding 
stent placement in panel D and immediately following stent placement in panel E (arrows 
are stent struts). F. Representative percent wall coverage from IVUS data collected 
along the length of a stented artery both preceding stent placement (dotted) and after 
four weeks recovery post-stent (solid). G. Proximal non-stent percent wall coverage 
(N=9). **p < 0.05 vs. Lean and XMetS, *p < 0.05 vs. Lean and MetS. H. Distal non-stent 
percent wall coverage (N=9). I. Percent wall coverage in peri-stent segments (N=9). J. 
In-stent percent wall coverage. 
 
Figure 4.3 Intra-stent histology. A. Representative trichrome section. B. 
Representative H&E section. C. Intima / media cross-sectional area. D. Collagen in 
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XMetS as a percent of intra-stent media and intimal area. E. Cellularity (H&E section) in 
media and intima. a: adventitia; m: media; i: intima; l: lumen; s: stent; v: vasa vasorum. 
 
Figure 4.4 Store-operated Ca2+ entry is increased in metabolic syndrome and 
attenuated by exercise. A&C. Representative data from standard protocols used to 
assess SOCE. Peak store depletion-mediated Ca2+ influx is assessed at minutes 17-20. 
Duration of exposure to solutions is shown by horizontal lines; caffeine (CAF, 5 
mM); cyclopiazonic acid (CPA, 10 μM);. B. Exercise attenuates peak SOCE compared to 
Lean and MetS in peri-stent sections of artery. C. Mn2+ as a Ca2+ surrogate quenches 
fura-2 fluorescence at the isosbestic (Ca2+-insensitive) 360 nm wavelength verifying 
divalent cation influx. D. Increased SOCE in CSM from non-stent and peri-stent MetS 
coronary arteries compared to Lean. E. Only caffeine is used to deplete the Ca2+ store in 
this SOCE protocol. F. Increased SOCE in CSM from MetS swine. G. Whole-cell patch 
clamp data demonstrate sustained inward current by caffeine. H. Current-voltage 
relationship of leak subtracted control (blue) and SOCE (red). 
 
Figure 4.5 Increased canonical transient receptor potential 1 and stromal 
interaction molecule 1 in metabolic syndrome is abolished by exercise. A. 
Representative agarose gel image quantifying TRPC1 using RT-PCR. B. TRPC1 mRNA 
normalized to β-actin. C&D. STIM1 (Panel C) and Orai1 (Panel D) mRNA using Q-RT-
PCR normalized to β-actin. E. Immunoblot using anti-β-actin, STIM1, Orai1, and TRPC1 
in Lean and MetS. F-H. TRPC1 (F), STIM1 (G), and Orai1 (H) protein expression using 
immunoblot analysis normalized to β-actin. I. Representative agarose gel image 
illustrating TRPC1 expression and no TRPC3, TRPC4, TRPC5, or TRPC7 expression. J. 
Agarose gel image illustrating TRPC6 expression in MetS coronary arteries. K. TRPC6 
mRNA in MetS coronary arteries. **, p<0.5 MetS compared to Lean and XMetS. 
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Abstract 
Objective. We tested the hypothesis that dyslipidemia was the principal 
component of metabolic syndrome (MetS; “prediabetes”) in the progression to type 2 
diabetes and increased store-operated Ca2+ entry (SOCE) in coronary smooth muscle 
that contributes to coronary artery disease (CAD). Accordingly, we focused on and 
eliminated dyslipidemia from MetS allowing the contribution of dyslipidemia to be 
determined. 
Methods and results. Ossabaw swine, an excellent humanoid model of MetS, 
were fed normal chow (Lean; N=9), high fructose diet that induced normolipidemic MetS 
(MetS; N=10), or high fructose/trans-fat/cholesterol diet that induced dyslipidemic MetS 
(DMetS; N=8) for 24 weeks before being assessed for MetS and CAD. MetS did not 
develop MetS, type 2 diabetes, increased SOCE, or CAD. DMetS developed MetS with 
type 2 diabetes, increased SOCE, and CAD. Swine fed the same atherogenic diet as 
DMetS, but short-term (sDMetS; N=?), developed dyslipidemic MetS with increased 
SOCE preceding CAD. Electrophysiology of coronary smooth muscle revealed absent 
Ca2+-induced cation conductance and increased monovalent cation (Na+) permeance via 
store-operated channels in DMetS compared to Lean. 
Conclusions. Taken together, our results demonstrate dyslipidemia is the primary 
contributor to increased SOCE and the development of type 2 diabetes that precedes 
CAD in the metabolic syndrome. 
 
Keywords: dyslipidemia, metabolic syndrome, coronary artery disease, type 2 diabetes, 
store-operated Ca2+ entry 
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Condensed abstract 
We examined the hypothesis that dyslipidemia is the principal component of 
metabolic syndrome leading to type 2 diabetes, increased store-operated Ca2+ entry in 
coronary smooth muscle, and coronary artery disease. Our results confirm our 
hypothesis. 
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Introduction 
Metabolic syndrome (MetS; “pre-diabetes”) is strongly associated with 
progression to type 2 diabetes (43), and both MetS and type 2 diabetes adversely 
increase incidence and severity of coronary artery disease (CAD) (39). CAD risk is 
elevated at least 3-fold in patients with diabetes, defined by elevated fasting blood 
glucose (39). Although some controversy exists over the precise definition of MetS, the 
presence of at least three metabolic risk factors (e.g. glucose intolerance, insulin 
resistance, increased triglycerides, increased LDL, decreased HDL, hypertension, and 
obesity) typically renders a diagnosis (159;160). By definition it is difficult to isolate 
individual MetS risk factor (e.g. dyslipidemia) contribution in the progression to type 2 
diabetes and development of CAD in human clinical trials. Contributing to the opacity, 
there has been a paucity of suitable animal models of MetS that progress naturally to 
type 2 diabetes and develop substantial CAD (248). 
Our group rescued the Ossabaw swine from their secluded island feast-and-
famine environment and has since characterized the Ossabaw swine as the premier 
model for the study of MetS and CAD (3;4;6-8;29). A recent study by our group 
demonstrated that swine fed a diet high in fructose developed MetS without concomitant 
dyslipidemia or CAD, suggesting the necessity of dyslipidemia within the MetS for the 
development of CAD (249). However, when fed excess calorie atherogenic diet, 
Ossabaw swine recapitulate every aspect of MetS (including dyslipidemia), develop 
extensive CAD, and demonstrate dysfunctional Ca2+ regulation in coronary smooth 
muscle (CSM) (29). 
While Ca2+ dysregulation is closely associated with CSM hyperplasia, a key 
contributor to the development of CAD (250), underlying mechanisms initiating CSM 
proliferation in MetS and type 2 diabetes remain unresolved. While our group was the 
first to show a strong association between increased CSM store-operated Ca2+ entry 
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(SOCE) and CAD in MetS (29), it has not been determined if SOCE is determinant or 
resultant in developing CAD. Additionally, while TRPC1 was implicated in contributing to 
increased SOCE, the molecular identity of the Ca2+ conducting pathway remains 
unclear.  
Accordingly, this study was designed to test the hypothesis that dyslipidemia is 
the primary component of MetS for increased SOCE and the development of type 2 
diabetes that subsequently contributes to the development of CAD in the MetS. 
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Methods 
Animal care and use. All protocols involving animals were approved by an 
Institutional Animal Care and Use Committee and complied fully with standards 
(175;176). Forty-five mixed gender Ossabaw swine at the age of ten to fifteen months 
(adult) were assigned to four diet groups for 22-24 weeks. Lean control swine (Lean, 
N=10) were fed standard chow. The trans fatty acid MetS (TMetS, N=9) group was fed a 
high fat/fructose/2% cholesterol (w/w) atherogenic diet (hydrogenated soybean oil; 56% 
trans fatty acid) (6;7;29). The mixed fat (MMetS, N=8) was fed a high fat/fructose/2% 
cholesterol (w/w) atherogenic diet (mixture of lard, hydrogenated soybean oil, and 
hydrogenated coconut oil (7). See supplemental material for detailed methods. 
Intravenous glucose tolerance test. IVGTT was preformed as previously 
described by our lab (3;4;29). Briefly, conscious swine acclimatized to low-stress 
restraint in a sling were fasted overnight and baseline blood samples were obtained. 
Glucose (1g/kg body weight; i.v.) was administered and timed blood samples were 
collected. 
Plasma lipid assays. Venous blood samples were obtained following overnight 
fasting and analyzed for triglyceride and total cholesterol as previously described by our 
laboratory (29). See supplement for detailed methods. 
Assessment of insulin-positive area. Pancreas tissue was sectioned and imaged 
using standard histological technique (29). The 5-μm pancreas sections were mounted 
on glass slides and assessed for insulin-positive area using mouse anti-insulin primary 
antibody (Sigma #I2018; a generous gift from Dr. Deborah Thurmond, Indiana University 
Purdue University Indianapolis) and mouse biotinylated secondary antibody (Vectastain 
Elite ABC Kit PK-6102). DAB (Sigma Fast D-4168) was used for visualization. Sections 
were counterstained with Mayer’s hematoxylin.  
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Assessment of coronary artery disease. IVUS pullbacks performed at the end of 
the study were used to assess native atheroma (17;20;29). Percent circumferential wall 
coverage was calculated similar to previous reports (3;20;29). See supplemental 
material for detailed methods. 
Cell dispersion. The procedure for the isolation of coronary arteries and the 
enzymatic dispersal of porcine coronary smooth muscle cells has been previously 
described (13;169). See supplement for detailed methods. 
Intracellular Ca2+ measurements. Whole cell intracellular Ca2+ levels were 
obtained at room temperature (22–23°C) using the fluorescent Ca2+ indicator, fura-2, and 
the InCa++ Ca2+ Imaging System (Intracellular Imaging, Cincinnati, OH) as previously 
described by our laboratory (13;18;169). See supplement for detailed methods. 
Patch clamp electrophysiology. Whole cell currents were measured at room 
temperature (22–23°C) using a standard whole cell voltage clamp technique as 
used routinely by our laboratory (29;138;182;251;252). Intracellular solution was (in mM) 
120 CsCl, 10 NaCl, 1 MgCl2, 20 HEPES, 5 Na2ATP, 0.5 Tris GTP, with 7.2 pH. Currents 
were amplified with a List EPC-7 headstage filtered through an eight-pole low-pass filter 
with a cutoff frequency of 400 Hz. Capacity currents were filtered at low-pass cutoff 
frequency of 8.4 kHz. Normalization for membrane capacitance was not performed. Data 
acquisition and analyses were performed with a Labmaster analog-to-digital converter 
and AxoBASIC 1.0 data acquisition software (Axon Instruments, Sunnyvale, CA). Cells 
were constantly superfused at 1–2 ml/min. See supplement for detailed methods. 
Statistical analysis. One-way or two-way analysis of variance with Student-
Newman-Kuels or Bonferroni post-hoc analysis, as appropriate, were performed using 
commercially available software (Prism 4.0) when comparing multiple groups. 
Independent t-test was used for comparing just two groups. In all tests, p <0.05 was the 
criterion for statistical significance. Unless otherwise noted; *, p <0.05 compared to 
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Lean; **, p <0.05 compared to Lean and MetS; ***, p <0.05 compared to all other 
groups. 
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Results 
Three indicators of glucose intolerance were quantified from blood glucose 
measurements: 1) fasting glucose, 2) peak response to glucose, and 3) integral of 
glucose response curve. Peak response to glucose (Figure 5.1A) was elevated in MetS 
and DMetS compared to Lean. Fasting glucose was increased in DMetS ~33% above 
Lean and MetS (Figure 5.1B), providing strong evidence for type 2 diabetes in DMetS 
swine. Integral of the glucose response was elevated ~150% in DMetS compared to 
Lean and MetS, while MetS was elevated above Lean (Figure 5.1C). MetS insulin 
response was elevated above Lean and DMetS as evidenced by elevated peak (Figure 
5.1D) and integral of the insulin response (Figure 5.1F). The homeostasis model 
assessment (HOMA) index is commonly used to diagnose insulin resistance clinically 
and MetS and DMetS HOMA index values were elevated ~200% above Lean (Figure 
5.1E). Importantly, DMetS were unable to increase insulin secretion in response to the 
intravenous glucose load above Lean. The integral of the insulin response was also 
reflected in the relative pancreatic β-cell abundance, which was increased ~6-fold in 
MetS compared to Lean and DMetS (Figure 5.1D). 
Angiography, used clinically to diagnose focal, stenotic atherosclerotic lesions, 
was performed on each pig and revealed no focal stenosis (Figure 5.2A) in any pig. 
Importantly, intravascular ultrasound (IVUS; Figure 5.2B) a more sensitive in vivo 
measure of CAD showed that DMetS developed extensive diffuse CAD compared to 
Lean and MetS (Figure 5.2C). Diffuse CAD was clearly evident by the ~2-fold greater 
arterial wall coverage with in proximal, intermediate, and distal coronary artery segments 
compared to MetS and Lean groups. MetS CAD was not significantly elevated compared 
to Lean.  
. Analysis of coronary smooth muscle (CSM) Ca2+ regulation was conducted by 
fura-2 fluorescence imaging using a standard protocol (Figure 5.3A). Baseline 
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intracellular Ca2+ (Ca2+i) was elevated in DMetS CSM compared to Lean and MetS 
(Figure 5.3B). Caffeine and cyclopiazonic acid (Caff, 5 mM; CPA 10-5 M, respectively) 
treatment in the absence of extracellular Ca2+ (Ca2+o) rapidly release Ca2+, resulting in a 
large amplitude Ca2+ and deplete the sarcoplasmic reticulum SR Ca2+ store (Figure 
5.3A). MetS demonstrated increased Ca2+ efflux capacity compared to Lean and DMetS 
(Figure 5.3C), as assessed using time to ½ minimum (time ½ min.) recovery from Caff 
and CPA response in the absence of Ca2+o. In the absence of Ca2+o the peak Ca2+i 
response to Caff and CPA was elevated in DMetS compared to Lean and MetS, and 
MetS compared to Lean (Figure 5.3D), indicating increased SR Ca2+-store. Store-
operated Ca2+ entry (SOCE), was assessed by addition of extracellular Mn2+ (Mn2+o) 
following SR Ca2+-store depletion. Mn2+o is permeant to Ca2+ conductance pathways, 
thus it served as a Ca2+o surrogate, quenching fura-2 (decreasing fluorescence) at its 
Ca2+-insensitive isobestic excitation wavelength (F360) and indicating inward divalent 
plasma membrane conductance (Figure 5.3A). SOCE was elevated ~2-fold in DMetS 
CSM compared to Lean and MetS, while MetS was not different than Lean (Figure 
5.3E). Swine fed the same atherogenic diet as in DMetS for only 9 weeks (short-term 
DMetS; sDMetS) developed complete MetS (Supplementary Table1), but CAD (not 
shown), baseline CSM Ca2+i (Figure 5.3F) and peak CSM Ca2+-response to Caff and 
CPA (Figure 5.3G) were not elevated above Lean cohorts. However, SOCE was 
elevated ~2-fold in sDMetS compared to Lean (Figure 5.3H). Thus, the development of 
CAD, increased CSM baseline Ca2+i, and increased SR Ca2+-store were preceded by 
increased SOCE in CSM. 
Whole-cell patch clamp experiments were conducted with Cs+-filled pipettes to 
block outward K+ currents and optimize detection of inward cation currents. Rapid 
release of the SR Ca2+ store using Caff and CPA in the presence of 2 mM Ca2+ activated 
robust inward current at the peak of the Ca2+I transient (at ~90 s in Figure 5.4A) in Lean 
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CSM, which was completely abolished in DMetS (Figure 5.4C). The ERev of +34 mV 
indicates significant Na+ and Ca2+ permeability. Following SR Ca2+-store depletion, a 
store-operated cation conductance (SOCC) was not different in the presence or absence 
of 2 mM Ca2+o in Lean (Figure 5.4D), but was increased in DMetS CSM in 0 mM Ca2+o 
compared to 2mM Ca2+o (Figure 5.4E). Importantly, SOCC in the presence of 2 mM 
Ca2+o was mildly inward rectifying in Lean CSM, but ohmic in DMetS CSM (Figure 
5.4F,G). The Erev of +26 mV for SOCC indicates more Na+ and Ca2+ permeability in CSM 
from Lean pigs, while the Erev of 0 mV argues for non-selective SOCC in CSM from 
DMetS pigs. These patch clamp data suggest different proteins mediate SOCC between 
Lean and DMetS. 
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Discussion 
The major novel findings of this study are that coronary smooth muscle (CSM) 
from Ossabaw swine with metabolic syndrome, coronary artery disease (CAD), and type 
2 diabetes (DMetS) strikingly demonstrate a complete absence of Ca2+-induced cation 
conductance (CICC), while profoundly increased store-operated cation conductance 
(SOCC) is completely non-selective. Importantly, increased SOCC precedes the 
development of CAD in short-term dyslipidemic MetS swine (sDMetS). Additional novel 
findings include greatly increased sarcoplasmic reticulum (SR) Ca2+-store and basal 
intracellular Ca2+ (Ca2+i) in CSM from DMetS swine. CSM from Ossabaw swine that 
develop normolipidemic metabolic syndrome (MetS) demonstrate increased SR Ca2+-
store, but have increased Ca2+ efflux, no change in basal Ca2+i, no SOCC, and no CAD. 
Together, these results support a primary role of dyslipidemia in mediating increased 
SOCC, progression to type 2 diabetes, and development of CAD.  
This is the first report of any swine model of MetS atherosclerosis progressing to 
type 2 diabetes mellitus characterized by ~30% increase in fasting blood glucose, 
elevated peak glucose and integral of glucose response without compensatory insulin 
response during intravenous glucose tolerance test (IVGTT), increased homeostasis 
model assessment (HOMA) index values, and the complete absence of pancreatic β-cell 
hypertrophy that typically compensates for decreased insulin sensitivity and glucose 
tolerance. MetS also develop glucose intolerance and insulin resistance, but are able to 
compensate through increased insulin output and pancreatic β-cell hypertrophy. The 
striking phenotypic contrast between normo- and dyslipidemic MetS swine, as well as 
the addition of sDMetS, provides absolutely unique experimental conditions to dissect 
the determinant mechanisms in the development of CAD. 
Ossabaw swine have previously been characterized as possessing a uniquely 
thrifty phenotype (253), but suffered a nearly 30 year gap in the literature. Our group 
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responded to a timely appeal by Brisbin to save Ossabaw swine from eradication from 
their feast and famine ecology on Ossabaw Island, GA, USA (254). We removed 
Ossabaw swine from their coastal island to form the only large breeding and research 
herd of Ossabaw swine in the world. Our group has consistently reproduced the MetS 
phenotype in Ossabaw swine through selective breeding and feeding (3;29;182). 
However, this is the most convincing report that Ossabaw swine indeed develop overt 
type 2 diabetes, induced through the simple feeding of hypercaloric, atherogenic diet. 
Diabetes mellitus is defined by an elevation in fasting blood glucose. While the 
threshold for diabetes is 126 mg/dL (7 mmol/L) in humans (45), it is expected that each 
species should have a different threshold as metabolism varies among species (255). 
Additionally, the mean fasting glucose for Lean in this study (74 mg/dL or 4.1 mmol/L; 
Figure 5.1B) is on the very low end of values observed in healthy humans (256). Thus, 
a lower threshold for diabetes should be considered in Ossabaw swine. MetS were 
clearly not diabetic with no elevation in fasting blood glucose (Figure 5.1B), however 
DMetS fasting blood glucose of 100 mg/dL (5.5 mmol/L; Figure 5.1B), representing an 
approximate 30% increase over Lean, should be considered significant evidence of type 
2 diabetes. During the development of type 2 diabetes (see timeline in Supplementary 
Figure 5.1), hepatic and peripheral insulin resistance leads to a compensatory increase 
in insulin secretion by the pancreas thus instigating a further decreased insulin 
sensitivity. Increased insulin secretion leads to pancreatic β-cell hypertrophy and stress 
and eventually decreased β-cell function, resulting in deficient insulin response to 
glucose load. MetS and DMetS demonstrated clear insulin resistance, as homeostasis 
model assessment values were elevated compared to Lean (Figure 5.1E). However, 
DMetS were not able to compensate for insulin resistance by increasing insulin secretion 
during the IVGTT (Figure 5.1 D&F) and there was no β-cell hypertrophy in DMetS 
(Figure 5.2D). Directly juxtaposing was the compensatory increase in insulin secretion 
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and β-cell hypertrophy observed in MetS (Figure 5.1 D&F and 2D). Given the elevated 
fasting blood glucose and HOMA values, the lack of insulin response to glucose load 
suggests DMetS were progressing towards β-cell collapse and a total inability to produce 
insulin. 
Pancreatic β-cell insulin signaling and hepatic and peripheral insulin sensitivity 
have been closely linked to dyslipidemia (257). Additionally, reducing circulating 
triglycerides and LDL cholesterol in patients with and without diabetes has been shown 
to lower the incidence of CAD (258). As such, the results of this study support a major 
contribution of dyslipidemia to the development of type 2 diabetes and, regardless of 
diabetic state, CAD. Specifically, MetS were normolipidemic and did not progress to type 
2 diabetes or increased CAD, and DMetS were dyslipidemic and developed overt type 2 
diabetes and CAD. 
Consistent with a diabetic state, DMetS developed diffuse CAD (Figure 5.3). As 
CSM hyperplasia is a major contributor to advanced coronary atherosclerosis (227) and 
Ca2+ regulation is a key regulator of excitation-transcription coupling (120), we 
investigated Ca2+ regulation in CSM. CSM have three major mechanisms for regulating 
Ca2+i: Ca2+ entry across the plasma membrane, Ca2+ efflux across the plasma 
membrane, and Ca2+ buffering by intracellular Ca2+ stores (e.g. sarcoplasmic reticulum 
[SR]). Elevated baseline Ca2+i suggested severe Ca2+ dysregulation in DMetS CSM 
compared to Lean and MetS (Figure 5.4B). Elevated peak Ca2+i change in response to 
Caff and CPA demonstrated increased SR Ca2+ store (i.e. (26;197)) in MetS and DMetS 
CSM compared to Lean, with DMetS also elevated above MetS (Figure 5.4D). 
Importantly, SR Ca2+ store capacity is strongly determined by Ca2+i and Ca2+ influx 
(259;260). 
No difference in time to ½ minimum in response to Caff and CPA in the absence 
of extracellular Ca2+ (Ca2+o) suggests Ca2+ efflux across the PM was not different 
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(13;26;261) between Lean and DMetS, while Ca2+ efflux was elevated in MetS (Figure 
5.4C). Decreased time to ½ minimum in MetS may suggest a compensatory mechanism 
contributing to normal Ca2+i through increased Ca2+ efflux, despite significantly increased 
SR Ca2+-store, consistent with previously reported up-regulation of Ca2+ sequestration by 
the SR in diabetic dyslipidemic Yucatan pigs (13;16;174). This would also suggest 
MMetS are not able to compensate a similar mechanism. 
Complete SR Ca2+-store depletion is accomplished in the presence of Caff and 
CPA, activating store-operated cation conductance (SOCC) pathways. SOCC has been 
strongly associated with CSM proliferation, migration, and CAD development, by our 
group and others (29;196). Indeed, CSM from DMetS exhibited a ~3-fold increase in 
SOCC compared to Lean and MetS (Figure 5.4E). Our group has previously shown that 
SOCC is mediated primarily through canonical transient receptor potential 1 (TRPC1), 
which is elevated in CSM from MetS swine (29). Importantly, this is the first report of 
increased SOCC in CSM preceding the development of CAD (i.e. sDMetS in Figure 
5.4H) that, along with the absence of SOCC and CAD in MetS, provides compelling 
evidence for the necessity of 1) dyslipidemia in SOCC induction and 2) SOCC in CAD 
development in MetS swine. 
Divalent cation influx, as measured by Mn2+ quench of fura-2 fluorescence, was 
significantly increased in DMetS compared to Lean and MetS when SR depletion was 
accomplished in Ca2+o-free media. Electrophysiological analysis of SOCC revealed 
monovalent SOCC was not changed in Lean CSM compared to divalent SOCC (Figure 
5D), but non-selective monovalent SOCC was greatly increased in DMetS CSM (Figure 
5E). Increased non-selective monovalent SOCC in DMetS is consistent with previous 
findings from our lab indicating TRPC1 mediates increased SOCC in CSM from MetS 
swine (29) and suggests an exciting mechanism involving the Na+/Ca2+ exchanger. 
Under normal circumstances NCX antiports three Na+ ions into the cell and one Ca2+ ion 
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out of the cell, thus reducing Ca2+i. However increased intracellular Na+ potentiates 
reverse mode NCX mediated Ca2+ influx (262). Additionally, decreased membrane 
polarity, reported in MetS Ossabaw CSM via decreased K+ channel function (140), 
would be induced by Na+ influx and further potentiate reverse mode NCX (262). 
Increased reverse mode NCX in regions of the plasma membrane closely associated 
with the SR membrane would lead to elevated SR Ca2+-store (e.g. Figure 5.4D; 
(260;263)). SR Ca2+ depletion leads to conformational changes in stromal interaction 
molecule 1 (STIM1) in the SR membrane, in turn leading to direct physical interaction 
with and activation of TRPC1 in the plasma membrane (264). Thus, a close apposition of 
plasma membrane and SR membrane is essential for SOCC induction and provides an 
ideal opportunity for SOCC-induced reverse mode NCX. Other TRPC isoforms are 
known to directly induce reverse mode NCX through Na+ influx involving receptor 
operated, but not store-operated, mechanisms of TRPC3/6 activation (265;266). Taken 
together, previous publications and the results of this study strongly suggest increased 
Na+ influx conducted by TRPC1-mediated SOCC leads to reverse mode NCX and 
divalent cation influx in CSM from DMetS (outlined in Supplementary Figure 5.2). 
Voltage-gated Ca2+ channels (VGCC) provide a significant Ca2+ conductance 
pathway in depolarized CSM, contributing to CSM contraction (267;268). Previous 
reports showed an ostensibly counter-intuitive decrease in voltage-gated Ca2+ 
conductance (VGCC) in CSM from hyperlipidemic and alloxan-induced diabetic Yucatan 
swine (13;267). However, strong evidence indicates that Ca2+ influx through VGCC 
preserves vascular smooth muscle contractile phenotype and genes, while down-
regulation of VGCC induces de-differentation associated with proliferation and migration 
(172). While this study cannot rule out VGCC contribution to Ca2+-dysregulation in MetS 
CSM, decreased VGCC Ca2+ conductance would not increase Ca2+i. Also, it is evident 
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that VGCC do not significantly contribute to SOCC, as nifedipine does not inhibit SOCC 
(Supplementary Figure 5.3). 
TRPM (melanostatin) 4 has been shown to directly inhibit SOCC in T 
lymphocytes (269). CSM from Lean demonstrated a cation conductance activated by 
increased Ca2+i. This Ca2+-induced cation conductance (CICC) is strikingly similar to 
previous biophysical characterizations of TRPM4b (270) (Figure 5C). This provides the 
exciting possibility that, although Lean CSM express TRPC1 (29) and minimal SOCC 
(Figure 5.4&5; (29)), the co-expression of TRPM4 provides an inhibitory mechanism 
preventing increased SOCC that is not present in DMetS, thus resulting in potentiation of 
SOCC in DMetS CSM. This intriguing hypothesis, while not directly assessed in this 
study, should be considered in future studies investigating the involvement of TRPM4 in 
smooth muscle from diabetic coronary arteries demonstrating elevated SOCC. 
This study provided compelling evidence of the first swine model of metabolic 
syndrome that progressed to type 2 diabetes mellitus and developed diffuse coronary 
artery. Extensive fura-2 based Ca2+ imaging studies clearly defined Ca2+ dysregulation in 
coronary smooth muscle from diabetic, dyslipidemic Ossabaw miniature swine 
characterized by 1) elevated baseline Ca2+i, 2) increased SR Ca2+-store, 3) and 
increased SOCC. This is the first report of SOCC preceding the development of CAD, 
thus providing compelling evidence for a causative role. Patch clamp studies revealed 
robust TRPM4-like CICC in Lean CSM and no evidence of CICC and, correspondingly, 
increased non-selective SOCC in DMetS CSM. It is evident that dyslipidemia is a 
primary mediator of increased CSM SOCC, progression to diabetes, and diffuse CAD. 
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Figure Legends 
Figure 5.1 Intravenous glucose tolerance test reveals glucose intolerance and 
insulin resistance in MetS and type 2 diabetes in DMetS. A Peak glucose is elevated 
in MetS and DMetS compared to Lean. B Fasting glucose was elevated ~30% in DMetS 
compared to Lean and MetS. C Integral of the glucose response is elevated in DMetS 
compared to MetS and Lean, while MetS was elevated compared to Lean. D Peak 
insulin response is elevated in MetS compared to DMetS and Lean. E HOMA index 
values were increased in MetS and DMetS compared to Lean. F Integral of the insulin 
response is elevated in MetS compared to DMetS and Lean. Immunohistochemistry was 
performed on pancreas histological sections targeting insulin (G,H). G Arrows show 
insulin positive islets in Lean group. H Increased insulin positive area shows beta cell 
expansion and increased adipocyte area in MetS (*). I Pancreas percent insulin positive 
area was increased in MetS compared to DMetS. 
 
Figure 5.2 Coronary artery disease is increased in DMetS, but not MetS. A 
Representative angiogram of left anterior descending (LAD) and circumflex (CFX) 
coronary arteries with schematic of proximal (Prox.), intermediate (Inter.), and distal 
segments. B Representative DMetS IVUS image with 63 percent wall coverage. C 
DMetS percent wall coverage is increased compared to Lean and MetS. 
 
Figure 5.3 Metabolic syndrome induces Ca2+ dysregulation in coronary smooth 
muscle. A Baseline Ca2+ concentration, SR Ca2+ store (peak), Ca2+ efflux (time to ½ 
min.), and store-operated Ca2+ entry (SOCE; slope in Mn2+) were assessed in CSM. 
CSM were in physiological salt solution before switching the extracellular superfusate to 
0 Ca2+ solution containing 5 mM caffeine (Caff) and 10-6 M cyclopiazonic acid (CPA) 
followed by addition of 2 mM Mn2+. Each solution was applied for the duration indicated 
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by the horizontal lines. B Baseline intracellular Ca2+ was elevated in DMetS CSM 
compared to MetS and Lean. C The time from peak Ca2+ response to caffeine to ½ 
minimum was significantly reduced in MetS compared to Lean and DMetS. D Peak Ca2+ 
response to caffeine was increased in MetS compared to Lean, and DMetS compared to 
Lean and MetS. E The rate of Mn2+ influx is increased in DMetS compared to Lean and 
MetS. Short-term DMetS (sDMetS) have no change in baseline (F) or peak response to 
caffeine (G), while Mn2+ permeability (SOCE; H) is increased in sDMetS compared to 
Lean. 
 
Figure 5.4 Dysfunctional mono- and di-valent cation conductances in DMetS 
compared to Lean. Whole cell current was recorded in freshly dispersed CSM at -80 
mV holding potential at 2-5 s intervals for A Lean and B DMetS. 2000-ms ramp functions 
(-100 mV to +70 mV) were inserted at (C) peak Ca2+-induced conductance or peak 
store-operated cation conductance (SOCC) in the (D) presence or (E) absence of 2 mM 
extracellular Ca2+. C-G Representative leak-subtracted currents with mean and SEM 
values at -90, -60, -30, +30, and +60 mV. C Ca2+-induced cation conductance is 
completely abolished in DMetS (Reversal potential, ERev = 0) compared to Lean (ERev = 
34). D In the presence (●, +Ca) or absence (○, -Ca) of 2 mM extracellular Ca2+, SOCC is 
not different in Lean. E Non-selective, ohmic SOCC is increased in DMetS (ERev = 0) in 
the absence of extracellular Ca2+, consistent with TRPC1-mediated SOCC. In the 
presence of 2mM extracellular Ca2+, expanded scale demonstrates (F) inward rectifying, 
Ca2+-selective current in Lean (ERev = 26), consistent with Orai1-mediated SOCC and 
(G) ohmic, non-selective current in DMetS (ERev = 0), consistent with TRPC1-mediated 
SOCC. 
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Table 5.1 
 Lean MetS DMetS p < 0.05 
Start body weight (BW, kg) 41.5 ± 1.8 45.7 ± 2.7 48.0 ± 2.5  
End BW (kg) 59.0 ± 2.4 94.4 ± 6.4 78.7 ± 5.3 *, ⁪ 
Girth (cm) 86.9 ± 2 117.5 ± 5 100.2 ± 3 *, ⁪ 
Total cholesterol (mg/dl) 52.8 ± 3.5 59.9 ± 4.3 244.7 ± 11.9 ** 
LDL (mg/dl) 17.3 ± 1.7 35.2 ± 3.1 168.9 ± 9.6 ** 
HDL (mg/dl) 34.7 ± 2.8 24.5 ± 5.3 75.8 ± 8.3 ** 
LDL/HDL Ratio 0.5 ± 0.1 2.4 ± 2.0 2.4 ± 0.8 * 
Triglycerides (mg/dl) 17.2 ± 2.6 30.1 ± 2.3 36.4 ± 9.8 * 
Systolic blood pressure 
(mmHg) 
123.9 ± 8.6 147.7 ± 6.6 139.6 ± 3.6 
* 
Diastolic blood pressure 
(mmHg) 
80.3 ± 6.5 92.6 ± 4.3 85.5 ± 3.1 
* 
Mean arterial pressure 94.8 ± 7.1 110.3 ± 5.0 103.6 ± 3.1 ** 
Table 5.1 MetS characteristics of Ossabaw swine. Comparisons between groups 
were made by one-way analysis of variance (ANOVA) with Newman-Keuls post-hoc 
analysis.  
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Figure 5.2 
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Figure 5.3 
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Figure 5.4 
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Chapter 6 
General overview 
The major hypotheses tested in this thesis were that 1) Ossabaw swine have a 
genetic predisposition for metabolic syndrome (MetS), type 2 diabetes, and coronary 
artery disease (CAD) compared to the lean Yucatan breed, 2) dyslipidemia is the 
primary component of MetS necessary for the development of non-alcoholic 
steatohepatitis, type 2 diabetes, and CAD, 3) MetS increases store-operated Ca2+ entry 
(SOCE) and CAD in non-stent and peri-stent segments of coronary artery and exercise 
attenuates these events, and 4) dyslipidemia is necessary for increased SOCE that 
significantly contributes to the development of CAD in MetS. Powerful study designs 
utilizing the only large animal model of MetS, type 2 diabetes, and CAD elucidated 
several novel findings with important implications for the fundamental treatment of 
human disease. 
The major novel findings of this thesis were: 1) Ossabaw swine are predisposed 
to MetS, features of type 2 diabetes, and diffuse native and in-stent CAD compared to 
Yucatan swine. 2) Fructose is a necessary, but not sufficient, dietary component for 
induction of NASH. 3) The diet components of high fructose, mixed-source fat, and 
cholesterol uniquely synergize in the development of severe CAD. 4) Insulin resistance 
in MetS, while possibly permissive and synergistic, is not predictive of NASH or CAD. 5) 
Individual fatty acid methyl esters (FAME) heptadecaenoic and vaccinate acid (among 
others previously reported in CAD trials) are strongly associated with severity of CAD. 6) 
Several individual and group FAME are strongly associated with NASH. 7) Dyslipidemia, 
defined by dyslipoproteinemia and hypertriglyceridemia, is a necessary component of 
MetS for the development of NASH and CAD. 8) Elevated integral of LDL cholesterol 
(LDL gram-years) is strongly predictive of NASH and CAD in MetS. 9) SOCE is elevated 
in coronary smooth muscle (CSM) of atherosclerotic arteries, and this increased SOCE 
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precedes the development of CAD. 10) Ca2+ induced cation conductance in completely 
abolished in MetS. 11) Increased monovalent permeance through store-operated 
pathways in CSM is primarily mediated by dyslipidemia in MetS. 12) Biophysical 
properties of SOCE in CSM are consistent with TRPC1 as the molecular mediator of 
SOCE. 13) Exercise training decreases SOCE function and transient receptor potential 
canonical 1 (TRPC1) and stromal interaction molecule 1 (STIM1) in CSM from native 
CAD in MetS. 14) Exercise training attenuates native CAD in MetS. 
 
Porcine model of metabolic syndrome 
Swine are commonly used in the study of diabetes (12;142;271-273) and 
cardiovascular disease (4;110;165;274-276) because of their similarities to human lipid 
metabolism, insulin signaling, cardiovascular anatomy and function, size, activity level, 
and omnivorous diet (reviewed elsewhere (277)). Yucatan swine have been used 
extensively in cardiovascular research, although they develop sparse CAD in the 
absence of combined atherogenic diet and chemically-induced diabetes (reviewed 
elsewhere (115)). As such, Yucatan swine are a lean breed that never develop obesity, 
primary insulin resistance, glucose intolerance, elevated triglycerides, or hypertension 
when fed excess calorie atherogenic diet (reviewed elsewhere (278)). As demonstrated 
in this report and elsewhere, Ossabaw swine have been shown to be prone to obesity 
when compared to leaner breeds (Chapter 2, (3;168;253;279-281)) and develop all 
aspects of the MetS when fed excess calorie atherogenic diet (Chapters 3, 4, and 5, 
(3;4;6;29;282)). Additionally, Ossabaw swine demonstrated CAD mediated by excess 
atherogenic diet (3). Therefore, in Chapter 2 we rigorously confirmed that Ossabaw 
swine have a propensity to obesity, MetS, cardiovascular dysfunction, native CAD, and 
in-stent stenosis compared to Yucatan swine when fed eucaloric diet (demonstrated to 
maintain healthy Yucatan body weight (4)) with either normal or high fat.  
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Similar to the Pima Indian population in the American southwest (283), Ossabaw 
swine developed a thrifty genotype through hundreds of years of natural selection in a 
harsh feast and famine ecology. While efficient storage of fat is beneficial when food 
supply is limited, when combined with long-term hypercaloric intake high in fat and 
carbohydrates (i.e. the modern diet) leads to obesity and propensity for type 2 diabetes 
(original thrifty genotype in modern times hypothesis outlined by Neel, J.V. in 1962 
(284)). The strong evolutionary process of natural selection sets Ossabaw swine apart 
as a model of MetS compared to Göttingen minipigs that develop dyslipidemia, but not 
glucose intolerance or insulin resistance (110), Yucatan swine that develop high LDL 
cholesterol, but no other MetS component (1;2;9), and various Chinese minipigs that are 
relatively resistant to insulin resistance and glucose intolerance (142). 
Chapter 4 and previous reports (3;4;20;21) induced MetS in Ossabaw swine 
using excess calorie atherogenic diet composed primarily of standard chow 
supplemented with partially hydrogenated soybean oil (high in trans-fat) and cholesterol. 
Excess high trans-fat/cholesterol induced complete MetS, including glucose and insulin 
resistance, mild atherosclerotic CAD, and no liver dysfunction or disease (7). Expanding 
on these studies, excess calorie high fructose alone was sufficient for the development 
of normolipidemic MetS, but was not sufficient for progression to type 2 diabetes, CAD, 
or NASH (Chapter 3). However, the addition of high fructose to excess calorie high fat 
(from varying source) and cholesterol diet enabled progression to type 2 diabetes and 
development of NASH and severe CAD (Chapters 3 and 5). 
 
Porcine model of type 2 diabetes 
Type 2 diabetes is clinically defined as fasting blood glucose above 126 mg/dL or 
2-hour plasma glucose levels on oral glucose tolerance test above 200 mg/dL (reviewed 
elsewhere (256)). Although similar to humans, important differences in swine glucose 
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homeostasis should be taken into careful consideration when defining diabetes in swine 
(reviewed elsewhere (277)). Chief among these concerns are the lower fasting glucose 
levels (65-75 mg/dL swine (Chapters 2-5; (285), 74-106 human, reviewed elsewhere 
(256)) in healthy swine compared to humans. Also of importance, swine have relatively 
high glucose tolerance to oral glucose load and increased clearance following 
intravenous glucose load (Chapters 2-5 (277)). Additionally, swine pancreatic β-
cell:body mass ratio is twice that in humans, suggesting significant insulin secretory 
reserve in swine (286;287). Taken together, these observations suggest a lower 
threshold for the diagnosis of prediabetes and diabetes mellitus should be considered for 
swine.  
Chapters 3 and 5 provide the most compelling evidence of progression to type 2 
diabetes in the Ossabaw swine model of MetS. OssH (Chapter 2), F/MetS (Chapters 3 
and 5), TMetS (Chapter 4), and XMetS (Chapter 4) swine groups in this report 
demonstrated fasting blood glucose levels between 75 and 90 mg/dL, consistent with a 
prediabetic state in swine, as outlined in Figure 6.1. Additionally, MMetS and DMetS 
fasting blood glucose were elevated above 90 mg/dL, the threshold for Ossabaw swine 
diabetes outlined in Figure 6.1. Additionally, histological analysis of pancreas insulin 
positive area was used to assess the relative density of pancreatic β-cells. MMetS 
demonstrated a significant increase in insulin positive pancreatic β-cell area compared to 
Lean, suggesting compensatory β-cell hypertrophy (Figures 3.1 and 6.1). DMetS fasting 
blood glucose were the highest of any group in this report, while insulin response during 
intravenous glucose tolerance test (IVGTT) and insulin positive pancreatic β-cell area 
was not different than their Lean cohorts (Figure 5.2). These results are suggestive of 
progression through pancreatic β-cell hypertrophy and into β-cell collapse, the late 
stages of type 2 diabetes (timeline outlined in Figure 6.1). It is possible that DMetS 
simply failed to compensate for peripheral insulin resistance by increasing insulin 
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secretion, however the underlying mechanism of such an event is uncertain. Importantly, 
50-75% of patients with diabetes demonstrate significant fatty liver (63). Additionally, 
non-alcoholic fatty liver disease predicts the future diagnosis of type 2 diabetes (288). 
 
Fructose and dyslipidemia mediate non-alcoholic steatohepatitis 
NAFLD is generally considered the manifestation of MetS in the liver (289). As 
such, insulin resistance (peripheral and hepatic), dyslipidemia, and elevated triglycerides 
are defining characteristics of NAFLD (290). The progression of NAFLD to NASH is 
poorly understood (57), and diagnosis of NASH is relatively intensive, typically requiring 
histological analysis following liver biopsy (291). NASH is characterized by steatosis, 
inflammation, hepatocyte ballooning, and increased fibrosis (57). While NAFLD is fairly 
benign, NASH is associated with cirrhosis and reduced life expectancy (292) adding to 
the importance of early detection. Until the recent description of NASH in Ossabaw 
swine with MetS (7), there was absolutely no animal model of NASH available. As such, 
Chapter 3 is the first report of NASH in a model of type 2 diabetes and MetS. 
NASH was never observed in swine fed high fat/cholesterol atherogenic diet 
(Chapters 2, 4, and 5), even when the diet regimen lasted 2-3 times as long as the 
current studies (293), until the addition of high fructose (7). However, high fructose alone 
was not sufficient to induce NAFLD or NASH, although it was sufficient for induction of 
MetS (e.g. FMetS in Chapter 3). This suggests that fructose within an atherogenic diet is 
permissive for the development of NAFLD and NASH. The exact mechanism of this 
action is not known, however a volume of literature showing altered fatty acid 
metabolism with high fructose feeding may provide clues. High fructose feeding for only 
six days in human subjects was shown to stimulate de novo lipogenesis, elevate fasting 
trigrlycerides, blunted suppression of endogenous glucose production during 
hyperinsulinemic-euglycemic clamp, indicating hepatic insulin resistance, and impaired 
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suppression of non-esterified fatty acids, indicating adipose insulin resistance (294). 
Chronic high fructose feeding in rats inhibited de novo lipogenesis in adipose tissue, 
while hepatic lipogenesis was elevated under the same condition (218). Importantly, de 
novo lipogenesis was significantly elevated in patients with NAFLD and NASH (214). 
Taken together, these observations suggest high fructose intake leads to significantly 
elevated triglycerides, both circulating and hepatic, that is an essential step in the 
development of NAFLD and NASH (295). 
We selectively eliminated dyslipidemia from the MetS milieu and tested the 
hypothesis that dyslipidemia, defined as the combination of dyslipoproteinemia and 
hypertriglyceridemia (210), is necessary for the development of NASH in the MetS 
(Chapter 3). Testing the role of dyslipidemia was important as many reports suggest 
that insulin resistance may be the primary mediator of NAFLD progression (reviewed 
elsewhere (296)). FMetS swine developed MetS without concomitant dyslipidemia, 
DMetS developed MetS with relatively mild dyslipidemia, and MMetS developed MetS 
with severe dyslipidemia and type 2 diabetes (Figure 3.1 and Table 3.1). This powerful 
study design allowed dissection of the dyslipidemic contribution and clearly 
demonstrated the necessity of dyslipidemia in NASH within the MetS. The major findings 
that cumulative LDL cholesterol (LDL gram-years) powerfully predicted NASH severity (r 
= 0.88; Figure 3.5) and adipose insulin resistance weakly (Chapter 3 discussion) and 
fasting insulin levels and homeostasis model assessment HOMA values (data not 
shown) do not predict NASH, provide powerful evidence that dyslipidemia is the primary 
mediator of NASH in the MetS, while insulin resistance may play a facilitatory and 
synergistic role. While NASH increases the risk of liver-related mortality (e.g. cirrhosis 
and hepatocellular carcinoma), the leading cause of death in patients with NASH is in 
fact CAD (64). 
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Dyslipidemia is necessary for coronary artery disease 
CAD and NASH are very tightly associated (Figure 5.5 and (57;58)). Additionally, 
type 2 diabetes is a major contributor to the extent, severity, and complications 
associated with treatment of CAD (74;86;234), while MetS is associated with increased 
risk of CAD (224). As such, here we report the most severe CAD ever observed in any 
animal model of type 2 diabetes and MetS (Figure 3.2). CAD in Ossabaw swine fed 
atherogenic diet is diffuse (Figures 2.4, 3.2, 4.2, and 5.2). 
Diffuse CAD is expected of CAD in diabetic humans (297), but this is a 
completely novel observation for any animal model of CAD. Interestingly, excess 
atherogenic diet, severe MetS, and overt type 2 diabetes are not prerequisite of diffuse 
CAD as observed in OssH (Figure 2.4). This leads to the speculation that diffuse CAD 
may be a preceding event to the onset of diabetes and that predilection to both disease 
states may in fact be driven by some primary defect, an interesting hypothesis which has 
not been tested either clinically or in any experimental model. Diffuse CAD is at highest 
risk of plaque rupture and thrombosis (reviewed elsewhere (298)) and drastically 
complicates treatment options of flow-limiting stenosis (76). Thus, Ossabaw swine may 
serve as an excellent model for studying thrombosis and plaque rupture, especially 
considering the total metabolic disease reliably demonstrated by Ossabaw swine with 
MetS. 
While it is clear that MetS is predictive of CAD (224), the relative contribution of 
individual factors is, by definition, difficult to discern in the complicated metabolic 
disease. F/MetS, demonstrating MetS without dyslipidemia (Chapters 3 and 5), were 
used to test the hypothesis that dyslipidemia is necessary for the development of CAD 
within MetS. The striking and absolutely clear requirement of dyslipidemia was made 
evident as F/MetS did not develop CAD despite similar insulin resistance, glucose 
intolerance, obesity, and hypertension compared to DMetS, MetS with addition of 
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dyslipidemia, that developed extensive CAD (Figures 3.2 and 5.2). Additionally, LDL 
gram-years showed immense predictive power for CAD (Figure 3.5), while all markers 
of insulin resistance and glucose intolerance that were investigated did not predict CAD 
(Chapter 3 and data not shown). 
TMetS (hypercaloric high trans-fat/cholesterol) developed MetS and mild CAD 
similar to DMetS (hypercaloric high fructose/trans-fat/cholesterol), however DMetS was 
fed atherogenic diet only 24 weeks compared to the 54 weeks of TMetS (Chapters 4 
and 5 Methods). Importantly, dyslipidemia was not different between TMetS and DMetS 
(Tables 4.1 and 5.1), suggesting that the addition of high fructose to atherogenic diet 
accelerates the progression of CAD in the MetS through a mechanism independent of 
increased dyslipidemia. These results are consistent with human clinical trials showing 
high fructose addition independently increases risk of CAD (reviewed elsewhere (299)). 
Accordingly, fructose should remain an important part of any atherogenic diet interested 
in maximizing CAD, as fructose represents an independent risk factor for CAD in MetS. 
While elevated dietary fructose is important, it is clearly not the only component 
of atherogenic diets mediating CAD, as the source of dietary fats greatly determines the 
physiological effects (reviewed elsewhere (300)). For many years, atherogenic diets high 
in saturated and cis-fat and cholesterol were used to produce mild atherosclerosis in 
Yucatan swine (10-19;174;301-309). More recently, human studies have shown 
hydrogenated cooking oil high in trans-fat acids result in more extreme increases in total 
LDL and decreases in HDL (310), implying a more atherogenic profile. As such, high 
trans-fat/cholesterol atherogenic diet produced elevated CAD in female Ossabaw swine 
(3); recent studies from our laboratory have almost exclusively used atherogenic diets 
high in trans-fatty acids (Chapters 2-5 and (4;6;20-22;29;311-314)). In collaboration with 
Purina TestDiets©, we formulated a unique atherogenic diet high in 
fructose/cholesterol/mixed-source fat (MMetS). 
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MMetS CAD was severe, with focal lesions in excess of 75% stenosis, and 
complex, with calcifications in 25% of the artery segments analyzed by IVUS (Figure 
3.2). Histological analysis of MMetS CAD revealed advanced, complicated lesions 
ranging from fibro-fatty streaks to lipid-laden cores surrounded by fibrous caps (Figure 
3.3). Compared to DMetS (high fructose/trans fat/cholesterol), MMetS intima contained 
less collagen and more cells/unit area, consistent with decreased plaque stability 
(Figure 3.3). Thus, Chapter 3 outlined the most severe CAD phenotype ever reported in 
a model of MetS and type 2 diabetes. 
 
Fatty acid methyl esters, not free fatty acids, predict coronary artery disease and non-
alcoholic steatohepatitis 
Free fatty acids (FFA) have been demonstrated to not be predictive of MetS or 
diabetes in longitudinal analysis, although cross-sectional analysis suggested FFA were 
highly associated with MetS and diabetes (211). Our results are in complete agreement, 
as total serum FFA did not correlate to either CAD or NASH (Table 3.3). Our study was 
powerfully designed to dissect any effect of FFA on CAD and NASH without the 
confounding effects of dyslipidemia already discussed (Figure 3.5). Accordingly, studies 
with concomitant dyslipidemia and elevated FFA should be interpreted with caution. 
Total FFA did not correlate to CAD or NASH. However, the recent 
Atherosclerosis Risk in Communities (ARIC) study found powerful associations between 
individual and grouped fatty acid methyl esters (FAME) and incidence of heart failure 
(212). Our results agreed with associations between heart failure and palmitoleic acid, 
oleic acid, linoleic acid, total monounsaturated fatty acids (TOTM), and total 
polyunsaturated fatty acids (PUFA), as each shared directionally identical associations 
with development of CAD and severity of NASH in Ossabaw swine (Table 3.2 and 3.3). 
Heptadecanoic and vaccinate acid, monounsaturated fatty acids, were not assessed in 
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the ARIC trial, but also strongly and directly correlated with CAD and NASH (Table 3.2). 
Thus, monounsaturated fatty acids demonstrated the most reliable direct predictive 
power, while polyunsaturated acids inversely correlated with CAD and NASH. Given that 
some FAME were directly associated while others were inversely associated with CAD 
and NASH, it should be of no surprise that total FFA showed no significant association 
with either. Although some FAME correlations to heart disease (e.g. CAD) outlined in 
Chapter 3 have been reported elsewhere, Chapter 3 was the first report of 
heptadecanoic and vaccinate acid associations with CAD, nonetheless in an animal 
model of CAD in type 2 diabetes and MetS. Additionally, Chapter 3 was the first report 
of any FAME associations with NASH. 
 
Stent-induced neointimal hyperplasia in metabolic syndrome 
Coronary stents are the most common form of treatment for flow-limiting 
stentoses (68). While the advent of drug-eluting stents has greatly diminished acute 
restenosis of the stented region, their use has led to increased risk of late stage 
thrombosis (315). Additionally, stenting is contraindicated in many cases involving 
complex lesions or coronary anatomy (e.g. diabetic shock; (76;77)). Recent questions 
regarding the necessity and safety of drug-eluting stents (99;101) may have been 
avoided had a suitable animal model of native stenosis in type 2 diabetes and MetS 
been available for preclinical trials. Stent efficacy preclinical trials have utilized over-
inflation injury in lean swine breeds (e.g. Yucatan). As such, Yucatan response to 
vascular injury is fairly well characterized, providing an opportunity to test the hypothesis 
that Ossabaw swine exhibit increased stent-induced neointimal hyperplasia. 
This hypothesis was tested by deploying a single stent at nominal diameter in the 
left circumflex coronary artery of Yucatan and Ossabaw swine fed either eucaloric chow 
or atherogenic diets (YucC, YucH and OssC, OssH, respectively). Ossabaw in-stent 
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neointimal hyperplasia after 4-weeks was increased compared to Yucatan, irrespective 
of diet (Figure 2.6I). Additionally, in-stent neointima was more cellular and contained 
more collagen, both suggesting increased CSM proliferation (Figure 2.6J and K). 
Accelerated neointimal hyperplasia induced by stent deployment is not limited to the in-
stent region, as artery segments outside the edges of the stent (peri-stent) also 
experience accelerated neointimal hyperplasia (29). Additionally, peri-stent disease is 
elevated in patients with complicated metabolic disease (e.g. diabetes (74)). Peri-stent 
CAD was elevated with atherogenic diet (Figure 2.5). Although there was no significant 
difference between peri-stent neointima in Ossabaw compared to Yucatan, there was a 
very strong trend for increased Ossabaw peri-stent disease irrespective of diet (Figure 
2.5). Accordingly, Ossabaw swine are a suitable model to test efficacy of treatment 
against stent-induced injury. 
 
Short term exercise training effects on metabolic syndrome and coronary artery disease 
Exercise is very efficacious in inducing regression of native CAD (235;236) and 
improves long-term outcomes following revascularization of coronary arteries (226). As 
such, MetS swine exposed to 3 weeks of exercise following induction of MetS and 
before stent placement, and 3 weeks of exercise following stent placement (XMetS; high 
trans-fat/cholesterol; see Figure 4.1 for study timeline) demonstrated significantly 
regressed native CAD and peri-stent neointima (Figure 4.2). These results are 
remarkably consistent with human clinical trials (226). However, angioplasty-induced 
neointimal hyperplasia was not changed with exercise (Figure 4.2) as previously 
demonstrated in non-diabetic swine (232). Key differences in study design may account 
for this discrepancy. First, our study employed a much shorter exercise regimen (7 
weeks compared to 20 weeks); second, our study deployed bare metal stents compared 
to simple balloon angioplasty (Chapter 4 and (232)). 
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Considering exercise has shown efficacy in treating MetS and prediabetes (237), 
it was somewhat surprising that exercise in XMetS did not improve any MetS 
characteristics (e.g. hypertension). However, exercise is typically prescribed along with 
dietary changes (237). As such, continued excess calorie atherogenic diet in our study 
may have ameliorated any effect of exercise. Additionally, Ossabaw swine have a loss-
of-function mutation in AMP kinase gamma 3 subunit. AMPKγ3 is an important 
mediating enzyme of skeletal muscle fatty acid oxidation and glucose utilization (238). 
Swine with loss-of-function AMPKγ3 mutation are less responsive to exercise, as 
measured by AMPK activation (238). Thus XMetS may not have received the full benefit 
of exercise. 
 
Ca2+ signaling events in coronary smooth muscle cells 
CSM are the predominant cell type in atherosclerotic lesions (316). Ca2+ 
regulation has been shown to be important in mediating CSM proliferation, migration, 
and extracellular matrix deposition (169-171;196;316;317) that are all pivotal events in 
the development of CAD (318-320). Extensive studies of Ca2+ regulation in CSM from 
multiple disease states were completed and are summarized in Table 6.1.  
Intracellular Ca2+ buffering, mediated primarily by SERCA (outlined in Figure 
2.5), decreases are associated with CSM proliferation in diabetes (321). Ossabaw swine 
have been shown to be predisposed to prediabetes and CAD (Chapter 2 and Figure 
6.2). Accordingly, SERCA function was decreased in CSM from Ossabaw swine 
compared to Yucatan (Figure 2.8). This was the only measurement of SERCA function 
in this thesis, as all other Ca2+ imaging experiments were primarily designed to measure 
Ca2+ flux across the plasma membrane. However, caffeine-sensitive SR Ca2+ store was 
quantified in Lean and MetS swine. 
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SR Ca2+ store is primarily mediated by SERCA, ryanodine receptor, and IP3 
receptor and Ca2+i (outlined in Chapter 1). Ryanodine- and IP3-sensitive SR Ca2+ stores 
have been shown to decrease in proliferating vascular smooth muscle cells (322;323), 
however the cells used in both studies were cultured aortic smooth muscle. Ossabaw 
CSM SR Ca2+ store was not different than Yucatan (Figure 2.7) or in short-term MetS 
(sDMetS; Figure 5.3). However, CSM from MetS demonstrated increased SR Ca2+ store 
in the absence of CAD, while DMetS was greater than MetS (Figure 5.3). SR Ca2+ store 
was decreased in peri-stent CSM. The relative distribution of ryanodine and IP3 
receptors is not clearly defined in smooth muscle compared to other cell types 
(324;325). However, there is some evidence that, rather than distinct SR Ca2+ pools 
accessible to only one receptor type, there is relative heterogeneity in ryanodine and IP3 
receptor distribution within the SR membrane of vascular smooth muscle (326-328). The 
implications of this are vital for proper interpretation of the caffeine-sensitive SR Ca2+ 
store results. In this report, the assumption is made that ryanodine (caffeine sensitive) 
and IP3 (caffeine insensitive) receptors access the same SR Ca2+ store, as the literature 
suggests. As such, the changes in caffeine response represent changes in bulk SR Ca2+ 
store (i.e. peri-stent < Lean < MetS < DMetS). It is not clear from these results if changes 
in SR Ca2+ store are due to Ca2+ leak from the SR or SERCA function.  
Ca2+ permeance across the plasma membrane is the primary determinant of 
Ca2+i. As outlined in Chapter 1, plasma membrane Ca2+ conductance is tightly 
regulated. Ca2+ efflux is primarily determined by NCX, PMCA, and SERCA via NCX 
(outlined in Figure 2.5) and is quantified by the time ½ minimum in response to caffeine 
(13;26). CSM from type 1 diabetic/dyslipidemic Yucatan swine with mild atherosclerosis 
demonstrated decreased PMCA-mediated Ca2+ efflux (13;26). Accordingly, total Ca2+ 
efflux in CSM from MetS-prone Ossabaw was decreased compared to the lean Yucatan 
breed (Figure 2.7). It is not clear whether this decreased Ca2+ efflux is mediated by 
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PMCA, NCX, or SERCA via NCX. All other studies measuring Ca2+ efflux in this report 
were completed in the presence of cyclopiazonic acid (10-5 M, selective SERCA 
antagonist), thus Ca2+ efflux was not mediated by SERCA via NCX. NCX-mediated Ca2+ 
efflux has been shown to not change in diabetic, dyslipidemic swine CSM, and PMCA 
has been shown to either primarily mediate decreased Ca2+ efflux due to diabetic 
dyslipidemia (13). However, it should not be assumed that CSM from Ossabaw swine 
will behave in a similar fashion (i.e. differential Ca2+ efflux in CSM from Lean Ossabaw 
and Yucatan swine, Figure 2.7) and studies in this report did not dissect the relative 
contribution. As such, “Ca2+ efflux” refers to PMCA/NCX-mediated Ca2+ efflux hereafter. 
Ca2+ efflux was decreased in CSM from peri-stent artery, accelerated, stent-
induced neointimal hyperplasia, compared to non-stented segments (Figure 6.4). 
Contrarily, Ca2+ efflux was not different in DMetS CSM compared to Lean (Figure 5.3), 
although DMetS developed extensive CAD. In the same study, CSM from MetS, 
normolipidemic MetS without CAD, demonstrated increased Ca2+ efflux. Summarily, Ca2+ 
efflux was increased (OssC) and decreased (MetS) in CSM from relatively healthy 
arteries, while Ca2+ efflux did not change (DMetS) or was increased (peri-stent) in CSM 
from disease arteries. Given the variability of Ca2+ efflux in differing degrees of CAD, it 
seems unlikely that Ca2+ efflux is causative in CSM proliferation and development of 
CAD. Changes in Ca2+ efflux may serve as a compensatory mechanism for primary 
defects in Ca2+ buffering or influx mechanisms (16). 
A major contributor to CSM Ca2+ influx is the voltage-gated Ca2+ channels 
(VGCC, reviewed elsewhere (329)). While general dogma equates elevated Ca2+i with 
cell cycle progression and proliferation, Ca2+ influx through the VGCC has been shown 
to be largely beneficial, leading to contractile and quiescent phenotype in vascular 
smooth muscle (172;330). As such, VGCC have been shown to be down-regulated in 
disease states such as dyslipidemia and diabetes, an effect reversed by exercise (13). 
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Table 6.1 summarizes nicely the lack of information obtained in this report on differential 
regulation of VGCC in Ossabaw CSM. One complete set of experiments suggested no 
change in VGCC between Ossabaw and Yucatan CSM, however this result should be 
interpreted with caution, as SERCA activity was not inhibited during the protocol 
(Chapter 2). Ca2+ influx through VGCC has been shown to refill the SR Ca2+ store in 
CSM (330). As such, differences in baseline SR Ca2+ store could alter Ca2+ buffering by 
SERCA of VGCC-mediated Ca2+ influx differentially in the two cell types. 
 
Effect of dyslipidemia in metabolic syndrome on canonical transient receptor potential 1-
mediated Ca2+ influx 
Store-operated Ca2+ entry (SOCE) function is strongly associated with CSM 
proliferation and progression of atherosclerosis (Chapter 4 and 5, (196;331)). SOCE has 
been associated with atherosclerosis in MetS (Chapter 4 and 5) and diabetes (332). 
Additionally, SOCE has been shown to regulate gene expression distinct from those 
regulated by VGCC Ca2+ influx (333), VGCC Ca2+ influx drives cell differentiation and 
quiescence (172;330). While SOCE is clearly important in regulating vascular smooth 
muscle transcription and cell cycle, the molecular identity has not been as forthcoming. 
Multiple proteins have been identified as the pore-forming subunit of SOCE 
pathways, such that the molecular identitiy responsible for SOCE may be dependent on 
the vascular bed (334;335). TRPC1 and Orai1 have recently become the leading 
candidates for mediating most vascular smooth muscle SOCE (reviewed elsewhere 
(336)). While prominent reviews have dismissed TRPC1 involvement in SOCE (117), 
there is now considerable evidence supporting TRPC1-mediated SOCE in vascular 
smooth muscle (337;338). Likewise, Orai1 is now dogmatically considered the molecular 
identity of the historical Ca2+ release activated Ca2+ current (ICRAC; (339;340)). In some 
reports significant interaction between Orai1 and TRPC1 have been demonstrated, such 
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that ICRAC, mediated by Orai1, is potentiated by TRPC1 expression (341) and TRPC1 
mediated SOCE relies on Orai1 expression (241).  
Our studies have consistently indicated an ~3-fold increase of SOCE in CSM 
from TMetS and DMetS compared to Lean (Figures 4.4 and 5.3). These are currently 
the only reports of elevated SOCE in smooth muscle (i.e. CSM) from MetS CAD. 
Additionally, we reported increased SOCE preceded development of increased Ca2+i in 
CSM and CAD in sDMetS, dyslipidemic MetS after 9 weeks on atherogenic diet (Figure 
5.3). Correspondingly, SOCE preceding development of arteriosclerosis was shown in 
aortic smooth muscle from ApoE-/- mice, although it is possible the SOCE measured in 
that study was mediated by receptor operated Ca2+ entry (317). MetS were critical in 
concluding that dyslipidemia is the principal MetS factor responsible for SOCE and CAD. 
MetS developed normolipidemic MetS without CAD (Figure 5.2) whose CSM did not 
develop increased SOCE (Figure 5.3). These results supported our hypothesis that 
dyslipidemia initiates increased CSM SOCE that primarily mediates the development of 
CAD in the MetS. 
CSM from Lean demonstrated a cation conductance activated by increased 
Ca2+i. This Ca2+-induced cation conductance (CICC) is strikingly similar to previous 
biophysical characterizations of TRPM4b (270) (Figure 5.5). TRPM (melanostatin) 4 has 
been shown to directly inhibit SOC in T lymphocytes (269). This provides the exciting 
possibility that, although Lean CSM express TRPC1 (29) and minimal SOC (Figure 4&5; 
(29)), the co-expression of TRPM4 provides an inhibitory mechanism preventing 
increased SOC that is not present in DMetS, thus resulting in potentiation of SOC in 
DMetS CSM. This intriguing hypothesis should be considered in future studies 
investigating the involvement of TRPM4 in smooth muscle from diabetic coronary 
arteries demonstrating elevated SOC. 
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Ossabaw CSM have decreased intracellular Ca2+ buffering (i.e. SERCA) and 
increased SOCE compared to Yucatan (outlined in Table 6.1). These results and a 
recent report demonstrating TRPC1 upregulation following SERCA gene silencing (342) 
may suggest that that TRPC1 is the molecular identity of SOCE in CSM from MetS 
swine. Accordingly, we found that TRPC1 protein was increased ratiometrically with 
SOCE function (~3-fold) in TMetS compared to Lean (Figure 4.5). Increased TRPC1 
protein and SOCE function were attenuated/abolished with exercise (Figures 4.4 and 
4.5). While Orai1 protein trended towards an increase in coronary arteries from TMetS, 
there was no statistical difference (Figure 4.5). Supporting the role of TRPC1 as the 
molecular identity of SOCE in CSM from TMetS, was the non-selective, ohmic I-V 
relationship of SOCE in a handful of CSM cells (Figure 4.4). TRPC1-mediated SOCE 
has been demonstrated to be exactly ohmic and non-selective in striking contrast to the 
extremely Ca2+-selective and inward rectifying current of Orai1 (243;343;344). 
Further electrophysiological characterization provides additional detail 
concerning the molecular identity of store-operated current (SOC) in CSM from Lean 
and DMetS swine. SOC in Lean CSM was consistent with Orai1, as SOC was not 
increased in the absence of Ca2+o and demonstrated significant Ca2+ selectivity (ERev = 
26; Figure 5.4). However, in CSM from DMetS, there was a significant shift in the SOC 
properties that were suggestive of TRPC1-mediated current, as SOC was non-selective, 
cation permeable, increased in the absence of Ca2+o, and demonstrated no Ca2+ 
selectivity (ERev = 0; Figure 5.4). Importantly, there was no change in SOC amplitude 
between CSM from Lean and DMetS, while SOC in the absence of Ca2+o was elevated 
in CSM from DMetS (Figure 5.4). This suggests SOC in CSM from DMetS is less of a 
Ca2+ entry pathway, instead demonstrating increased monovalent cation permeability 
compared to Lean.  
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Irrespective of the pore-forming subunit identity, STIM1 has been clearly 
demonstrated to be necessary in activation of SOCE in vascular smooth muscle, and 
upregulated concordantly with increased SOCE (151;331;345;346). Accordingly, 
increased STIM1 protein in coronary arteries from TMetS was proportional to increased 
SOCE, and both were attenuated with exercise (Figure 4.5). From previous reports and 
our novel findings, this report concludes that STIM1 is involved in SOCE in CSM from 
MetS CAD. 
 
Revised model of coronary smooth muscle cell Ca2+ regulation  
Resting Ca2+i and SR Ca2+ store were increased in CSM from DMetS compared 
to Lean (Figure 5.3). These Ca2+ regulation changes were preceded by increased 
SOCE in CSM from sDMetS (Figure 5.3). SOC was primarily mediated by Na+ 
permeance at physiological membrane potentials (Figure 5.4). Additionally, SOC has 
been demonstrated to mediate increases in Ca2+i through the involvement of NCX (347-
349). Taken together, these findings support a model of SOCE whereby store-operated 
Na+ influx potentiates reverse mode NCX-mediated Ca2+ influx (outlined in Figure 6.5; 
first proposed by Ashida and Blaustein (262)). 
Significant Ca2+ influx through reverse mode NCX was first proposed by Ashida 
and Blaustein in 1987 (262). If we assume that SOCE in sDMetS is similar to DMetS, 
then increased Na+ permeance through SOCE precedes other Ca2+ signaling 
dysfunction. This would shift ENa/Ca to more negative values leading to more positive 
VNa/Ca, shown to potentiate reverse mode NCX (262). DMetS CSM have less negative MV 
compared to Lean because of decreased large-conductance Ca2+-activated K+ channels 
(BK) as demonstrated by Borbouse et al. (8), and BK channel function has been shown 
to be inhibited by increased TRPC1-mediated SOCE (350). NCX is voltage dependent 
such that depolarization leads to propensity for reverse mode function (262). Increased 
  157 
Ca2+ entry via reverse mode NCX and as well as TRPC1 increases Ca2+i, further 
inhibiting BK function, and SR Ca2+ store (262). Additionally, NCX reverse mode, by 
definition, does facilitate Ca2+ efflux. In this model, increased SOCE and reverse mode 
NCX lead to BK channel inhibition, increased SR Ca2+ store, and decreased Ca2+ efflux. 
It should be noted that the description of “store-operated Ca2+ entry” is accurate 
concerning TRPC1-mediated reverse mode NCX Ca2+ entry. While we have not directly 
tested the involvement of NCX in CSM SOCE, the results of this study are entirely 
consistent with the model proposed by Ashida and Blaustein. Further, the complete 
abolition of TRPM4-like Ca2+ induced cation current in CSM from DMetS suggests that 
TRPM4 may act as an inhibitory factor of TRPC1-mediated SOCE. This report 
concludes that SOC is mediated primarily by Orai1 in CSM from Lean, while SOCE is 
mediated by TRPC1/reverse mode NCX in CSM from DMetS. 
 
Future directions 
While the NASH and CAD in Chapter 3 and type 2 diabetes in Chapter 5 are 
striking, there is great opacity concerning the systemic, cellular, and molecular 
mechanisms underlying the gross phenotypes. It may be tempting to investigate which 
dietary components relate the greatest contribution to the individual pathological states. 
Indeed this approach has significant basic research and clinical implications, namely 
providing the opportunity to further improve the model and providing insight into dietary 
modifications that may be beneficial to the general population. However, the goal was 
not to confirm extensive clinical dietary studies in a different species. The impetus was to 
design a humanoid animal model of MetS and type 2 diabetes that develops CAD. In 
pursuit of these goals, we serendipitously produced an animal model of NASH, thus 
providing additional metabolic relevance and producing an ideal framework to 
investigate the underlying mechanisms of CAD as observed in the general population. 
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Having achieved the goal of properly framing the incredibly complex metabolic disease 
state, future studies should focus on the systemic, cellular, and molecular mechanisms 
driving the pathologic endpoint of CAD.  
Great effort has focused on the contribution of Ca2+ signaling in CSM to 
atherosclerotic and stent-induced atheroma. The major findings of this thesis suggest 
TRPC1-, STIM1-, and Orai1-mediated SOCE may play a pivotal role in the development 
of CAD in stent-induced injury and MetS CAD. Future studies should utilize specific 
inhibition of TRPC1 in vitro using organ culture experiments to determine its relative 
contribution to CSM proliferation, medial thickening, and collagen deposition. Dr. 
Leonidas Tsiokas, University of Oklahoma, has available an excellent and specific 
TRPC1 antibody that inhibits channel function and has, in the past, offered it for 
investigative use. Additional studies should utilize short interfering RNA techniques to 
knock-down expression of TRPC1, STIM1, and Orai1 individually or in conjunction in 
organ culture. This will allow elucidation of individual protein contribution to organ culture 
CAD. Expanding these findings to in vivo settings will require advanced techniques 
including stents designed to elute antagonizing agents (e.g. DES). 
Custom-made DES allow relatively expensive or toxic compounds to be 
administered with local specificity and controlled release kinetics. Thus, costs and 
systemic effects are ameliorated while targeting drug treatment to the area of interest. 
Additionally, DES with highly specific and efficacious antagonist compounds essentially 
eliminate the contribution of their target within the treated area. Significant efforts to 
produce a TRPC1-targeted DES were unsuccessful in the tenure of this author. 
However, in collaboration with other key investigators, successful inhibition of adenosine 
A1 receptor using specific antagonist DES proved efficacious in preventing stent-
induced injury below control stent. Thus, as more antagonists of TRPC1 and/or Orai1 
become available, in vivo studies using DES should be considered. 
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Any future study investigation into the role of SOCE in CAD should include 
extensive patch clamp, Ca2+ imaging, and expression analyses. These intensive 
measures will allow confidant interpretation and facilitate publication of experimental 
results. However, the relative contribution of particular Ca2+ signaling pathways to CSM 
proliferation, migration, and plasticity remains unresolved, particularly in MetS, type 2 
diabetes, and progression to advanced CAD. 
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Figure Legends 
Figure 6.1 Type 2 diabetes and pre-diabetes in humans and Ossabaw swine. A 
Fasting blood glucose levels are used to define healthy (75-106 mg/dL; green), 
prediabetes (100-126 mg/dL; yellow) and diabetes (>126 mg/dL; red) in humans. Given 
variation in glucose homeostasis compared to humans, Ossabaw swine generally 
demonstrate overall lower fasting blood glucose values across normoglycemia (65-75 
mg/dL; Lean), prediabetes (76-90 mg/dL), and overt type 2 diabetes (>90 mg/dL). *, 
p<0.05 compared to respective study controls. B Genetic predisposition to type 2 
diabetes accelerates the effects of environmental factors. Thus, lean swine breeds (a) 
are resistant to progression to type 2 diabetes compared to the metabolic syndrome-
prone Ossabaw (b). OssH, NMetS, TMetS, and XMetS (c) are insulin resistant and 
glucose intolerant, while pancreatic β-cell function was sufficient to partially compensate 
and maintain moderately elevated fasting blood glucose. MMetS+ (d) represent the 
threshold of type 2 diabetes with hyperglycemia, elevated insulin response to glucose 
load, and pancreatic β-cell hypertrophy. TMetS+ (e) were unable to compensate for 
glucose load by increasing insulin response, demonstrated more severe hyperglycemia 
and fasting insulin values, and pancreatic β-cell staining that was not different than their 
Lean cohorts. 
 
Figure 6.2 Revised model of Ca2+ regulation. A Ratiometric analysis of Ca2+ handling 
in coronary smooth muscle (CSM) from healthy swine (Lean), loaded with Ca2+-sensitive 
fluorescent dye fura-2, reveals virtually no store-operated cation entry. Fura-2 
fluorescence at excitation wavelength F360 nm is Ca2+ insensitive, and global fura-2 
fluorescence is quenched my Mn2+. B Caffeine (Caff; 5 mM) and cyclopiazonic acid 
(CPA; 10-5 M) inhibit SERCA and activate ryanodine receptors (Ry) in the SR, leading to 
massive depletion of the SR Ca2+ store into the cell, thus raising intracellular Ca2+. Ca2+-
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induced cation conductance, consistent with transient receptor potential melanostatin 4 
(TRPM; M), rapidly activates and (de/in)activates parallel to SR release Ca2+ transient. 
NCX and PMCA mediated Ca2+ efflux return cell to normal intracellular Ca2+ as the SR 
Ca2+ store remains depleted. Stromal interaction molecule 1 (STIM1; S) proteins in the 
SR membrane sense depletion of the SR Ca2+ store and homomultimerize into distinct 
puncta in regions of the SR in close apposition to the PM. TRP canonical 1 (TRPC1; R) 
is inhibited by presence of TRPM4. C Ratiometric analysis of Ca2+ handling in CSM from 
metabolic syndrome swine reveals elevated store-operated divalent cation (Mn2+/Ca2+) 
entry compared to Lean. D CSM from MetS swine have elevated baseline Ca2+i. 
Decreased L-type Ca2+ entry, Ca2+ efflux mediated by NCX and PMCA, and SERCA 
contribute to Ca2+ regulation abnormalities. TRPC1 and STIM1 protein is upregulated 
~3-fold compared to Lean. E Reduced L-type channel activity in CSM from MetS leads 
to reduced Ca2+ influx upon high K+ depolarization compared to Lean. F SR Ca2+ store 
depletion does not activate any Ca2+ induced current, suggesting lack of TRPM4. STIM1 
activates store-operated cation entry increasing Na+ concentrations in the superficial 
buffer barrier. Elevated resting Ca2+i, decreased MV, and sudden rise in local Na+ via 
TRPC1 activation all contribute to NCX reverse mode that moves Na+ out of the cell and 
Ca2+/Mn2+ into the cell. 
   
Table 6.1 
Ca2+ regulation Disease state 
Mechanism Putative mediator 
Ossabaw 
(genetic) F/MetS MetS XMetS DMetS MMetS sDMetS+ 
Basal Ca2+i multiple 
No Δ 
Not Shown 
No Δ 
Chapter 5 ??
 ?? ↑ Chapter 5 -- 
No Δ 
Chapter 5 
Voltage gated 
Ca2+ influx VGCC 
NC ?? 
Chapter 2 -- -- -- -- ?? -- 
Store-operated 
Ca2+ influx 
NCX 
via 
TRPC1 
monoval./ 
Dv↑ (s) 
Chapter 5 
(13;240) 
DvNC (l) 
Chapter 5 
DvNC (s) 
Dv↑ (s/l) 
Chapter 4 
Dv↓ (s) 
Chapter 4 
Dv↑ (l) 
Chapter 5 
monoval.↑ 
(s) 
DvNC (s) 
Chapter 5 
Dv↑ (l) 
Chapter 5 
Ca2+-induced 
 cation influx TRPM4 -- -- -- -- -- 
↓ 
Chapter 5 -- 
Sarcoplasmic 
reticulum Ca2+ 
store 
RyR, IP3, 
and 
SERCA 
No Δ 
Chapter 2 
↑ 
Chapter 5 ?? ?? 
↑ 
Chapter 5 -- 
No Δ 
Chapter 5 
Plasmalemmal 
Ca2+ extrusion 
NCX, 
PMCA, 
SERCA 
↓ 
Chapter 2 
↑ 
Chapter 5 ?? ?? 
No Δ 
Chapter 5 -- ?? 
Table 6.1 Summary of disease state affect on coronary smooth muscle Ca2+ regulation. Changes for Lean Ossabaw (genetic) 
are relative to Lean Yucatan. Changes for all other disease states are relative to Lean Ossabaw (genetic). Abbreviations: VGCC, 
voltage gated Ca2+ channel; NCX, Na+/Ca2+ exchanger; TRPC1, transient receptor potential canonical 1; TRPM4, TRP melanostatin 
4; RyR, ryanodine receptor; IP3, inositol trisphosphate; SERCA, sarco/endoplasmic reticulum Ca2+ ATPase; PMCA, plasma 
membrane Ca2+ ATPase; --, did not test; ↑, increased; ↓, decreased; Ca 2+i, intracellular Ca2+; ??, not clear; Dv, divalent; monoval., 
monovalent. Group codes: F/MetS, fructose/normolipidemic metabolic syndrome; MetS, high trans-fat/choleterol atherogenic diet; 
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XMetS, exercised MetS; DMetS, MetS with addition of high fructose; MMetS, high mixed-source-fat/cholesterol/fructose atherogenic 
diet; sDMetS, short-term DMetS (9 week on diet). 
163 
  164 
Figure 6.1 
 
 
   
Figure 6.2 
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Appendices 
Appendix A Angiography 
 See also reference 4 for figures and description of methods and references 
therein for more information.  
1. All Radiation Safety protocols should be followed during all steps of procedure. 
2. Sterile technique should be followed unless procedure is non-survival. During 
non-survival angiography, care should still be taken to perform tasks in sanitary 
fashion. 
3. Anesthesia  
Persons performing angiography procedure are all responsible for insuring a 
satisfactory plane of anesthesia is maintained during entire procedure. If 
isoflurane is used, check fill level on isoflurane dispenser. Generally 1.5-2% 
isoflurane and 2 L of O2 is required for the health and sedation of intubated 
swine. Isoflurane should be adjusted based on blood pressure, heart rate, 
movement of pig, voluntary stomach contraction, or other visual cues during the 
procedure. 
4. Secure pig to table. 
Insure that swine is properly secured to table and table wheels are locked. This is 
essential for the safety of the pig and compliance with Institutional Animal Care 
and Use Committee protocol guidelines.  
5. Intubation and respiration 
Check proper intubation of pig. Chest should rise and fall with respirator without 
voluntary muscle contraction. Proper tidal volume is equal to 6-8 ml/kg body 
weight. Pressure should not exceed 20 atmospheres at any point during 
respiration and should fall to near zero on exhalation. 
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6. Insure angiography system is active and ready for use, but in a safe mode, such 
that no radiation is being emitted. 
7. General cleanliness and organization 
Work place should be clean, dry, and orderly. A proper angiography procedure 
minimizes fluid mess (e.g. blood or saline). This is especially important during 
sterile procedures, but should be a point of pride for any procedure. 
8. Check that all necessary equipment for procedure is present and prepared for 
use. Steps 9-27. 
9. Hang 1L saline bag, attach fluid line, and inflate to pressure (200-300 mm Hg). 
10. Hang radio-opaque contrast, attach fluid line, and open vent on fluid line to 
prevent vacuum in contrast container. 
11. Hang pressure transducer at same height as pig heart. Attach fluid line. 
12. Connect pressure transducer to pressure transducer/ECG unit. 
13. Attach three fluid lines, outflow line to three-way stopcock, and 12 mL NAMIC® 
Angiographic Control Syringes to NAMIC® Perceptor Manifold. 
14. Open contrast to manifold/outflow and allow contrast to fill line. Close contrast at 
manifold. Insure no bubbles in line. 
15. Open saline to manifold/outflow and allow saline to fill line. Open saline to 
syringe and fill syringe half way. Open saline to pressure transducer. Insure no 
bubbles in line or manifold. 
16. Open pressure transducer to air and allow saline to fill line. Insure no bubbles. 
Close pressure transducer to air, keeping line open to saline at manifold. Close 
saline at manifold. Open outflow three-way stopcock to air. Pressure transducer 
should now be open to air. Zero pressure. Close pressure transducer at manifold. 
a. Do not touch table, manifold, or tubing while zeroing pressure.  
17. Attach extender to three-way stopcock away from manifold. 
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18. Attach NAMIC® Gateway™ Y-adapter to extender. 
19. Attach guiding catheter to Y-adapter. 
a. Typically a 7 French (F) 0.75 to 1.5 Amplatz left (AL) with side holes or 
hocky stick (HS) guiding catheter is used for cardiac procedures on the 
left main coronary artery. Side holes enable blood flow, which can 
minimize ischemia and arrhythmias when the coronary artery is 
selectively accessed by placement of the guiding catheter into the artery. 
20. Open saline to guiding catheter, flushing any air out of three-way, tubing, Y-
adapter, and guide catheter. 
a. Be sure to flush deadspace in Y-adapter near hemostatic valve. 
21. Open saline to syringe and fill, flushing any air out of manifold and into syringe. 
a. If large amount of air is in syringe (>1 mL), take off syringe and empty of 
air, then attach to manifold and flush with saline again. 
22. Surgical tub should be available with introducer, guide wire, PTCA wire, and 
torquer. Fill tub with sufficient saline to coat equipment. A small waste tub should 
be available on table. Several gauze pads and some paper towels should be 
readily available on table throughout procedure. 
a. When not in use, wires should be coiled loosely (just enough to fit in 
surgical tub) with ends tucked into coil. 
23. Percutaneous transluminal coronary angioplasty (PTCA) guidewire 
a. Check quality of PTCA wire. PTCA wire (typically 0.04 inch diameter) 
should be without any bends, but may be slightly curved/bent at very tip 
(approximately 5-10° angle). Good care of PTCA wire is critical as it is 
very fragile and expensive. 
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b. Insure there are no jagged edges or severe bends in the guide wire. 
Guide wires are typically very durable and should be used for up to 30 
cases. Tip should be curved back on itself and floppy. 
24. Move table top back and forth until the center of movement is determined. Center 
table. 
25. Adjust table to desired height. Generally, forearm of arm bent at elbow should be 
roughly parallel with table top. 
26. If using C-arm system, position C-arm to the end of the table near pig’s head. 
a. Zero all axes of C-arm before moving. 
b. Do not run over cords with wheels. 
27. Don lead apron, thyroid protector, and glasses. 
28. Wear radiation badges. Proper radiation procedures should be observed at all 
times. 
29. If using C-arm, turn on key and set up C-arm. Move image transducer as close to 
pig as possible. Radiation exposure is reduced when the image transducer is 
close to the pig. 
30. Run brief test image of pig.  
a. Remove any metal or radio-opaque objects in field.  
b. Never place any part of self in imaging zone while actively imaging. 
c. All angiography should be kept to a minimum. Exposure is cumulative, so 
reducing a brief angiography from 3 to 2 seconds will reduce exposure by 
30%. 
31. Adjust angiography zoom to include as large field as possible without large air 
space on either side of pig. Proper zoom improves visualization and reduces 
radiation exposure. 
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32. Collimate to reduce visual field as much as possible. Advancement of guiding 
catheter/wire is easiest with large visual field, as a large distance is covered 
relatively quickly. Collimation reduces radiation exposure. 
33. Move image intensifier close to legs. 
34. Introduce 0.35 inch diameter guide wire into guiding catheter. 
a. As the lead end of the guide wire is floppy, this is generally achieved by 
putting the stiff end of the guide wire into the tip of the guide catheter and 
pushing the wire through the catheter backwards.  
b. When the back tip of the wire sticks out the Y-adapter hemostatic valve, 
pull the guide wire until the tip of the wire is just inside the tip of the guide 
catheter. It is important that the two tips be relatively close, as will be 
evident in steps below. 
35. Insure all pre-heparin and pre-contrast blood samples have been collected. 
36. Insure administration of heparin. 
a. If heparin was not previously administered, wait 5-10 minutes after 
administration to allow proper circulation of heparin systemically. 
37. Double check for air bubbles in tubing and manifold. 
38. Flush guide catheter and hemostatic valve with saline. 
39. Introduce guiding catheter into femoral sheath. Use care as the tip of guiding 
catheter is easily damaged. Advance just past side-holes on guiding catheter so 
that blood does not flood out of holes. Do not advance further. 
40. Advance guide wire 2-3 cm out of tip of guiding catheter. 
a. This will minimize any damage caused to vasculature by advancing 
guiding catheter and enables passage of the guiding catheter through the 
iliac bifurcation, past renal arteries, and over the aortic arch for placement 
near the tricuspid valve. 
  171 
41. Keep Y-adapter hemostatic valve tightened throughout procedure to limit blood 
backflow. 
42. Steadily advance guiding catheter about 10 cm. Stop advancing immediately if 
any resistance or tugging is felt. 
43. Visualize guide wire/catheter with angiography. 
44. Continue advancing guide wire/catheter to thoracic cavity visualizing each step of 
the way with angiography and using steady motions. Stop advancing immediately 
if any resistance or tugging is felt. 
45. Rotate angiography image if needed to insure that cranial is up and caudal is 
down on the monitor. 
46. Under angiography, advance guide wire/catheter until aortic arch is reached.  
a. Twist guiding catheter clockwise slightly to pop catheter into arch and not 
advance up carotid artery. 
b. Clockwise and counterclockwise refer to direction if pointing end of 
guiding catheter that attaches to Y-adapter at face. 
c. After tip of guiding catheter is near tricuspid valve, then remove 0.35 inch 
diameter guidewire. 
47. Rotate angiography unit to left anterior oblique 30° (LAO30) and center 
angiography image on heart. 
48. Zoom, then collimate to improve view and reduce radiation exposure. The tip of 
the guiding catheter and the heart should be the only thing in the visual field. 
49. Fill guiding catheter with contrast to visualize on angiography. 
50. Advance guiding catheter into left coronary ostium, using bursts of contrast 
(approximately 5 mL) to determine position. Minimal contrast should always be 
used. 
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a. Use a slight clockwise twist if necessary. (Accessing the right coronary 
ostium typically requires counterclockwise twists and is easier with a 
hocky stick guiding cathether.)  
b. Do not advance the guiding catheter into the left ventricle. This can cause 
fibrillations.  
c. Engage left main coronary artery, slowly rotating guiding catheter 
clockwise. Small bursts of contrast infusion will allow determination of 
catheter position. 
51. Perform LAO30 cine.  
a. Person taking notes should record blood pressure and heart rate. 
b. Announce cine.  
c. Step on cine pedal immediately followed by bolus of 10 mL contrast. If pig 
is particularly sensitive to contrast, infusion should be 50% saline and 
50% contrast. 
d. Cine should last no longer than the time it takes for contrast to flush 
away. 
52. Disengage guiding catheter from selective and deep access of left main coronary 
artery by slightly rotating counterclockwise.  
a. Do not disengage coronary ostium completely; instead, the tip of the 
guiding catheter should be close enough for quick angiograms, infusion of 
drugs, placement of PTCA guidewire, etc.  
b. Remaining tightly engaged to left main coronary artery occludes blood 
flow and can lead to ischemia, fibrillation, and death. 
c. If interrogation of the left anterior descending (LAD) is desirable at this 
point, go to step 63 for access methods.  
53. Rotate angiography unit to right anterior oblique 30° (RAO30).  
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a. Center heart in visual field by moving table. 
b. The RAO30 view typically provides better views of the circumflex artery 
and branches 
54. Engage left main coronary artery with guiding catheter as previously described. 
a. It is important to note that the electrocardiogram (ECG) provides the best 
evidence during angiography as to the health of the heart. Watch for any 
ECG abnormalities during all procedures, especially when occluding 
blood flow with the guiding catheter, wires, or balloons. Pull out if in 
doubt. An artery accessed once can be accessed again, but not on a 
dead pig. 
55. Perform RAO30 cine as previously described for LAO30 cine. 
56. Disengage guiding catheter from left main coronary artery as previously 
described in step 52. 
57. Place floppy end of PTCA guide wire into PTCA introducer sheath and introducer 
into Y-adapter hemostatic valve. 
a. Do not allow PTCA wire to be exposed out the other end of the 
introducer. 
58. Advance PTCA wire until the first demarcation on the wire reaches the Y-
adapter. 
59. Use angiography and advance the PTCA wire near the end of the guiding 
catheter, but still within the guiding catheter. 
60. Engage left main coronary artery with guiding catheter as previously described. 
61. Use angiography and advance PTCA wire into left main coronary artery. If 
engaged properly with guide catheter, PTCA wire will likely direct into either the 
left circumflex (CFX) or left anterior descending (LAD) coronary artery. 
a. Distinguishing both coronary arteries may be easier in LAO30. 
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62. If there is difficulty accessing the CFX, rotate the guiding catheter clockwise and 
advance down the left main to selectively access the CFX. Then, feed the PTCA 
wire into the artery and slowly retract the guiding catheter by pulling with a slight 
counterclockwise twist. 
63. Accessing the LAD tends to be more difficult. 
a. Slightly bending the tip of the PTCA wire (described previously) before 
introduction and placement of torquer on PTCA wire may allow twisting 
the wire and allowing better access to select arteries. 
b. Alternatively, selectively engaging the LAD with the guiding catheter is 
effective, but occludes flow to the LAD. 
c. First move to LAO30 to provide the best possible distinction between LAD 
and CFX. 
d. Advance guiding catheter down left main coronary artery into the CFX, 
this generally requires only slight advancement and no manipulation. 
e. Then, while slowly retracting guiding catheter, provide very slight rotation 
in a clockwise direction. 
f. Upon reaching the LAD/CFX bifurcation, the guiding catheter may “pop” 
into the LAD. It may also be a smooth transition made evident as the 
guiding catheter tip will twist in the direction of the screen and move 
upward and to the left of the screen. 
g. As soon as the guiding catheter pops or slowly moves into place, cease 
movement of the guiding catheter. This is a precarious position and often 
the guiding catheter will pop completely out of the left main coronary 
artery because of the tension in the catheter. 
h. Immediately advance the PTCA wire down the LAD and slowly twist the 
guiding catheter slightly counter-clockwise, thus relieving tension and 
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easing it into the left main coronary artery. If the guiding catheter pops out 
of place, it may bring the PTCA wire with it. 
64. Complete intravascular ultrasound, stent placement, or flow measurements as 
required and described in other Appendices. To perform flow measurements, use 
a flow wire instead of a PTCA wire. 
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Appendix B Intravascular ultrasound (IVUS) 
 See also reference 4 for figures and description of methods and references 
therein for more information. 
1. All Radiation Safety protocols should be followed during all steps of procedure. 
2. Sterile technique should be followed unless procedure is non-survival. During 
non-survival angiography, care should still be taken to perform tasks in sanitary 
fashion. 
3. Anesthesia 
Persons performing angiography procedure are all responsible for insuring a 
satisfactory plane of anesthesia is maintained during entire procedure. If 
isoflurane is used, check fill level on isoflurane dispenser. Generally 1.5-2% 
isoflurane and 2 L of O2 is required for the health and sedation of intubated 
swine. Isoflurane should be adjusted based on blood pressure, heart rate, 
movement of pig, voluntary stomach contraction, or other visual cues during the 
procedure. 
4. Follow steps 1-27 under Appendix A Angiography to prepare angiography 
equipment for use. 
5. Check that all additional equipment for IVUS procedure is present and prepared 
for use. Steps 6-26. 
6. Turn on IVUS instrument (Hewlett Packard) and set up for recording.  
a. Enter case information using rolling ball or arrows to move cursor and tab 
to change fields.  
b. Include study, pig number, pig name, date, operators, and any other 
necessary identifying information. 
7. Label VHS tape with case information and insert into IVUS machine. 
a. Do not record over previous data on VHS tape. 
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8. Press Image to move from patient information to catheter selection screen. 
9. Attach image transducer to pullback device. 
a. During sterile procedure, image transducer and pullback device are to be 
kept at end of surgical table on top of sterile sheet and under sterile gown 
or Chucks pad with stationary arm of pullback device accessible. 
10. Move image transducer/pullback 10 mm away from stationary arm of pullback 
device.  
a. Rock image transducer/pullback tray away from front of pullback device to 
free from locking mechanism. 
11. Attach extender tubing to IVUS catheter. 
a. Attach three-way stopcock, 3 mL syringe, and 10 mL syringe to extender 
tubing. 
12. Flush IVUS catheter with saline from 3 mL syringe. Insure no bubbles exist in the 
syringes, stopcock, extender or IVUS catheter. 
a. IVUS catheter should be flushed with saline from only the 3 mL syringe to 
minimize pressure. 
b. The 10 mL syringe should be used as saline reservoir to fill 3 mL syringe 
if needed. 
13. Insert catheter into image transducer. Connection is unidirectional and catheter 
should click into place. 
a. During sterile procedure IVUS catheter should not be beneath the cover 
of pullback device and image transducer should remain sterile. 
14. Pull outer sheath of IVUS catheter away from image transducer just enough to 
connect it to stationary arm of pullback device. 
15. Connect IVUS catheter to stationary arm of pullback device. 
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16. Rock image transducer/pullback tray all the way forward towards stationary arm 
of pullback device. 
a. Keep IVUS catheter between image transducer and stationary arm 
straight and do not allow bending or crimping. 
17. Press Image to move from catheter selection screen to imaging screen. 
18. Select UltraCross 3.2F 30 MHz or 3F 40 MHz catheter as appropriate on IVUS 
machine. 
19. Place imaging transducer (tip of IVUS catheter, yellow colored metal) in surgical 
tub of saline. 
20. Flush IVUS catheter with saline. 
21. Press (un)Freeze to start IVUS image collection. Image transducer will begin 
rotating. 
22. Snap fingers near microphone and watch they audio voltmeter for reaction to 
insure audio is functioning properly and will record when appropriate. 
23. Press image transducer to bottom of bowl. The bottom of bowl will appear as 
white arc on IVUS machine. 
24. Position forceps over image transducer to visualize. 
25. Calibrate gray scale of IVUS system. 
a. Adjust brightness, contrast, and grayscale such that forceps are 
maximally bright. 
b. Differences in plaque brightness between cases will convey actual 
morphological differences based on the maximum brightness 
(echogenicity) of metal forceps.  
c. Record forceps calibration images on VHS tape.  
26. Press Freeze to stop imaging collection. 
27. IVUS machine is now ready to operate. 
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28. Follow steps 38-63 under Appendix A Angiography to access desired coronary 
artery with PTCA wire. 
a. It is essential to record in the notes key landmarks of the angiogram, such 
as the most distinct branches, ribs, etc., for narrating the aspects of the 
IVUS images along a pullback through the artery. These precise notes 
will greatly assist everyone in analysis of the IVUS images. 
29. Flush IVUS catheter with saline. 
30. Insert stiff end of PTCA wire into lumen of IVUS catheter and feed out side-hole 
of IVUS catheter. 
31. Operator number 2 (assistant to main operator) should secure end of PTCA wire 
already through IVUS catheter to table with fingers or thumb. 
32. Operator number 1 should loosen Y-adapter hemostatic valve and advance IVUS 
catheter along PTCA wire without displacing PTCA wire from position in coronary 
artery. Holding the IVUS catheter only ~1 cm from the valve and advancing for 
the first ~10-15 cm is needed to protect the pliable section of the IVUS catheter 
where the imaging transducer is located. Beyond ~10-15 cm the IVUS catheter is 
stiffer and more durable.  
33. Once the IVUS catheter is well advanced through Y-adapter (e.g. side-hole is 
through Y-adapter valve), operator number one should take control of both PTCA 
wire and IVUS catheter. 
34. Advance IVUS catheter down PTCA wire until first white demarcation reaches 
valve, keeping PTCA wire stationary in coronary artery.  
a. Because there often is slack in the PTCA guidewire, brief fluoroscopy 
should be done to make certain that the guidewire has not advanced 
further into the coronary artery, which could cause damage to the very 
small distal segments. 
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35. Continue advancing IVUS catheter using angiography to guide it to the end of the 
guiding catheter. 
a. The IVUS catheter is radio-lucent, but a radio-opaque marker at the distal 
end allows visualization with angiography. Another radio-opaque marker 
is the imaging transducer (18-28 mm from the tip of the IVUS catheter). 
36. Start IVUS imaging by pressing (un)Freeze.  
37. Label IVUS image by pressing Text and using roller ball and keyboard. Once 
labeling is complete, press Text again. 
38. Press record to start the VHS tape. 
39. Advance IVUS catheter down PTCA wire into coronary artery such that image 
transducer is in desired position. 
a. PTCA wire and IVUS catheter can be advanced together and/or 
separately at this point.  
b. Do not allow IVUS catheter to come off end of PTCA wire as it may 
damage the artery and will lose ability to advance easily. 
c. A very brief cine with or without contrast may be captured to document 
precisely the location of the IVUS imaging transducer.  
40. Holding wires steady, operator 1 announces start of IVUS pullback (e.g. “IVUS 
pullback of X artery in 3, 2, 1, GO”).  
a. Operator 2 flips switch on pullback device to desired pullback speed, 
either 0.5 or 1.0 mm/sec (0.5 used almost exclusively).  
b. Note taker or Operator 2 presses Pullback before IVUS pullback starts 
and then Start/Stop on “GO” to begin IVUS pullback on IVUS machine. 
41. During IVUS pullback:  
a. Operator 1 is responsible for maintaining steady wires.  
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b. All operators are responsible for watching IVUS pullback and commenting 
on artery morphology and IVUS features along length of pullback and 
watching ECG for abnormailities. 
c. The ribs are labeled in the notes as #1 in the most cranial position to #x 
(typically 3 or 4) in the most caudal position to be used as landmarks for 
narrating the position of the imaging transducer during the pullback.  
d. A very brief cine without contrast may be captured to document precisely 
the location of the IVUS imaging transducer relative to ribs, locations of 
arterial branches, etc. 
42. Once image transducer is in guiding catheter, IVUS pullback is stopped 
simultaneously on pullback device and IVUS machine (press Start/Stop again) 
and lengths are recorded on pullback device and IVUS machine. 
43. IVUS of another artery can be performed by repeating steps 34-41. 
a. The IVUS catheter must first be pulled back into the guiding catheter 
proximal to the Amplatz or hockey stick bend. 
b. The PTCA guidewire is pulled back within the tip of the guiding catheter 
and the artery of interest accessed as described in step 27 and Appendix 
A Angiography.  
c. This is a challenging method for accessing an artery because the PTCA 
guidewire is not as easily maneuvered while the IVUS catheter is in place, 
so it may require complete removal of the IVUS catheter and 
reintroduction after the PTCA guidewire is in place in the artery.  
44. Remove IVUS catheter by pulling back over the PTCA wire and advance image 
transducer/pullback device back towards stationary arm of pullback device. 
a. Do not bend or crimp IVUS catheter between image transducer and 
stationary arm. 
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b. Upon completion of angiography/IVUS/stent/flow procedures, special care 
must be taken to preserve IVUS catheter.  
1) Flush blood out of IVUS catheter with saline.  
2) Flush saline out with water.  
3) Flush water out with air.  
4) Hang IVUS catheter in gentle coil or in safe place in laboratory 
with the imaging transducer end down to enable any water residue 
to leak out and assist in drying. 
45. Leave PTCA wire in artery if stent is to be placed. Otherwise, PTCA wire may be 
removed from artery when all procedures are complete. 
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Appendix C Stent procedure 
1. All Radiation Safety protocols should be followed during all steps of procedure. 
2. Sterile technique should be followed unless procedure is non-survival. During 
non-survival angiography, care should still be taken to perform tasks in sanitary 
fashion. 
3. Anesthesia  
Persons performing angiography procedure are all responsible for insuring a 
satisfactory plane of anesthesia is maintained during entire procedure. If 
isoflurane is used, check fill level on isoflurane dispenser. Generally 1.5-2% 
isoflurane and 2 L of O2 is required for the health and sedation of intubated 
swine. Isoflurane should be adjusted based on blood pressure, heart rate, 
movement of pig, voluntary stomach contraction, or other visual cues during the 
procedure. 
4. Follow steps 1-27 under Appendix A Angiography to prepare angiography 
equipment for use. 
5. Follow steps 1-26 under Appendix B Intravascular ultrasound to prepare IVUS 
equipment for use. 
6. Check that all additional equipment for stent procedure is present. Complete 
stent kit and necessary accessories include: 
a. Pressure device (indeflator) 
b. Extender tubes 
c. Three-way stopcock 
d. Percutaneous angioplasty balloon 
e. Wire clip 
f. Blunt needle 
g. Syringes (2) 
  184 
h. Stents with varying diameter. 
7. Follow steps 28-64 under Appendix A Angiography to access desired coronary 
artery with PTCA wire. 
8. Follow steps 27-43 under Appendix B Intravascular ultrasound to collect IVUS 
data of desired coronary artery. 
a. Note carefully the diameter of the artery at distinct landmarks that help 
determine where the stent(s) will be deployed, so that the stent will be 
deployed to the exact diameter.  
9. Using IVUS and angiography, determine site to be stented. 
10. Obtain lumen diameter for mildly diseased artery or reference lumen diameter for 
stenotic lesion and calculate stent deployment diameter. 
11. Choose angioplasty balloon that will inflate to desired diameter. 
12. Prepare angioplasty balloon for inflation. 
a. Attach three-way stopcock to pressure device (indeflator). 
b. Connect three-way stopcock to balloon catheter using extender tubing. 
c. Fill 10 mL syringe with 5 mL saline and attach to three-way stopcock. 
d. Open syringe to balloon catheter and put negative pressure on syringe. 
This will cause balloon catheter to fill with saline without inflating balloon. 
Syringe may be pulled to 10 mL mark and suddenly released. This 
technique may be helpful in removing bubbles from balloon catheter. Use 
a hemostat to tap any visible bubbles out of the line while negative 
pressure is applied with syringe. 
e. Close balloon catheter from three-way stopcock. 
f. Remove syringe from three-way stopcock. 
g. Fill indeflator with saline. 
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h. Rotate handle in clockwise motion to remove air from indeflator and 
tubing to three-way stopcock. 
i. Open indeflator to balloon catheter. 
j. Attach blunt needle to syringe filled with saline. 
k. Insert blunt needle into lumen on end of balloon catheter nearest balloon. 
l. Fill dead-space with saline. 
m. Balloon catheter is now prepared for inflation. 
13. If using custom-made Burpee stents (most typical), perform test inflation of 
angioplasty balloon to pressure necessary for inflation diameter. Deflate balloon. 
a. The deflated balloon will have folds in it that will help the stent grip onto 
balloon and not become dislodged when advancing through hemostatic 
valve, guiding catheter, and into artery. 
14. Choose stent size within 10% of the desired diameter. 
a. Stents can be deployed to 90-110% of nominal diameter if necessary, 
because the stent surface area relative to the artery surface area will be 
similarly close. 
b. A 3.0 mm diameter stent is the size used for >90% of the stents placed in 
Ossabaw pigs.  
c. A stent length of 8 mm has been used exclusively in Ossabaws because 
it enables placement between arterial branches (i.e. branches are not 
“jailed”) and provides opportunity for easy placement of 2 stents per 
artery.  
15. Place stent on balloon and center between two radio-opaque markers. 
16. Gently crimp stent on balloon with fingers using great care to not damage stent 
architecture. 
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17. Insert the stiff, firm end of the PTCA guidewire into lumen of the balloon catheter 
and feed the guidewire out through a side hole.  
18. Insert balloon/stent into guiding catheter through Y-adapter using the same 
technique as required for the IVUS catheter in Appendix B Intravascular 
ultrasound steps 30-33, except that the hemostatic valve is opened wider and 
saline from the pressurized bag is flowed through the valve to permit easier 
introduction and verification that the stent was introduced successfully. 
 
19. Use angiography to guide balloon/stent over PTCA wire to desired region of 
artery. 
a. Balloon is bounded by two radio-opaque markers. 
b. PTCA wire and balloon catheter can be advanced together and/or 
separately at this point. Do not allow balloon catheter to come off end of 
PTCA wire as it may damage the artery and will lose ability to advance 
easily. 
c. A very brief cine with or without contrast may be captured to document 
precisely the location of the stent in the artery.  
20. Holding wires steady, operator 1 announces start of stent deployment (e.g. “Stent 
deployment in 3, 2, 1, GO”).  
a. Operator 2 quickly inflates the balloon to desired diameter adjusting 
pressure in the balloon by twisting the indeflator handle. 
b. Note taker or Operator 2 is responsible for watching the clock. 
21. Balloon inflation should persist for 30 seconds.  
a. During stent deployment, operator 1 is responsible for maintaining steady 
wires and watching the ECG.  
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b. Operator 2 is responsible for maintaining constant desired pressure in the 
balloon, making adjustments as needed.  
c. Note taker is responsible for keeping track of time and counting down last 
10 seconds (e.g. 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, DEFLATE).  
d. Upon DEFLATE, Operator 2 presses the pressure release button on the 
side of the pressure device and deflating the balloon by pulling back on 
the handle sharply. 
22. Remove balloon catheter by pulling back gently over the PTCA wire, which 
should be done with fluoroscopy to make certain the balloon moves successfully 
without snagging the stent. 
23. Perform angiography (cine) with contrast infusion to visualize any damage, over-
inflation of the stent, etc. 
a. Angiography should be performed in either LAO30 (Appendix A 
Angiography steps 57-52) or RAO30 (Appendix A Angiography steps 53-
56) to obtain best resolution of stented artery. 
24. Perform IVUS to insure proper deployment diameter, etc. following Appendix B 
Intravascular ultrasound steps 28-44. 
25. Leave PTCA guidewire in artery if a second stent is to be placed. Otherwise, 
PTCA guidewire may be removed from artery when all procedures are complete. 
Typically, however, the PTCA guidewire retracts into the guiding catheter when 
the balloon is completely removed from the catheter. 
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Appendix D In vivo coronary blood flow measurements in anesthetized Ossabaw 
swine using percutaneous vascular access 
1. All Radiation Safety protocols should be followed during all steps of procedure. 
2. Sterile technique should be followed unless procedure is non-survival. During 
non-survival angiography, care should still be taken to perform tasks in sanitary 
fashion. 
3. Anesthesia  
Persons performing angiography procedure are all responsible for insuring a 
satisfactory plane of anesthesia is maintained during entire procedure. If 
isoflurane is used, check fill level on isoflurane dispenser. Generally 1.5-2% 
isoflurane and 2 L of O2 is required for the health and sedation of intubated 
swine. Isoflurane should be adjusted based on blood pressure, heart rate, 
movement of pig, voluntary stomach contraction, or other visual cues during the 
procedure. 
4. Follow steps 1-28 under Appendix A Angiography to prepare angiography 
equipment for use. 
5. Follow steps 1-26 under Appendix B Intravascular ultrasound to prepare IVUS 
equipment for use. 
6. Prepare flow equipment for use. 
a. Connect flow transducer to flow machine. 
b. Connect flow wire to flow transducer. 
c. After starting ComboMap flow machine, flow and pressure wire must be 
zeroed while still in plastic sheath. 
d. Connect flow machine to pressure transducer/ECG unit. 
7. Follow steps 28-67 under Appendix A Angiography to access desired coronary 
artery with flow wire. 
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a. Flow wire is very similar to PTCA wire. However, flow wire is very fragile 
and if bent or crimped will not work. Also, flow wires are very expensive 
relative to PTCA guide wire. 
b. Before advancing flow wire out of guide catheter, line up very tip of flow 
wire with end of guide catheter and normalize proximal pressure reading 
for flow wire to pressure reading from aortic pressure transducer. 
8. Position flow wire in proximal/intermediate section of target artery.  
a. Avoid branch points or acute bends in the artery trajectory. 
b. Desirable position is achieved when consistent/low noise flow envelopes 
are strong enough to obtain reasonable flow velocity measurements. 
9. Obtain first baseline flow measurements. 
a. This will allow reference point for normal flow preceding introduction of 
IVUS catheter and/or pharmacological agents. 
b. Adenosine dose-response may be obtained now (outlined in steps 15-17). 
10. Follow steps 27-43 under Appendix B Intravascular ultrasound to collect IVUS 
data from desired coronary artery, if conduit artery diameter is needed. 
a. Use flow wire instead of PTCA guidewire to guide IVUS catheter into 
desired coronary artery.  
11. To use IVUS catheter for steady-state infusion of drugs into the artery via the 
IVUS lumen, advance IVUS wire to very tip of flow wire and then retract flow wire 
to remove from IVUS catheter lumen. 
a. Do not allow IVUS catheter to slip out of target artery, as it cannot be 
guided back into artery without re-introducing flow wire into lumen of 
IVUS catheter. 
b. IVUS catheter should not be advance, but may be retracted, while IVUS 
catheter is free from flow wire. This will prevent damage to target artery. 
  190 
c. Flow wire is now free to advance or retract as needed. 
12. Reposition flow wire into optimal position for flow recording. 
13. Retract IVUS catheter such that distal marker is proximal to the tip of the flow 
wire, but not less that ~10 mm distal to the coronary ostium within target artery. 
a. This will insure minimal interaction of IVUS catheter with flow 
measurements. 
b. This will also insure any solution infused into IVUS catheter will reach 
target artery with desired concentration. 
14. Obtain second baseline flow measurements. 
a. These measurements compared to first baseline measurements will 
reflect either 1) change in flow wire position or 2) affect of IVUS catheter 
on target artery flow. 
15. All bolus injections through guiding catheter should equal ~3-fold of dead-space 
of guiding catheter (typically 3 mL dead space and 10 mL saline bolus).  
a. Bolus through guiding catheter is achieved using three-way stop cock 
attached between manifold and guiding catheter. 
b. Boluses should be through guiding catheter selectively accessing target 
coronary artery. If completely selective access of target artery cannot be 
achieved, selective access to left main coronary artery may suffice. 
16. Bolus saline and measure any change in flow. 
a. Strong flow artifact will be present as long as bolus is sustained. It should 
immediately stop when bolus stops. 
b. If contrast solution is present in guiding catheter, variable flow response 
should be observed following initial flow artifact. 
c. Pure saline does not typically elicit sustained flow response past initial 
flow artifact (17). 
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d. Repeat 3-4 times for first bolus following angiography with contrast to 
properly flush contrast out of catheter. 
e. Contrast will generally elicit strong vasodilatory response. 
f. If saline elicits sustained flow response (elevated flow ~20-30 seconds 
following bolus), any following boluses should be normalized to saline 
response. 
17. Adenosine dose-response should be obtained using bolus injections. 
a. Load guiding catheter with 3 mL of solution with desired adenosine 
concentration. 
b. Make certain that selective access of the target artery with guiding 
catheter is maintained. 
c. Obtain baseline average peak velocity (APV). 
d. Bolus 10 mL of saline in less than 1 second, flushing adenosine into 
target artery. 
e. Wait 5-10 seconds for flush artifact to subside. 
f. Record flow measurements and obtain APV of maximal adenosine 
response in the following 45 seconds. 
g. Repeat with each desired adenosine dose. 
18. Begin continuous infusion of pharmacological agent through lumen of IVUS 
catheter, if desired. Continuous infusion should be maintained at constant rate, 
typically 1-2 mL/min. 
a. IVUS catheter dead-space is approximately 1 mL, so first mL of infusion 
can be fast.  
b. If more than one continuous infusion in series are desired, IVUS catheter 
should be saline flushed into target artery with at least 3 mL saline 
immediately following previous drug infusion and with sufficient time 
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between serial infusions to allow previous drug to wash out or become 
inactive. 
19. Time to efficacy will be drug-dependent, but may occur in as little as 5 minutes. 
a. Be sure to record any changes in baseline flow to continuous infusion. 
b. After drug is fully efficacious, compare flow to baseline flow. 
c. Make certain that position of flow wire, etc. have remained constant 
during the continuous infusion.  
20. Bolus dose responses can be obtained during continuous drug infusion. Be sure 
to include continuously infusing drug in bolus solution at desired concentration to 
prevent wash-out during bolus. 
21. Reactive hyperemia data can be obtained using existing setup. 
a. Following IVUS catheter detachment from flow wire, introduce angioplasty 
balloon catheter of appropriate diameter over flow wire. 
b. Advance balloon catheter into coronary artery, but do not advance past 
flow wire. Insure IVUS catheter is not placed within balloon markers. 
c. Deploy balloon while balloon catheter is still attached to flow wire. Flow 
measurements will decrease with increasing balloon inflation. 
d. Inflate balloon rapidly to completely occlude flow measurements. Balloon 
should remain inflated for 15-45 seconds. 
e. Deflate balloon and record flow measurements. Increased blood flow 
following occlusion is reactive hyperemia. 
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Appendix E Sterile dissection of coronary artery from intact heart 
Procedures are adapted from “CORSMC1_METv2.doc”, which was updated 
6/25/08 by M. Sturek. Each step should be completed with sterile technique and in a 
sterile laminar flow hood whenever possible. All instruments, containers, dissecting dish, 
gloves, etc. should be sterile. Solutions should be sterile filtered with 0.2 μm filter. 
“Sterilization” of tissue is facilitated by serial dilution technique noted below. 
1. Rough / gross dissection of coronary arteries from heart ensues immediately 
after heart is obtained within 60 seconds following removal of heart from chest 
cavity.  
a. Rinse coronary artery area on heart with cold, sterile 2CaNa + 2% PS.  
b. Scissors are run from within 5 mm of coronary ostium into cardiac tissue 
on either side of each artery. Artery is cut away from heart with some 
cardiac tissue still attached. The aim of this step is expediency to place in 
sterile buffer solution. 
c. Rinse dissected arteries again thoroughly with ~20-50 mL of 2CaNa + 2% 
PS.  
2. Quickly plunge arteries into 500 mL ice-cold 2CaNa + 2% PS. Container should 
be kept on ice through entire dissection procedure. 
3. Immediately take arteries to dissecting microscope in cell culture hood for further 
dissection. 
4. Clean artery of excess adventitia, cardiac tissue, and adipose that may be 
attached to artery following rough / gross dissection in the cell culture hood in 
100 x 20 mm culture dish in ~30 ml Low Ca. Treat artery gently (do not stretch 
excessively, if possible). 
5. Any coronary artery that needs to be isolated/frozen for later molecular analysis 
should be attended to first. 
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6. At this point, the artery can be stored in the refrigerator in storage media for 2-5 
days, if necessary.  
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Appendix F Fura-2 digital imaging methods   
Michael Sturek, Ph.D. 
Revised by Jason M. Edwards 4-14-06 
Further revision by Zachary P. Neeb 12-30-09 
 
PRELIMINARY NOTES 
1. This text is for the “Rig 5” Intracellular Calcium Imaging experiments using multiple 
cells. 
2. These procedures are mainly the "hows" of doing microfluorometry experiments with 
some of the "whys 
3. Check with Jason or Dr. Sturek if this text is unclear.  Please make suggestions for 
improvement.  A team effort will make these instructions better and the resulting 
uniform data collection procedures will make our data more reliable, etc.  
4. Note the accompanying "BRIEF CHECKLIST" of procedures. 
 
BEFORE STARTING EXPERIMENTS 
1. Turn off all equipment:  the computer, monitor, and the shutter on top of the lamp.   
2. Turn on xenon arc lamp power supply (Blue box, power switch is in the back).   
You will hear the lamp switch on and the fan in the power supply will start.   
3. VERY IMPORTANT: MAKE SURE COMPUTERS IN THE ROOM ARE OFF 
BEFORE IGNITING XENON LAMP!   
The arc lamp igniter elicits 15,000 - 20,000 volt pulses to ignite the xenon lamp, thus 
damage to integrated circuits is possible.  (To convince yourself, have a radio 
playing in the room as you ignite the lamp and listen to the static interference.)   
 
a.    The stability of the lamps is best if allowed to warm up for ≈ > 10-15 min.  You 
should begin to put get your cells ready immediately, it will take at least 10 
minutes by the time you start the experiment.   
4. Turn on Shutter   
5. During the 10-15 period of xenon lamp warm-up: 
6.   Turn on computer and monitor.   
7. Prepare superfusion chamber. 
(An illustration of the superfusion chamber can be found in Thayer, Sturek, and 
Miller. Measurement of neuronal Ca2+ transients using simultaneous 
microfluorimetry and electrophysiology. Pflugers Arch. 412:216-223, 1988.) 
A) Apply vaseline to bottom side of chamber around the opening of the 
chamber with cotton swab, being careful not to slop vaseline on inside of 
chamber where cells are placed or in the inflow chamber. 
B) Place coverslip on bottom using small forceps. 
C) Place metal retaining ring on the four threaded screws and place one nut 
loosely on one of the screws to hold the coverslip loosely in place. 
D) Verify that the coverslip is centered over the opening of the chamber and the 
retaining ring  uniformly contacts the coverslip around the entire perimeter of 
the coverslip.  This prevents leakage of solutions from the chamber.  If small 
movements of the coverslip are needed for centering, care must be taken to 
avoid getting vaseline inside the chamber where the cells will be placed. 
E) Place the remaining 3 nuts on the screws and tighten firmly with fingers. 
F) Place 1-2 ml of solution (e.g. 2CaNa) in the superfusion chamber.  This 
allows a quick check for leaks in the superfusion chamber/coverslip junction.  
G)   The objective on the scope is a 20x objective, make sure it is locked in 
place.  This is a dry objective so do not place oil or water on it.  Clean 
objective with lens paper. 
8. Place superfusion chamber on microscope.  
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Metal ring should face down toward objective and the glass outflow tubing 
toward the back of the microscope.   
9. Attach vacuum tubing to the glass outflow tubing on superfusion chamber.  Be 
careful not to break the glass tube.  If you do break a glass capillary tube, 
there are some spares either on the rig 5 table or on the lab bench  behind you.   
If the outflow tubing breaks, remove the superfusion chamber and replace the 
ouflow tubing.   
Always use a double trap in line with suction.  Empty first trap after each use.  It 
may be appropriate to partially fill the second trap with an absorbent material to 
prevent condensation in vacuum line. 
10. Prepare solutions and cell superfusion reserviors (syringes). 
A) The superfusion syringe system must be checked for proper flow rate of ≈ 
1-2 ml/min, which is ≈ > 1-2 drops/s.   
1) Plunging of the 60 ml syringes, unclogging the needles with blasts of air, 
etc. may be needed to insure proper flow.  Plunging may shread part of 
the black rubber on the plunger into the syringe.  A better method may 
be to apply negative gauge pressure with a 20 ml syringe to the common 
outflow (with a needle). 
2) Needles are 20 gauges, are cut with wire cutters, bent, and filed as 
needed to create a smoother edge. 
B) Add desired solutions to the syringes and run solution through to be certain 
that each solution is in the tubing leading from the syringe to the valve.  
Solutions are collected in beaker marked "waste".  Often it is necessary to 
tape the polyethylene (PE) tubing to the waste beaker to avoid slipping of the 
PE tubing out of the waste beaker and leakage of solutions on the bench, 
etc. 
C) In the 7-syringe systems any chemicals that have rapid and/or irreversible 
actions should be placed in syringes 5, 6, or 7.  The reason is that if some 
chemical is left in the dead space in tubing from the valve for syringes 1-4, a 
partial Cai response may be elicited in the cell.   
D) Chemicals that notoriously stick to tubing (ie:  Thapsigargin) , syringes, etc. 
should have a designated syringe and that syringe should not be used for 
any other chemical.  For example, ionomycin is very stable and may stick to 
syringes.  Label the syringes with appropriate numbers.  Additional 
precaution should include rinsing syringes and tubing with ethanol following 
each use. 
E) Always have list indicating contents of each syringe taped near the 
superfusion chamber for clarity.  Confusion about what solution is in what 
syringe should be avoided during the experiment. 
F) The superfusion flow is turned off by positioning the arrow between numbers 
on the valve control.  Note that in the 4 and 7 syringe systems (Anspec, blue 
valve) the arrow on the control (handle) is very small and opposite of the 
direction of the handle.  The 8 syringe Valco system is clearly marked. 
1. Place superfusion system on left of the RIG. 
2. Attach PE tubing from superfusion syringe system to superfusion inflow 
tubing (metal tube on right of chamber). 
3. Turn on vacuum pump in room 366.  Suction of the solution from the 
superfusion chamber should occur quickly and be evident from the brief 
slurping noise as the solution is aspirated from the superfusion chamber.  
The rate of flow should not be measured by the frequency of aspiration.   
4. Verify solution flow characteristics of the superfusion system on the 
microscope stage. 
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This is VERY IMPORTANT because: a) it will insure rapid and complete 
exchange of solutions bathing the cell or tissue and, b) AVOIDANCE OF 
FLOODING THE MICROSCOPE. 
G) Turn on flow for physiological salt solution (PSS or 2CaNa) by turning handle 
on syringe system to appropriate syringe.  The fluid level in the superfusion 
chamber should start rising and/or the slurping sound will start again. 
H) The fluid level should be ideally 1-2 mm for single cells and flow rate of ≈ 1-2 
ml/min.  The higher the fluid level the greater the volume of solution in the 
superfusion chamber.  Thus, even if the flow rate is very high it will require 
longer to exchange solutions if the superfusion chamber volume is greater. 
I) Fluid level may be changed by adjusting the outflow tubing (glass tubing), 
usually by turning the opening from side to side.   
J) Sometimes it is necessary to place wet the nylon mesh in front of the outflow 
tubing. 
K) Place a folded Kimwipe™ under inflow tubing and against the outside of the 
superfusion chamber (on top of microscope stage). This will serve the 
purpose of alerting the operator of any leak between inflow tubing and 
superfusion chamber. Also, if leak is slow, one Kimwipe™ will function as a 
sufficient wick for several hours of experiments. When performing patch 
clamp experiments, be sure wet Kimwipe™ does not touch any metal 
objects or it may introduce noise. 
 
 
CONDUCTING EXPERIMENTS 
1. Turn off PSS (2CaNa) and remove some solution from superfusion chamber by 
gentling swabbing with Kimwipe.   
2. Add 1-3 drops of cell suspension (5-30uL) to the superfusion chamber on the 
coverslip directly at the objective aperture.   
Do not add too much cell suspension because it might fill the superfusion chamber 
perhaps enough to cause the vacuum system to aspirate a large fraction of the 
solution (taking the cells, also).  If you have few cells obtain the drop from the bottom 
of the conical centrifuge tube and take extra care to place the drop directly over the 
objective aperture. 
3. Allow the cells to settle onto coverslips for 1 to 3 minutes depending on 
concentration of the cells, the longer you wait, the more cells will stick to the 
coverslip. 
4. Observe cell through the binocular eyepieces. 
a. Turn off room lights.   
c.  Turn on the arc lamp on the right.  Excitation light will be transmitted to the 
microscope and the fura-2 loaded cells can thereby be visualized. 
d. Focus on cells. 
1) The top slider rod should be pushed to the right of the binoculars to see the 
cells.   
2) Usually only fine adjustment of the focus is needed.   
3) If it is difficult to find cells the most common problems are too few cells or the 
cells are grossly out of the focal plane. 
e. Adjust binocular eyepiece distance as needed to accomodate your eye spacing. 
5. Start superfusion of PSS (2CaNa). 
a. View through binocular eyepieces.  The top slider is pushed to the right. 
b. When superfusion is started some cells may be swept away (easily noted if 
looking in the binocular eyepieces).  This is normal and usually an ample 
number of cells adhere to the coverslip.  If cells are not adhering try changing 
  198 
the coverslip.  It seems that after long usage of the same coverslip the adhesion 
properties decrease. 
c. Monitor closely the superfusion characteristics. 
The nylon mesh sometimes becomes dried out during the several minutes 
required for the cells to adhere to the coverslip.  Sometimes it is necessary to 
apply solution to the nylon mesh with a dispo pipette, change the vacuum line, 
etc. as described above. 
d. Definitely start superfusion before searching for cells because it is very 
frustrating to select a cell, start an experiment, then have the cell swept away 
when the superfusion is started. 
6. Search for a cell or cells. 
a. Vascular smooth muscle cells having a "glowing" appearance in brightfield view 
(through the bionocular eyepieces), thick looking, and elongated are usually 
reactive to vasoconstrictors.  Refer to the book chapters for photomicrographs of 
smooth muscle and endothelial cells.  These morphological criteria are not 
absolute.  Some dispersions may yield many cells with this appearance, but the 
cells may be functionally unreactive.  To our knowledge no laboratory can 
explain this.   
b. Freshly dispersed endothelial cells typically clump together like a cluster of 
grapes and are spherical.  A single cell at the edge of a clump or several cells in 
a clump may be studied. 
c. After finding a good group of cells you may want to look for an even better group 
of cells.   
1) Search at right angles to cell because it is easier then to return to that same 
cell should you not find a better cell.  Movement around the field is possible 
with X and Y stage movement controls located on lower right, toward back of 
microscope.  The search area will be limited by objective hitting retaining ring 
of superfusion chamber. 
2) Make sure the cell is located near the middle 1/2 (x-y direction) of the 
superfusion chamber because the exchange of solutions is not complete in 
the peripheral 1/4 of the chamber.  A cell located near the opening of the 
inflow chamber is ideal.   
d. Place the cell near the cross hairs in the center of the field.  For each Rig there 
is a unique location near the crosshairs that provides a view of the cell in the 
center of the video monitor.  Also, the crosshair area is that which is excited by 
the arc lamp. 
e. Check fluorescence of cells by blocking transillumination (with small piece of 
cardboard placed on phase condenser or by turning off the light) and observing 
visually.  If no fluorescence signal or signal is weak then check several points 
along the excitation and emission path: 
1) Arc lamp shutter is open. 
2) If blue/violet light is not visible coming through the objective, push “local” on 
the filter controller then press 2 or 3.  2 and 3 are the 340 and 380 filters 
respectively, while 1 blocks the laser.    
3) Make sure Objective aperture is opened fully.   
Your eyes are quite sensitive and usually if you see only faint fluorescence you 
will have to take extra care to measure the fluorescence with the optical 
processor.  If the cells are too faintly fluorescent it may be necessary to load with 
dye again or obtain a different fraction of cells.   
f. Record notes on cells if the morphology is unusual, etc. 
7. Observe cell in video monitor.   
1) Pull slider under the binoculars of the microscope over (to the left).  Then open 
the program “Inca” and click Experiment on the top, then New Experiment.  
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2)  Click Video Preview and fluorescent light will illuminate the cells.  If this does not 
occur, adjust the power of the lamp by turning the black wheel on the front of the 
lamp clockwise.  You may also need to reset the timer on the lamp by pushing 
the black button on the front of the lamp. 
3)  Click Check Brightness and the screen will turn green and red.  Adjust the 
stretch at the bottom of the screen until no red is present on the image.   
  
8.   Exposure time   
1)  Increase the exposure time as an alternative to increasing intensity of the lamp( 
which is done by turning the black wheel on the front of the laser).  As you 
increase exposure time, you decrease the rate at which you collect images.  The 
exposure times should be a 2:1 ratio with 340:380 respectively.  Click Ok. 
2) Record background. 
1) Click Record New Background.  Move the slide under the binoculars to the 
right and click Accept new background.  Move slide back to the left.   
2) If background fluorescence is too high (>20% for single cells) try to reduce 
the background further by several methods. 
a) Decrease transillumination light intensity.  Light may be turned off, but 
this is rarely necessary. 
b) Last resort - Close black curtains. 
3) Move cell back in measurement aperture. 
9.  Make “areas of interest” (AOI).   
1)  Click Find cells and set Threshold.  Click Freehand.  Then move mouse to 
cell perimeter and click the left mouse once and circle the cell once, then click 
the mouse again to complete the circumference.  Repeat until all the desired cell 
are circled.  Circle and note a background area.   
2)  Adjust the threshold, Begin at 10 click measure.  Look for the largest 
difference in the background (dark) circle compared to the cell intensity (bright).  
Readjust the number to higher or lower than 10 to obtain optimal conditions.  
Click OK. 
10.   Click Select File Name.  Make a file name for the upcoming experiment.   
 
Start experiment. 
Press “Start Experiment” 
 
11. TAKE MANY NOTES ON EXPERIMENTS BECAUSE: 
a. Precise observation of subtle, but consistent, changes in cells, etc. may lead to 
new avenues of experimentation. 
b. "Audit" of research programs by NIH.  Documentation of effort and results is 
essential to justify funding of grants and to resolve any issues regarding validity 
of our findings. 
 
12. Other precautions during experiments: 
a.  VERY IMPORTANT:  Check the superfusion chamber for leaks periodically 
throughout the experiment.  Usually a leak is noticed first as a fluid front 
beween the superfusion chamber and the plastic ring on which it sits on the 
microscope stage.  If a leak is remedied at this time there is little harm done.  
Putting a drop of solution purposely on the plastic ring before placing the 
superfusion chamber on the microscope will illustrate this.  Be especially aware 
of leaks when using saponin, Triton X-100, or >70% ethanol because these 
agents dissolve the vaseline.  If a leak goes unnoticed the solution may flow 
down onto the objective and into the body of the microscope.  Servicing the 
microscope requires IMMEDIATE ATTENTION and involves disassembly of 
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the microscope.  It is a major operation, but better than servicing the microscope 
after the solutions have dried in the joints of the microscope and the parts are 
immobilized.  If you ever suspect a leak please ask for help!!   
b.  Wipe solution spills from air suspension tables and microscopes immediately.   
c. Check the fluid trap on right of the Rig cage.   
If the trap is getting full empty it, otherwise the solution will be aspirated into the 
vacuum pump and ruin the pump. 
13. Rinse chamber thoroughly between experiments on cells.  Distilled water sprayed 
into the superfusion chamber with a wash bottle equipped with flexible tubing is 
ideal.  Wiping of the chamber is also needed, because some cells are strongly 
adherant. 
14. Remember...cell heterogeneity -- not all cells will respond to all agents.   
 
SHUTTING DOWN RIG AND CLEANING 
1. Very Important:  Turn off the filter wheel controller first, then the computer, then the 
Arc Lamp last.   
2. Clean superfusion chamber. 
a. Remove the chamber from the microscope.   
b. Wash the chamber well with water.  Then remove suction tube.   
c. Remove coverslip and wipe vaseline from superfusion chamber.   
d. Place nuts in jar. 
e. Place coverslip in "SHARPS" trash (small box in each Rig). 
3. Turn off other equipment in whatever order is convenient. 
4. Flush distilled water through superfusion system. 
5. Double check that all shutters are closed and turn off power strip for arc lamp fan. 
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Appendix G Mechanical isolation of in-stent neointima from in-stent media 
 
First conduct all steps in Appendix E Sterile dissection of coronary artery 
from intact heart. 
1. Separate stent from rest of artery by cutting as close to the stent edges as 
possible without crimping stent. 
2. Under magnification, all adventitia and adipose should be carefully removed. Do 
not perforate artery wall. Do not crimp or otherwise disturb the artery wall. 
Healthy looking artery equals healthy cells and clean mechanical isolation. 
3. The stent struts should be apparent through the wall of the artery. Pick a stent 
window longitudinally at the middle of the stent. Using very sharp, fine dissecting 
scissors, cut through the adventitia outside the stent window. The cut should be 
cross-sectional and only through the adventitia. 
a. When cutting through adventitia, do not push the scissors into the stent. 
Sufficiently sharp scissors should cut without a lot of downward pressure.  
b. Alternatively to scissors, a scalpel can be used to cut through the 
adventitia. 
4. In the section of cut adventitia, poke one scissor through the media and 
neointima. If the adventitia was cut through and the scissor is sharp, it should 
poke through without crimping the stent. 
5. Cut the media and neointima within the stent window in a cross-sectional 
direction. 
6. Place sturdy, yet sharp scissors into the cut made. Use small cuts with the tips of 
the scissors to cut through the stent and tissue in a cross-sectional manner. 
a. Large cuts result in crimping. 
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b. The tissue may require a bit more up and down cutting. Cut through the 
tissue so that the scissors stop on the stent strut without cutting through. 
A sharp cutting motion should be used to cut through the stent to prevent 
twisting the stent struts or crimping the stent. 
c. Rotate the stent with each cut, placing the scissors in optimal cutting 
position to minimize crimping pressure. 
d. A clean cut will result in a cross-sectioned stent with no crimping. 
7. One half of the stent may be used for molecular studies and should be 
immediately taken care of. Place the other half of the stent in ice-cold 2CaNa if 
there is a prolonged delay. 
8. Cut one wall of the stent-half longitudinally. Crimping will not be an issue.  
9. Pull the stent open using tweezers exposing the lumenal side. 
a. This causes tension in the neointima aiding mechanical isolation. 
10. Firmly grab the thickest section of neointima near the cross-sectional cut with 
sharp tweezers. Optimally, grab the neointima near the corner of the cross-
sectional and longitudinal cuts. 
a. When grabbing the neointima with tweezers, one point of the tweezers 
should be between the stent and neointima and one point should be on 
the lumenal side of the neointima. 
11. Using sturdy tweezers or even clamps, grab a stent strut nearest the other 
tweezers. 
12. Gently pull/peel the neointima up and away from the stent struts. It should come 
off in one intact sheet. The stent should remain apposed to the media. 
13. Pull the stent away from the media. It should easily come away in one piece. 
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Appendix H Sterile organ culture 
1. Complete Appendix E Sterile dissection of coronary artery from intact heart. 
Cleanly dissect any adventitia and adipose because they will detract from quality 
of cell isolation later. Adipose cells lyse during organ culture, may secrete 
indeterminate adipokines, and consume media nutrients.  
2. Cut artery segment into smaller segments of ~equal length. 
3. Fill each well of 6-well culture dish with sterile phosphate buffered saline. 
4. Transfer each artery segment separately into the top left well. 
5. Allow to sit for several seconds before transferring to top middle well. Each 
segment should be moved separately and with as little solution from the previous 
well transferred as possible. 
6. Continue to transfer artery segments in a clock-wise manner through each well. 
7. Serial “sterilization” is achieved after each artery segment has been moved in 
sequence through each well of the plate. 
8. Set up 6-well culture dish with 5 mL of sterile RPMI solution with 1% 
penicillin/streptomycin in each well. 
9. Transfer one “sterilized” artery segment to each well. 
10. Appropriate labeling is essential. Cover of 6-well dish should be marked with pig 
number, start date of organ culture, and any treatments unique to each well. 
11. Culture dish should be transferred to 37°C incubator with 4.6% CO2. 
12. Depending on desired time of organ culture, media should be changed every 2-3 
days using sterile technique. 
a. Color of the media should be noted, as amber yellow indicates acidity and 
darker purple indicates alkalinity. Acidity is much more common and 
would indicate high cellular metabolism and need for nutrients, thus more 
frequent changing of media.  
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Appendix I Intracellular pipette solutions for recording of ionic currents (whole 
cell) 
Adapted from hardcopy ”SOLUT1.MET, 121787; Michael Sturek, PhD. 
Always check notes and specific instructions below table. 
1. Cs+ pipette, highly buffered Ca2+ (10 mM EGTA) 
Cs10EGTA 
Components Conc. (mM) 100 mL total Notes 
Cs+ (CsCl) 
100 
+24 
+13 
137 Total 
10 mL of 1 M 
 
pH’ed (~40 μL) 
 
 
– from CsOH add to STOCK 
– from CsOH after add ATP system & 
GTP 
MgCl2 1 1 mL of 0.1 M  
HEPES 10 1 mL of 1.0 M  
EGTA 10 380.4 mg  
pH 7.3 w/CsOH   
   Components above here  STOCK solution 
MgATP 3.6 19.1 mg / 10 mL Components below here add to STOCK (10 or 20 mL aliquots) 
Tris2CP 14 63.5 mg / 10 mL  
CPK 50 U/mL 4.0 mg / 10 mL Lot# 96F-9555; optional 
TrisGTP 1 6.4 mg / 10 mL  
Other?   enzymes, cofactors, etc. 
GMPP(NH)P 60 μM 0.32 mg / 10 mL Optional 
Instructions: 
i. Dispense 10 mL of STOCK into small beaker with stirring bar. Add ATP and Tris2CP 
 pH <6. Add >40 μL of dilute (1 CsOH stock:3 ddH2O) CsOH  pH 7.3.  
ii. Add CPK (avoids possible adverse pH effect; optional) filtered with Millex-GS 0.22 
μm filter. 
iii. Add 0.5 mL to micro centrifuge tubes and place at -80°C. 
iv. Store in plastic bottles in order to avoid leeching of Ca2+ from the container. 
v. Suck STOCK solution into electrode, then backfill with ATP system solution. 
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2. Cs+ pipette, slightly buffered Ca2+ (0.1 mM EGTA) 
Cs0.1EGTA 
Components Conc. (mM) 100 mL total Notes 
Cs+ (CsCl) 
120 
+11 
+8 
140 Total 
12 mL of 1 M 
 
pH’ed (~40 μL) 
 
 
– from CsOH add to STOCK 
– from CsOH after add ATP system & 
GTP 
MgCl2 1 1 mL of 0.1 M  
HEPES 10 1 mL of 1.0 M  
CsEGTA 0.1 1 mL of 10 mM  
pH 7.3 w/CsOH   
   Components above here  STOCK solution 
MgATP 3.6 19.1 mg / 10 mL Components below here add to STOCK (10 or 20 mL aliquots) 
Tris2CP 14 63.5 mg / 10 mL  
   ; optional 
TrisGTP 1 6.4 mg / 10 mL  
Other?   enzymes, cofactors, etc. 
GMPP(NH)P 60 μM 0.32 mg / 10 mL optional 
Instructions: 
1. Dispense 10 mL of STOCK into small beaker with stirring bar. Add ATP and 
Tris2CP  pH <6. Add >40 μL of dilute (1 CsOH stock:3 ddH2O) CsOH  pH 
7.3. 
2. Add CPK (avoids possible adverse pH effect) filtered with Millex-GS 0.22 μm 
filter. 
3. Add 0.5 mL to micro centrifuge tubes and place at -80°C. 
4. Store in plastic bottles in order to avoid leeching of Ca2+ from the container. 
5. Suck STOCK solution into electrode, then backfill with ATP system solution. 
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3. Cs+ pipette, Fura-2 K5, slightly buffered Ca2+ (0.1 mM EGTA) 
CsFura-20.1EGTA 
Components Conc. (mM) 100 mL total Notes 
Cs+ (CsCl) 
120 
+11 
+8 
140 Total 
12 mL of 1M 
 
pH’ed (~40μL) 
 
 
– from CsOH add to STOCK 
– from CsOH after add ATP system & 
GTP 
MgCl2 1 1 mL of 0.1M  
HEPES 10 1 mL of 1.0M  
CsEGTA 0.1 1 mL of 10mM  
pH 7.3 w/CsOH  
Components above here  STOCK 
solution 
MgATP 3.6 19.1 mg / 10 mL Components below here add to STOCK (10 or 20 mL aliquots) 
Tris2CP 14 63.5 mg / 10 mL  
CPK 50 U/mL 4.0 mg / 10 mL Lot# 96F-9555 
TrisGTP 1 6.4 mg / 10 mL  
Fura-2 100μM 0.1 mg / 1.0 mL Only 1 mL; Fura-2 K5 
Other?   enzymes, cofactors, etc. 
GMPP(NH)P 60μM 0.32 mg / 10 mL optional 
Instructions: 
1. Dispense 10 mL of STOCK into small beaker with stirring bar. Add ATP and 
Tris2CP  pH <6. Add >40 μL of dilute (1 CsOH stock:3 ddH2O) CsOH  pH 
7.3. 
2. Add CPK (avoids possible adverse pH effect) filtered with Millex-GS 0.22 μm 
filter. 
3. Add 0.5 mL to micro centrifuge tubes and place at -80°C. 
4. Store in plastic bottles in order to avoid leeching of Ca2+ from the container. 
5. Suck STOCK solution into electrode, then backfill with ATP System solution. 
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4. K+ pipette, highly buffered Ca2+ (10 mM EGTA). 
K+, 10 EGTA 
Components Conc. (mM) 100 mL total Notes 
K+ (KCl) 
100 
+29 
+9 
140 Total 
10 mL of 1M 
 
pH’ed (~70μL) 
 
 
– from KOH add to STOCK 
– from KOH after add ATP system & 
GTP 
TEACl 10 10 mL of 1.0M  
MgCl2 1 1 mL of 0.1M  
HEPES 10 1 mL of 1.0M  
KEGTA 10 380.4 mg  
pH 7.3 w/KOH  
Components above here  STOCK 
solution 
MgATP 3.6 19.1 mg / 10 mL Components below here add to STOCK (10 or 20 mL aliquots) 
Tris2CP 14 63.5 mg / 10 mL  
CPK 50 U/mL 4.0 mg / 10 mL Lot# 96F-9555 
TrisGTP 1 6.4 mg / 10 mL  
Other?   enzymes, cofactors, etc. 
GMPP(NH)P 60μM 0.32 mg / 10 mL optional 
Instructions: 
1. Dispense 10 mL of STOCK into small beaker with stirring bar. Add ATP and 
Tris2CP  pH <6. Add >70 μL of 1M KOH  pH 7.3. 
2. Add CPK (avoids possible adverse pH effect) filtered with Millex-GS 0.22 μm 
filter. 
3. Add 0.5 mL to micro centrifuge tubes and place at -80°C. 
4. Store in plastic bottles in order to avoid leeching of Ca2+ from the container. 
5. Suck STOCK solution into electrode, then backfill with ATP System solution. 
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5. K+ pipette, slightly buffered Ca2+ (0.1 mM EGTA). 
K+, 0.1 EGTA 
Components Conc. (mM) 100 mL total Notes 
K+ (KCl) 
130 
+5 
+9 
144 Total 
13 mL of 1M 
 
pH’ed (~70μL) 
 
 
– from KOH add to STOCK 
– from KOH after add ATP system & 
GTP 
MgCl2 1 1 mL of 0.1M  
HEPES 10 1 mL of 1.0M  
KEGTA 0.1 1 mL of 10 mM  
pH 7.3 w/KOH  
Components above here  STOCK 
solution 
MgATP 3.6 19.1 mg / 10 mL Components below here add to STOCK (10 or 20 mL aliquots) 
Tris2CP 14 63.5 mg / 10 mL  
CPK 50 U/mL 4.0 mg / 10 mL Lot# 96F-9555 
TrisGTP 1 6.4 mg / 10 mL  
Other?   enzymes, cofactors, etc. 
GMPP(NH)P 60μM 0.32 mg / 10 mL optional 
Instructions: 
1. Dispense 10 mL of STOCK into small beaker with stirring bar. Add ATP and 
Tris2CP  pH <6. Add >70 μL of 1M KOH  pH 7.3. 
2. Add CPK (avoids possible adverse pH effect) filtered with Millex-GS 0.22 μm 
filter. 
3. Add 0.5 mL to micro centrifuge tubes and place at -80°C. 
4. Store in plastic bottles in order to avoid leeching of Ca2+ from the container. 
5. Suck STOCK solution into electrode, then backfill with ATP System solution. 
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6. K+ pipette, Fura-2 K5, slightly buffered Ca2+ (0.1 mM EGTA). 
K+, Fura-2 K5, 0.1 EGTA 
Components Conc. (mM) 100 mL total Notes 
K+ (KCl) 
130 
+5 
+9 
144 Total 
13 mL of 1M 
 
pH’ed (~70μL) 
 
 
– from KOH add to STOCK 
– from KOH after add ATP system & 
GTP 
MgCl2 1 1 mL of 0.1M  
HEPES 10 1 mL of 1.0M  
KEGTA 0.1 1 mL of 10mM  
pH 7.3 w/KOH  
Components above here  STOCK 
solution 
MgATP 3.6 19.1 mg / 10 mL Components below here add to STOCK (10 or 20 mL aliquots) 
Tris2CP 14 63.5 mg / 10 mL  
CPK 50 U/mL 4.0 mg / 10 mL Lot# 96F-9555 
TrisGTP 1 6.4 mg / 10 mL  
Fura-2 100μM 0.1 mg / 1.0 mL Only 1 mL; Fura-2 K5 
Other?   enzymes, cofactors, etc. 
GMPP(NH)P 60μM 0.32 mg / 10 mL optional 
Instructions: 
1. Dispense 10 mL of STOCK into small beaker with stirring bar. Add ATP and 
Tris2CP  pH <6. Add >70 μL 1M KOH  pH 7.3. 
2. Add CPK (avoids possible adverse pH effect) filtered with Millex-GS 0.22 μm 
filter. 
3. Add 0.5 mL to micro centrifuge tubes and place at -80°C. 
4. Store in plastic bottles in order to avoid leeching of Ca2+ from the container. 
5. Suck STOCK solution into electrode, then backfill with ATP System solution. 
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Appendix J Extracellular solutions 
Adapted from hardcopy ”SOLUT1.MET, 121787; Michael Sturek, PhD. 
Always check notes and specific instructions below table. 
1.  2CaNa or 2BaNa 
2BaNa or 2CaNa 
Components Conc. (mM) 4000 mL total 3000 mL total 11.5 L total 
BaCl2 
or 
CaCl2 
2 
 
2 
80 mL of 0.1 M 60 mL of 0.1 M 230 mL of 0.1 M 
NaCl 138 552 mL of 1.0M 414 mL of 1.0M 92.74 g 
MgCl2 1 40 mL of 0.1M 30 mL of 0.1M 115 mL of 0.1M 
KCl 5 200 mL of 0.1M 150 mL of 0.1M 57.5 mL of 1.0M 
HEPES 10 40 mL of 1.0M 30 mL of 1.0M 115 mL of 1.0M 
Glucose 
(D-glucose) 10 7.2 g 5.4 g 20.7 g 
pH 7.4 w/NaOH 15-17 mL of 1.0M 10-12 mL of 1.0M 48-50 mL of 1.0M 
Total Na+ 142    
 
2. 0.5Ca2+ 
Low Ca 
Components Conc. (mM) 1000 mL total 500 mL total Notes 
CaCl2 0.5 5.0 mL of 0.1 M 2.5 mL of 0.1 M  
NaCl 140 140 mL of 1.0 M 70 mL of 1.0 M  
MgCl2 1 10 mL of 0.1 M 5 mL of 0.1 M  
KCl 5 50 mL of 0.1 M 40 mL of 0.1 M  
HEPES 10 10 mL of 1.0 M 5 mL of 1.0 M  
Glucose 
(D-glucose) 10 1.8 g 0.9 g  
pH 7.4 (w/NaOH) 3-5 mL of 1.0 M 2-3 mL of 1.0 M  
BSA 1.5% 15 g 7.5 g  
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3. 0Ca 
0CaNa 
Components Conc. (mM) 1000 mL total 500 mL total Notes 
CaCl2 – – – – – –  
NaCl 140 140 mL of 1.0 M 70 mL of 1.0M  
MgCl2 1 10 mL of 0.1M 5 mL of 0.1M  
KCl 5 50 mL of 0.1M 40 mL of 0.1M  
HEPES 10 10 mL of 1.0M 5 mL of 1.0M  
Glucose 
(D-glucose) 10 1.8 g 0.9 g  
EGTA 10-2 (10-5 M) 3.8 mg 1.9 mg  
pH 7.4 (w/NaOH) 3-5 mL of 1.0M 2-3 mL of 1.0M  
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